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ABSTRACT 
Trace amounts of activated pharmaceutical ingredients (APIs) have been reported in aquatic 
environments worldwide, and their toxicity to non-target organisms is of increasing concern. 
Algae are primary producers in aquatic food chains, and as such are very sensitive to external 
disturbance. The understanding of the adverse effects on the algal species such as growth 
and physiological effects is vital to understand the risks of APIs in the aquatic environment. 
This thesis therefore describes desk-based studies and a series of laboratory experiments to 
characterise the risk of APIs, and to investigate the effects of APIs on a wide range of algal 
species. 
In the desk-study, a review summarising the available ecotoxicological data of APIs to algal 
species was initially performed, where differences in the sensitivity of the algal species 
towards API exposures were found. After that, an approach for prioritising APIs and associated 
metabolites in the UK environment was developed, where three major-use antibiotics 
lincomycin, tylosin and trimethoprim that pose a potential threat to algal species in the natural 
environment were identified for further experimental investigation. Laboratory experiments 
were then conducted to investigate the effects of three antibiotics on the growth and 
physiology of a range of algal species from chlorophytes, cyanobacteria and diatoms. Risk 
arising from the antibiotic mixture in the European surface waters was characterised   
In conclusion three major-use antibiotics could cause inhibitory effects on both algal growth 
and physiology. At environmentally relevant concentrations the antibiotic mixtures can pose 
potential risks in European surface waters. 
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Chapter 1 
Introduction 
1.1 Pharmaceuticals and Pathways into the environment 
Active pharmaceutical ingredients (APIs) are used primarily to prevent or treat human and 
animal disease. APIs produced by manufacturers are predominantly used by households and 
hospitals, in aquaculture and in livestock farming (Figure 1.1). Following consumption by 
humans, the parent compounds APIs as well as any associated metabolites are typically 
discharged to wastewater treatment plants (WWTP) (Ellis, 2006, Rosi-Marshall and Royer, 
2012). Effluents produced from manufacturing sites are primarily emitted to WWTPs, but in 
some region (e.g. in areas of India) they are emitted directly into surface waters (Monteiro and 
Boxall, 2010). During the wastewater treatment process, APIs may be biodegraded, adsorb to 
the sewage sludge and/-or survive the treatment process and be released in the wastewater 
effluent (Halling-Sorensen et al., 1998). APIs in effluent can then be emitted to surface waters 
by direct discharge or to the soil compartment where the effluent is used for irrigation purpose. 
APIs adsorbed onto sewage sludge can also enter the terrestrial environment when sewage 
sludge is spread to land as a fertiliser (Sabourin et al., 2009). APIs used in aquaculture will be 
directly discharged into the aquatic environment. Following use, veterinary APIs used in 
livestock farming will be excreted and enter soil systems when manure and slurries are applied 
as fertilisers. The APIs can then be transferred from the soil to the underlying groundwater, 
aquifers and surface water by leaching and runoff (Wu et al., 2008). 
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Figure 1.1 Pathways of APIs into the environment 
1.2 Occurrence and side effects of APIs in the environment 
The contamination of surface water with pharmaceutical residues has become an emerging 
environmental concern. Over the past 15 years, a large number of studies on the risk 
evaluation and control of APIs have been undertaken involving the determination of the 
occurrence, fate and effects of APIs in the environment (Boxall, 2004). The occurrence of a 
wide range of APIs from different therapeutic classes in surface water has been reported 
worldwide at concentrations ranging from ng L-1 to ug L-1 levels (Monteiro and Boxall, 2010). 
While the reported concentrations are generally low, many APIs have been detected 
throughout the year across a variety of hydrological, climatic and land-use settings and some 
APIs can persist in the environment from months to years (Monteiro and Boxall, 2010). APIs 
are biologically active molecules that are designed to either interact with the receptors in 
humans and animals or kill infectious organisms (e.g. bacteria, fungi and parasites) (Boxall, 
2004). However, many groups of non-target organisms (i.e. invertebrates and vertebrates) 
which have similar receptor systems could also be affected. Effects not related to the 
Chapter 1                                                               Introduction 
22 
 
therapeutic mode of action of a pharmaceutical are also possible as illustrated by the effects of 
diclofenac on Indian vulture species. Diclofenac is a commonly used anti-inflammatory drug 
and is highly toxic to some vulture species. Diclofenac was used as a veterinary treatment in 
areas of India and Pakistan. Vultures were exposed to the diclofenac when they consumed 
contaminated animal carcasses resulting in mortality and, over time, a large decline in 
population numbers of vultures (Oaks et al., 2004).  
While a wide range of standard studies (i.e. following OECD protocol) indicate that the 
detected concentration of APIs in the environment do not trigger evident negative effects on 
test organisms, APIs are continuously released to the environment and subtle side effects after 
a long-term exposure are therefore possible (Daughton and Ternes, 1999) For example, it is 
believed that continuous exposure to 17-alpha-ethinylestradio (EE2), the active ingredient in 
many oral contraceptives, could result in the reduction of fish reproduction (e.g. fertility of 
sexually maturing male rainbow trout) and the collapse of fish populations (Jobling et al., 2006, 
Kidd et al., 2007, Schultz et al., 2003). As a result of findings like those described above,  
three APIs (diclofenac, EE2 and 17-beta-estradiol (E2)) have been included in the Water 
Framework Directive (Directive 2013/39/EU) watch list (EC, 2013), with the goal of generating 
monitoring data and determining the most appropriate mitigation measures for their risk.  
1.3 Algae and APIs in the environment  
Algae, as a particularly sensitive class of organisms to APIs exposure, are suitable, quick and 
cost effective indicator organisms for environment health assessment studies (Pavlic et al., 
2005). Side effects of APIs on algae could not only result in the inhibition of their growth but 
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also affect the entire ecosystem as a results of their important ecosystem functions such as 
oxygen production, nutrient cycling and food supply (DeLorenzo and Fleming, 2008). Algae 
often provide one of the first signals of ecosystem impact due to their short response times, 
which allows corrective regulatory and management actions on APIs to be taken before the 
occurrence of further damage occurs within the ecosystem (Pavlic et al., 2005). Algal species 
are therefore routinely used in the risk assessment of APIs for human and veterinary use 
(EMEA, 2008, EMEA, 2006). 
While a wide range of investigations have previously focused on the effects of APIs on algal 
species, most studies have only looked at the effects on a handful of algal species, mainly on 
chlorophytes. Differences in the responses of algal species towards APIs have been found in 
some studies i.e. cyanobacteria have been shown to exhibit higher sensitivity to APIs with 
antibacterial properties than chlorophytes (Halling-Sorensen, 2000). Model species (i.e. 
chlorophytes) used for effect assessment may therefore not be the most appropriate test 
organisms to all API exposures. As a result of their observed sensitivity to antibacterial 
compounds, cyanobacteria are now incorporated into risk assessment procedures for human 
and veterinary medicines. However, for some classes of algae (e.g. diatoms) our 
understanding of sensitivity to APIs is limited as is our understanding of sensitivity of different 
species from the same organism class. A study systematically exploring the sensitivity of 
commonly used indicator algal species (i.e. species recommended in OECD 201 guideline) 
towards API exposures is therefore needed to ensure the natural environment is protected. 
In the current ecotoxicological test protocols of APIs on algae (i.e. OECD 201, 2011) (OECD, 
2011), while the cell density has commonly been used as surrogate endpoint for growth, it 
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might be misleading as the unviable cells, having lost their biomass, are still counted over the 
test period (Bellinger and Sigee, 2015). To overcome this defect, photosynthetic endpoints 
such as oxygen evolution rate which are directly related to viable cells might be an alternative 
to replace cell number. In this case, the sensitivity comparison between the endpoints of 
oxygen evolution rate and cell density should be initially clarified. Despite the inhibitory effects 
of APIs on algal growth having been extensively observed, the toxic mechanisms are still 
unclear. As algae are photosynthetic organisms, inhibition of growth might be due to the 
damage of the algal photosynthesis processes (Liu et al., 2011). Effects of APIs on the algal 
physiology such as light-harvesting pigment synthesis and light utilisation efficiency therefore 
warrant further consideration. 
Surface waters are more likely to be exposed to the antibiotic mixtures than single substances 
(Backhaus et al., 2011), so it is vital to assess the combination effects and potential risks of 
antibiotic mixtures in the natural environment. Environmental risk should be assessed on the 
organisms that are likely to protect the broader environment.  
1.4 Aims of the Thesis 
The overall aim of this thesis was therefore to assess the impacts of selected APIs on a wide 
range of algal species. The work was performed using three major use antibiotics and seven 
algal species from the chlorophytes, cyanobacteria and diatom classes. The specific 
objectives were to: 
1. Review the current knowledge regarding the effects of APIs on the growth of algal species 
to explore the evidence base as to whether APIs pose a threat to algae in surface waters 
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and to investigate the algal sensitivity towards API exposures (Chapter 2). 
2. Prioritise APIs in use based on their toxicological and ecotoxicological risks in the natural 
environment and combine the results with findings from objective 1 to target the antibiotics 
for further laboratory study (Chapter 3). 
3. Compare the sensitivity of chlorophytes, cyanobacteria and diatoms to major use 
antibiotics (Chapter 4). 
4. Investigate the effects of antibiotics on the growth and physiology of four of the most 
sensitive species to obtain information on the underlying toxic mechanisms (Chapter 5).  
5. Assess the risks of mixtures of major use antibiotics in the European Union by using the 
most sensitive species identified in earlier Chapters (Chapter 6). 
1.5 Thesis overview 
This thesis comprises seven chapters. A description of each is given below: 
Chapter 2 synthesises the existing knowledge on the toxicity of APIs to algal species and 
communities. This Chapter explores the differences in the sensitivity of a range of algal groups 
to APIs and assessed the potency of commonly used APIs to algae. The data generated are 
combined with predicted exposure levels for APIs in order to establish the potential risks of 
APIs to algal populations. The importance of algae in the ecosystem, potential toxicity 
mechanisms, and a comparison of the risks of APIs to that of herbicides and future 
recommendations are also discussed.  
Chapter 3 describes the development and implementation of a holistic risk-based prioritisation 
approach for pharmaceuticals entering the aquatic and terrestrial environment through 
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wastewater in the UK. The prioritisation approach considered APIs used in primary and 
secondary care, medicines sold over the counter and major pharmaceutical metabolites. Both 
aquatic and terrestrial exposure routes and acute and chronic effects on algae, invertebrates, 
fish, birds, model mammals and humans are considered. The approach was applied to 146 
active ingredients and associated metabolites to identify APIs with high potential risk in the UK 
environment. Combined with the results in Chapter 2, three major use antibiotics, tylosin, 
lincomycin and trimethoprim, were identified for further experimental investigation. 
Chapter 4 explores the sensitivity of seven algal species towards major use antibiotic 
exposures at EC50 levels. Dose-response curves of the target antibiotics were generated for 
seven test species from chlorophytes (Pseudokirchneriella subcapitata, Desmodesmus 
subspicatus and Chlorella vulgaris), cyanobacteria (Synechococcus leopoliensis and 
Anabaena flos-aquae) and diatoms (Navicula pelliculosa and Phaeodactylum tricornutum).  
Chapter 5 investigates the inhibitory effects of the major use antibiotics on the physiological 
endpoints including oxygen evolution rate, chlorophyll a, chlorophyll b, total carotenoid content 
and light utilisation efficiency for the four most sensitive algal species identified in Chapter 4 (P. 
subcapitata, D. subspicatus, A. flos-aquae and N. pelliculosa). The endpoint sensitivity of 
growth and oxygen evolution rate was compared at EC50 levels. The information generated 
was used to explore the potential toxic mechanisms of APIs on algal growth. 
Chapter 6 describes work to determine the combined effects of the major use antibiotics on the 
cyanobacterial species A. flos-aquae. An evaluation of the predictive capability of two mixture 
toxicity models, concentration addition (CA) and independent action (IA), is presented. The CA 
model was then used alongside predictions of exposure for different European scenarios to 
Chapter 1                                                               Introduction 
27 
 
characterize the risks arising from the exposure of European surface waters to the three 
antibiotics. 
Chapter 7 discusses the main findings of the study and the potential implications for 
environment risk assessment approaches. Recommendations for specific studies following on 
from the work in this thesis and for more general studies into API impacts in the environment 
are presented. 
1.6 Study Compounds 
In this thesis, three major use antibiotics, trimethoprim, tylosin and lincomycin are used in the 
experimental investigations. The antibiotics were selected using a prioritisation study based on 
the risk of APIs to a broad range of algal species. The substances represent different groups of 
antibiotics: tylosin is a macrolide; lincomycin is a lincosamide; trimethoprim is a pyrimidine. To 
facilitate the test (high solubility) and to be consistent with published literatures, tylosin tartrate 
and lincomycin hydrochloride were used as the test compounds, but in this thesis these two 
substances are referred to as lincomycin and tylosin. The physico-chemical properties of the 
antibiotics tested are shown in Table 1.1. The maximum occurrences of the three antibiotics 
were found in the US with concentrations of 0.05 (Kim and Carlson, 2007), 0.73 and 0.71 ug 
L-1 (Monteiro and Boxall, 2010) being found for tylosin, lincomycin and trimethoprim, 
respectively.  
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Table 1.1: Physicochemical properties of tylosin, lincomycin and trimethoprim, 
 Tylosin tartrate Lincomycin hydrochloride Trimethoprim 
CAS-no. 1405-54-5 859-18-7 738-70-5 
Structure 
  
 
Molecular weight 
(g mol-1) 
1066.19 443 290.32 
Log Kow 1.63a 0.56b 0.91b  
Pka 7.73c 7.6c  7.12b 
Solubility in H2O Very soluble 
(5X104 mg L-1)d 
Free Soluble d  Slightly soluble 
(400 mg L-1)e  
Mode of action Inhibit bacterial protein 
synthesis by binding to 50S 
ribosomeb  
Inhibit bacterial protein synthesis by 
binding to 50S ribosomeb  
Inhibit dihydrofolate 
reductased   
a. (Loke et al., 2002); b. (Drugbank, 2013); c. (HSDB, 2015); d. (Sigma-Aldrich, 2015); e. (EPA, 
2013). 
1.7 Study species 
Six algal species recommended in the OECD 201 guidelines along with a widely used diatom 
species were chosen as study organisms. Speices included three chlorophytes 
Pseudokirchneriella subcapitata, Desmodesmus subspicatus and Chlorella vulgaris; two 
cyanobacteria Anabaena flos-aquae and Synechococcus leopoliensis; and two diatoms 
Navicula pelliculosa and Phaeodactylum tricornutum. The appearance, characteristics and 
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distributions of test species are shown in Table 1.2. Details of the algal culturing 
methodologies and test procedures are described in Chapter 4 – 6. 
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Table 1.2: Appearance, characteristics and distributions of the algal test species 
 P. subcapitata D. subspicatus C. vulgaris A. flos-aquae S. leopoliensis N. pelliculosa P. tricornutum. 
Strain CCAP 278/4 CCAP 258/137 CCAP 211/11b CCAP 1403/13A CCAP 1405/1 CCAP 1050/9 CCAP 1052/1b 
Test meidum 
and pH 
Kuhl, 6.8 Kuhl, 6.8 Kuhl, 6.8 JM, pH 7.8 JM, pH 7.8 ESAW + f/2, 8.2 ESAW + f/2, 8.2 
Picturea 
  
 
 
   
Appearanceb Curved, twisted single 
cells 
Oval, mostly single 
cells 
 Spherical, single Chains of oval 
cells 
Rods Rods Fusiform, triradiate, and 
ova (paper) 
Size (LXW) 
µmb 
8-14 X 2-3 7-15 X 3-12 3 (diameter)d 4.5 X 3 6 X 1 7.1 X 3.7 n.a 
Cell volume 40-60 60-80 n.a. 30-40 2.5 40-50 n.a 
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(µm3 cell-1)b 
Cell dry weight 
(mg cell-1) b 
2-3 X 10-8 3-4 X 10-8 n.a. 1-2 X 10-8 2-3 X 10-9 
Freshwater/ 
marinea  
Freshwater Freshwater Freshwater Freshwater Freshwater 
Distribution 
reported in the 
literaturec 
Bulgarian, Denmark, 
Egypt, Estonia, 
Finland, Germany, 
Italy, Nigeria, 
Romania, Spain, 
Thailand, 
Britain, Germany, 
New Zealand,  
Romania, Russian, 
Singapore, Spain, 
Taiwan, Turkey. 
Austria, Brazil, Britain, 
Czech Republic, 
Denmark, Egypt, 
France, Germany, 
Ireland, Iran, Mexico, 
New Zealand， 
Netherlands,  
Pakistan,  
Australia, Brazil, 
Britain, China, 
Denmark, 
Germany,  
Israel, Lithuania, 
Nepal,        
New Zealand 
Romania, Russia, 
Norway, US. 
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Romania, Spain, 
Sweden, Taiwan, 
Turkey, US. 
Senegal, Spain, 
Sweden, 
Singapore, US. 
a. (CCAP, 2015); b. (OECD, 2011); c. (AB, 2015); d. (Bionumber, 2015). 
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Chapter 2 
Do pharmaceuticals pose a threat to primary producers? 
2.1 Introduction 
Over the past ten years, our understanding of the environmental fate and effects of APIs has 
increased significantly and numerous published scientific papers relating to the toxicity of APIs 
to non-target organisms are now available (Figure 2.1). These include studies on the 
ecotoxicity of APIs to fish and invertebrates and a number of syntheses have discussed data 
on these taxonomic groups (Nentwig, 2007, Corcoran et al., 2010). However, while data are 
available on the toxicity of many APIs to algae (around a third of published papers out of all 
toxicity studies; Figure 2.1), no attempt has been made to synthesise and make sense of this 
information. This Chapter therefore brings together available information on the toxicity of APIs 
to algae and use this information to explore differences in sensitivity of a range of algal groups 
and also differences in potency of common API groups to algae. The data are also used 
alongside exposure predictions to establish the potential risks of APIs to algal populations. 
Finally gaps in our current knowledge are identified and recommendations provided on 
priorities for future research.  
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Figure 2.1 Published paper numbers of algae and all the standard toxicity organisms including 
algae, fish and invertebrates identified by Web of Science (2014). Term 1: (Algae AND ecotox* 
AND (antibiotic OR pharmaceutical OR medicine)); Term 2: (Algae OR fish OR daphni* OR 
invertebrate*) AND ecotox* AND (antibiotic OR pharmaceutical OR medicine) 
2.2 Why are algae important? 
Algae are widely distributed in aquatic ecosystems, and comprise a large proportion of the 
aquatic biomass. Supplying food to the early larval stages of animals such as molluscs and 
fish, algae are an essential component of aquatic food chains (Lai et al., 2009). Detrimental 
effects of a compound on algae could therefore pose a potential threat not only to algal 
populations but also to higher trophic levels. Algal groups also perform important ecosystem 
functions. For example, cyanobacteria perform a nitrogen-fixing role in the marine environment. 
Cyanobacteria filaments contain cells that specialize in photosynthesis and heterocysts that 
can fix nitrogen, and in the nitrogen cycle they convert dinitrogen gas to more easily 
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assimilated forms for organisms such as ammonia (Amin et al., 2012). Like other plants, algae 
produce a large amount of oxygen as a by-product of photosynthesis. If they are destroyed, 
other aquatic organisms could therefore be adversely affected due to an oxygen shortage 
(DeLorenzo and Fleming, 2008, Larned, 2010, Backhaus et al., 2011). 
While algae play a pivotal role in nutrient cycling, they can also cause negative effects on 
ecosystems. Harmful algal bloom (HAB) events have been reported worldwide that negatively 
affect human health and the ecosystem balance (Fire et al., 2011, Laycock et al., 2012, 
Capper et al., 2013). Potent algal toxins produced by toxic HABs can cause mortality and 
morbidity in humans and aquatic organisms and the decomposition of the bloom also results in 
a drastic reduction in dissolved oxygen (Laycock et al., 2012). 
2.3 Why might algae be vulnerable to pharmaceutical exposure? 
Pharmaceuticals are designed, and used, to prevent and cure diseases and improve the 
quality of life of humans and animals. The principal way in which they do this is by interacting 
with receptors and pathways inside the human or animal or in infectious organisms such as 
bacteria and fungi (Boxall, 2004). Many of these receptors and pathways might be conserved 
in other organisms in the natural environment (Boxall, 2004). Some evidence has been 
presented in the literature indicating that receptor conservation will occur in algae and that 
therefore subtle effects could be expected. For example, Brain et al. (2008) reported that a 
very high degree of homology existing between the chloroplast and bacteria in terms of 
general translation factors and most of the ribosomal proteins (through phylogenetic analysis) 
infering that numerous basic processes of translation are conserved in both bacteria and the 
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chloroplast. As macrolide and lincosamide antibiotics hinder protein synthesis by interacting 
with the peptidyl transferase domain of bacterial 23S rRNA, and aminoglycosides block 
bacterial protein synthesis by irreversibly binding to 30S and 50S subunits of ribosomes, these 
might disrupt transcription/translation in the chloroplasts of photosynthetic organisms such as 
green algae (Brain et al., 2008b). 
Statins are a class of pharmaceuticals that decrease total cholesterol and low-density 
lipoprotein cholesterol (LDLc). They are highly specific inhibitors competing with 
3-hydroxy-3-methylglutaryl coenzyme-A reductase (HMGR), which is the rate-limiting enzyme 
in cholesterol biosynthesis. In plants, HMGR is also an essential enzyme that regulates the 
mevalonic acid (MVA) pathway of isoprenoid biosynthesis, and as in humans, statins inhibit 
this enzyme (Brain et al., 2008a). The MVA pathway is also present in the red alga Cyanidium 
caldarum and the diatom Ochromonas danica (Lange et al., 2000), and this may therefore 
represent one potential toxicity mechanism of statins to algae.  
2.4 Indirect effects from bacteria 
Algae could also be affected by a pharmaceutical indirectly as a result of toxicity of some 
pharmaceuticals to bacterial species. Algae (especially diatoms) and bacteria have co-existed 
for more than 200 million years, resulting in synergistic interactions between them (Liu et al., 
2012). One such interaction between diatoms and bacteria is the way that bacteria produce 
and supply vitamins, such as Cobalamin, or vitamin B12, to different diatom species. Croft et al. 
(2005) demonstrated that more than half of diatoms investigated cannot grow in B12-limited 
medium, and they also confirmed that bacteria provide vitamins to most B12-auxotrophic 
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phytoplankton in exchange for fixed carbon (Croft et al., 2005).  
In natural aquatic environments, bacteria are usually embedded in a biofilm (microbial cells 
immobilised in a matrix of extracellular polymers acting as an independent functioning 
ecosystem, homeostatically regulated) (Percival et al., 2011). In this form, bacteria obtain 
benefits such as the sharing of metabolic capabilities, niche separation and resistance against 
toxic substances. However, a variety of antibiotics (e.g. amoxicillin and erythromycin) at 
environmentally relevant concentrations (µg L-1) can block the initial adhesion of bacteria (first 
step for biofilm formation), especially for amoxicillin which strongly inhibits the adhesion of 
Escherichia coli and Aquabacterium commune (Schreiber and Szewzyk, 2008). A range of 
antibiotics also show their own capacity to damage bacteria. Polymyxins alter bacterial outer 
membranes irreversibly by dissolving the fatty acid portion in its hydrophobic region; 
chloramphenicol behaves through a bacteriostatic action by inhibiting the peptidyl transferase; 
aureomycin inhibits bacterial protein synthesis by combining with the small (30S) subunit of 
the ribosomes - all these antibiotics have been shown to be toxic to luminescent bacterium 
(Duggar, 2011, Ji et al., 2013). Though toxicity of these antibiotics to bacteria is observed at 
the experimental scale, similar damage mechanisms are also likely to occur in bacteria that 
supply nutrients to algal species in the natural environment. Evidence for API effects on algae 
is presented in the next section. 
2.5 Ecotoxicological effects of pharmaceuticals on algae 
A wide range of data on the ecotoxicity (EC50) of APIs to various algal species is now available. 
Table 2.1 summarises all the published ecotoxicity data covering 350 pharmaceuticals and 
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related products from 43 therapeutic classes for different algal species (the original toxicity 
data extracted from published literature and databases are shown in Tables A.1 to A.4 
(Appendix 1). Most of the research summarised in Tables A.1 to A.4 (Appendix 1) was 
undertaken using the OECD (2011) Guidelines for alga growth inhibition tests (72h/ 96h 
duration, biomass yield/ growth rate endpoint; nominal/ measured concentration used for test 
is indicated as a footnote in Tables A.1 to A.4, Appendix 1). In the tests, nine species of 
chlorophytes have been used, three species of cyanobacteria, three algal communities and 
one diatom species (Tables A.1 to A.4, Appendix 1). 
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Table 2.1 Summary of ecotoxicity data of pharmaceuticals to algae 
Pharmaceutical 
class 
Mode of action for human Example of pharmaceuticals in 
this class 
 EC50 range (mg L
-1) 
Chlorophy- 
tes 
Cyanobacteria Others 
(e.g. 
diatom) 
Analgesic Inhibit both isoforms of cyclooxygenase, COX-1, COX-2, and COX-3 enzymes involved in 
prostaglandin (PG) synthesis 
Fentanyl 
Paracetamol 
0.98-134   
Androgenic  Activate the androgen receptor; activate certain estrogen receptors by conversing to 
estradiol 
Testosterone 
 
0.5   
Anesthetic Block the sodium-channel and decrease chances of depolarization and consequent 
action potentials 
Prilocaine 
Ropivacaine, 
 
0.045- 
154 
  
Antiarrhythmic Inhibit voltage gated sodium (Na+) channels Lidocaine 
Dronedarone 
0.045- 
780 
0.25  
 Na, K-activated myocardial adenosine triphosphatase Amiodarone    
Antiasthmatic Antagonize leukotriene D4 (LTD4) at the cysteinyl leukotriene receptor Montelukast 
 
 100   
Antibiotic Inhibit ptidyl transferase; inhibit amino acids  (Macrolide) 
Clarithromycin Erythromycin,  
Tylosin,  
0.002- 
1.38 
0.034  
 Inhibit cell-wall synthesis enzyme  (β-lactam) 
Amoxicillin,  
Cefradine 
1.77- 
630 
0.0022- 
1.38 
 
 N.A. Chloramphenicol 
Florfenicol 
0.1- 
1283 
 1.3-38b 
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Thiamphenicol 
 Inhibit DNA gyrase  (Fluoroquinolone) 
Levofloxacin 
7.4   
 Inhibit peptide bond formation  (Lincosamide) 
Lincomycin 
0.07   
 Inhibit bacterial nucleic acid synthesis  (nitroimidazole) 
Metronidazole 
39.1   
 Inhibit water reabsorption in the nephron by blocking sodium-potassium-chloride 
cotransporter (NKCC2)  
(Sulfonamides) 
Furosemide 
 
322.2   
 Inhibit the protein synthesis by binding of tRNA to the mRNA-ribosome (Tetracycline) 
Minocycline, Tetracycline 
0.31 0.09-0.24  
 Inhibit the enzymatic conversion of pteridine and p-aminobenzoic acid (PABA) to 
dihydropteroic acid 
(Sulfamethoxazole) 
Bactrim (mixture) 
70 112  
 Inhibit dihydrofolate reductase Trimethoprim 
 
9   
 
 
Block 30S ribosomal subunit of susceptible organisms  Streptomycin 
 
0.13- 
20.08 
0.28  
Anticholinergic  Inhibit cholinesterase Galantamine 100   
Anticoagulant Inhibit vitamin K reductase Warfarin  
 
11   
Anticonvulsant Inhibit voltage-sensitive sodium channels and/or calcium channels  Carbamazepine 
Lamotrigine, 
Topirmat 
4.48- 
100 
  
Antidementia Inhibit butyrylcholinesterase and acetylcholinesterase Rivastigmine 83   
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Antidepressant Inhibit serotonin reuptake  Fluoxetine, 
Sertralin,  
Trimipramine  
0.027- 
240 
 0.038a 
 Inhibit serotonin-norepinephrine reuptake Duloxetine 
 
 
0.2   
 Block dopamine uptake Bupropion  0.95   
Antidiabetic Reduce potassium conductance and cause depolarization of membrane on the 
pancreatic cell surface 
Glimepiride 
Metformin 
 
320- 
1000 
  
 Inhibit dipeptidyl peptidase-4 (DPP-4)  Sitagliptin 
 
39   
Antidiarrheal Inhibit peristaltic activity of intestine and affect water and electrolyte movement through 
the bowel 
Loperamide 
 
54-76   
Antiemetic Inhibit 5HT-3 receptor Aprepitant 
Granisetron 
0.18- 
22.6 
  
Antifungal Block cytochrome P-450 dependent enzyme, sterol 14α-demethylase  Itraconazole 
Posaconazole, 
 
0.19- 1000 1000  
 Inhibit sterol ergostol Clotrimazole 
Ketoconazol 
0.0032  0.15a 
 Inhibit bacterial Fatty Acid Synthesis Triclosan 0.0036  0.34a 
 Disrupt membrane transport by blocking the proton pump Zinc-Pyrithione  
 
  0.0023a 
Antihistamine Compete with free histamine for binding at H1-receptors in the GI tract  Fexofenadin  
Levocabastine 
0.7-200 32  
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Loratadine 
Antihyperlipidemic Inhibit cholesterol absorption  Ezetimibe 
 
4   
 Inhibit 3-hydroxy-3-methylglutaryl coenzyme Simvastatin 
 
22.8   
Antihypertensive Block angiotensin-receptor; Candesartan 
Irbesartan 
56-460   
 Interfere with the binding of  angiotensin II to the angiotensin II AT1-receptor Telmisartan 
 
 
9.88   
 Antagonize Alpha1-receptor Terazosin 160   
 Inhibit angiotensin converting enzyme (ACE) Captopril 
Ramipril 
 
100-168   
 Block catecholamine stimulation of β1-adrenergic receptors Atenolol, 
Pindolol 
Propranolol 
5.8-620  0.084a 
 Block alpha-adrenergic receptors in the lower urinary tract   Alfuzosin 0.7- 
52.7 
  
Anti-inflammatory Inhibit phospholipase A2 inhibitory proteins  Mometasone 3.2   
 N.A. Budesonide 8.6   
 Inhibit leukocyte migration and the enzyme cylooxygenase (COX-1 and COX-2)  Diclofenac 
Ibuprofen 
Naproxen 
10-320  7.1c 
Antilipemic Activate peroxisome proliferator activated receptor a (PPARa)  Lipanthyl 
 
0.102   
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 Inhibit hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase Rosuvastatin 330   
Antimalarial Interact with heme Lariam (mixture) 
Mefloquine, 
0.16- 
0.33 
  
Antineoplastic Alkylate DNA and lead to single and double-strand DNA breaks and apoptotic cell death  Temozolomide 
 
90   
 Inhibit inosine monophosphate dehydrogenase (IMPDH)  Mycophenolate mofetil 
 
0.068   
 Inhibit Epidermal growth factor receptor (EGFR) tyrosine kinase Gefitinib 
Imatinib 
 
1.02- 
2.5 
  
 Inhibit proteasome  Bortezomib 
 
0.3   
 Inhibit DNA synthesis and cytotoxicity Gemcitabine  
Nelarabine 
5.4-100   
 Inhibit mitotic and interphase cellular functions  Cabazitaxel 
 
0.013   
 Inhibit tyrosine kinase  Nilotinib 0.016   
Antiobesity Inhibit pancreatic lipase orlistat 1.92   
Antiparkinsonian Stimulate dopamine receptors Pramipexol 
Ropinirole 
29.3- 
240 
  
Antiplatelet Prevent binding of adenosine diphosphate (ADP) to its platelet receptor Clopidogrel 
 
0.85   
Antipsychotic Block 5-HT2 receptors clozapine 
Olanzapine 
Paliperidon 
2.5- 
141 
  
Antiretroviral Inhibit reverse transcriptase  Efavirenz 0.012- 0.76  
Chapter 2                                                                                 Do pharmaceuticals pose a threat to primary producers?                 
44 
 
 Lamivudine 
Nevirapine 
96.9 
 Inhibit protease  Darunavir 
Telzir 
43-100   
Antirheumatic 
 
Inhibit pyrimidine synthesis Leflunomide 
 
22.4   
Antispasmodic Block muscarinic receptors Butylscopolamine  80   
Antithrombotic Inhibit phosphodiesterase Dipyridamole 2.36   
Antitusivo Stimulate synthesis and release of surfactant by type Ⅱ pneumocytes Ambroxol 25.6   
Antiulcer Block a non-imidazole histamine receptors   Esomeprazole 
Omeprazole 
Ranitidine 
85-150   
Antiviral 
 
Inhibit viral DNA polymerase  Acyclovir 
 
99   
 Inhibit influenza virus neuraminidase  Oseltamivir 
 
463   
 Inhibit viral replication process Entecavir 110   
 Block nucleic acid synthesis Ribavirin 100   
 Inhibit nonpeptidic protease Tipranavir 40.4   
Anxiolytic Inhibit neurotransmitter gamma-aminobutyric acid (GABA) Midazolam 
 
11.4   
Bronchodilator Stimulate beta2-adrenergic receptor Terbutaline 
Salmeterol 
2.8- 500   
Calcium regulator Inhibit farnesyl pyrophosphate (FPP)enzyme Ibandronate 
Zoledronic acid  
diltiazem 
0.76-15   
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Cardiovascular Compete with adrenergic neurotransmitters Metoprolol 
Seloken 
 
7.3- 
58.3 
  
Diuretic n.a. Furosemide 322   
Iron Chelating 
Agents 
Bind ferric iron to form a stable complex  Deferasirox  0.32   
Hypnotics Potentiate gamma-aminobutyric acid (GABA) Zolpidem 2.2   
Immunosuppressive Inhibit calcineurin, lymphokine and interleukin Ciclosporin 
 
100   
 Inhibit mammalian target of rapamycin (mTOR) Everolimus 16   
Psychoanaleptics n.a. Methylphenidate 6   
Vasodilator Activate of enzyme guanylate cyclase Glyceryl trinitrate 0.4   
N.A. not available; Bracket shows the subcategory of antibiotics. 
a Natural community 
b Isochrysis galbana (Isochrysis) (Lai et al., 2009) 
c Skeletonema costatum (Diatom) 
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The EC50 values range from 0.002 mg L
-1 (clarithromycin to chlorophyte Pseudokirchneriella 
subcapitata) (Isidori et al., 2005) to 1283 mg L-1 (Thiamphenicol to chlorophyte Chlorella 
pyrenoidosa; (Lai et al., 2009) with many compounds not causing any toxicity at the highest 
concentrations tested. Antibiotics (e.g. macrolide and β-lactam) from classes operating with 
different modes of action show high toxicity to algal species. Other pharmaceutical classes, 
including compounds from the analgesic, androgenic, anesthetic, antiarrhythmic, 
antidepressant, antifungal, antihypertensive, antilipemic, antimalarial, antineoplastic, 
antiplatelet, antiretroviral, calcium regulator, iron chelating agents and vasodilator groups also 
exhibit high toxicity with EC50 values below 1 mg L
-1 for selected compounds and species. The 
toxicity data extracted from the Swedish Fass (2012) database are mainly for pharmaceutical 
products, and their ingredients are listed in a separate column in Tables A.1 to A.2 (Appendix 
1). Some pharmaceutical products are mixtures of APIs e.g. Bactrim (sulfamethoxazole and 
trimethoprim) and Riamet (artemether and lumefantrine), as it is uncertain which ingredient is 
tested, the toxicities of these products are listed separately (Tables A.1 to A.2, Appendix 1). 
Therapeutic classes with more than 4 sets of toxicity data to algae were selected and 
compared by using EC50 values (Figure 2.2). Previous algal toxicity tests were mainly focused 
on antibiotic, antidepressant, antifungal and antineoplastic, however the values cover a wide 
range (e.g. antibiotic EC50 varies from 0.01 to 1000 mg L
-1). Antiretroviral, antifungal and 
antibiotic were all found at EC50 values less than 0.01, but there are also antibiotics with 
available data in this range (Figure 2.2). Cytochrome p450 (CYP) is primarily responsible for 
drug metabolism in some higher trophic levels organisms (e.g. human and fish), and occurs in 
some algal species (e.g. chlorophyte Chlamydomonas reinhardtii; (Gangl et al., 2015). While a 
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range of pharmaceuticals (e.g. ketoprofen and fluoxtine) were observed to inhibit the 
cytochrome P450 activity in human and fish liver microsomes (Jenkins et al., 2011, Smith et al., 
2012), no evidence linking the traditional ecologically endpoint (e.g. growth) and this specific 
molecular level responses has been currently reported (Boxall et al., 2012).  
EC50 values (mg L-1)
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Figure 2.2 Toxicity value comparisons for selected therapeutic classes of pharmaceuticals 
A large number of data were obtained on two chlorophytes Pseudokirchneriella subcapitata 
(previously known as Selenastrum capricornutum) and Desmodesmus subspicatus (previously 
known as Scenedesmus subspicatus) following the OECD (2011) Guidelines (Tables A.1 to 
A.2, Appendix 1). Other algal species have also been used for testing such as isochrysis 
(antibiotics to Isochrysis galbana (EC50 1.38-38 mg L
-1; (Lai et al., 2009) and diatoms 
(anti-inflammatory to Skeletonema costatum (EC50 7.1 mg L
-1; (Halling-Sorensen et al., 1998), 
but the data are few. Some data are also available on the effects of APIs (antifungals and 
antidepressants) on natural algal communities with EC50 values ranging from 0.0023 to 0.34 
mg L-1 (Tables A.1 to A.4, Appendix 1). In terms of tested algal species, only chloramphenicol, 
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oxytetracycline, streptomycin, diclofenac and amoxicillin have been tested on three or more 
algal species with ecotoxicity values ranging from 0.007 (streptomycin to M. aeruginosa; 
(Halling-Sorensen, 2000) to 630 mg L-1 (amoxicillin to P. subcapitata; (Fass.se, 2011). While 
the available ecotoxicity data on chloramphenicol, oxytetracycline and diclofenac only focus on 
chlorophytes, their toxicity data varies considerably (e.g. chloramphenicol, EC50 0.1 – 41 mg 
L-1; (Sanchez-Fortun et al., 2009, Goncalves Ferreira et al., 2007).  
2.6 Environmental risk assessment (ERA of active pharmaceutical ingredients (APIs) to 
algal species 
From the previous section it appears that some APIs are highly toxic to algal species. 
Therefore in this section, to assess whether this toxicity could be realised in the natural 
environment under typical usage scenarios, the environmental risk assessment guidelines 
proposed by the European Medicines Agency (EMEA) for human and veterinary 
pharmaceuticals are used alongside the ecotoxicity data discussed in the previous section, to 
estimate the level of risk to algal communities.  
Data on the amount/or sales of human pharmaceuticals were obtained from the Prescription 
Cost Analysis (PCA) (2011) in England (NHS, 2012). Using data on usage the potential 
amounts of APIs released to environment were estimated. Exposure concentrations of APIs in 
the aquatic environment were estimated separately for human and veterinary use compounds 
(EMEA, 2006, EMEA, 2008). 
Predicted Environmental Concentration (PECsurfacewater) values for human pharmaceuticals 
were calculated using Equation 2.1 (EMEA, 2006). 
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PECSURFACEWATER =                        Equation 2.1
𝑐𝑜𝑛𝑠𝑢𝑚𝑝𝑡𝑖𝑜𝑛
𝑊𝐴𝑆𝑇𝐸𝑊𝑖𝑛ℎ𝑎𝑏 ×  𝐷𝐼𝐿𝑈𝑇𝐼𝑂𝑁 × 𝑖𝑛ℎ𝑎𝑏𝑖𝑡𝑎𝑛𝑡𝑠 × 365
Where WASTEWinhab: Amount of wastewater per inhabitant per day, default value, 200, [L 
inh-1 d-1]; DILUTION: Dilution factor, default value, 10; PECSURFACEWATER: Local surface water 
concentration, [mg L-1]; Consumption: the total quantity of an active molecule consumed in a 
defined area, [mg year-1]; Inhabitants: the population in UK, 62641000 in 2011. The 
PECsurfacewater results for human pharmaceuticals are listed in Tables A.1 to A.4 (Appendix 1). 
The PECsurfacewater for veterinary usage (listed in Table 2.2) were calculated using Equation 2.2 
(EMEA, 2008):
PECSURFACEWATER =                     Equation 2.2
380.46 × 𝑆𝑂𝐿 × 𝐷 × 𝐴𝐷 × 𝐵𝑊 × 𝑃 × 𝐹ℎ
𝑁𝑦 × 𝐻 × (𝑉𝑃 × 𝑀𝑊 + 2369.49 × 𝑆𝑂𝐿 + 355.42𝐾𝑜𝑐)
Where D = Daily dose of the active ingredient [mg.kgbw-1.day-1]; Ad = Number of days of 
treatment [d]; BW = Animal body weight [kgbw], calves 140kg, cattle 450kg and pig 12.5kg; P 
= Animal turnover rate per place per year [place-1.year-1], calves 1.8, cattle 1 and pig 6.9; Fh = 
Fraction of herd treated, 1 for antibiotics (feed and water medication) and 0.5 for antibiotics 
(injectable); Ny= Nitrogen produced in one year per place [kg.N.place-1.year-1], calves 10, 
cattle 35 and pig 2.25; H = housing factor, calves 1, cattle 0.5 and pig 1; VP = Vapour 
pressure [Pa]; MW = Molar mass [g.mol-1]; SOL = Water solubility [mg.L-1]; Koc = water-
organic carbon distribution coefficient [1.kg]. The information on daily dose of the active 
ingredient and number of days of treatment were identified from Compendium of Data Sheet 
for Animal Medicines (NOAH, 2011). Vapour pressure, water solubility and Koc were 
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the Environment Protection Agency EPI suite software (4.1 version; (EPA, 2013)).  
Table 2.2 Toxicity of veterinary pharmaceuticals and environmental risk assessment to algae 
Species Pharmaceuticals Test duration EC50 
(mg L-1) 
Reference PEC 
(mg L-1) 
PEC:PNEC 
ratio* 
Chlorella pyrenoidosa Florfenicol  
 
72h 
 
215 
 
(Lai et al., 
2009)1 
0.046 
 
0.021 
Chlorella vulgaris 
 
Oxytetracycline 48h 6.4 (Pro et al., 
2003)3 
0.00021 0.0033 
Desmodesmus 
subspicatus 
Paracetamol 
 
72h 
 
134 
 
(FASS, 2012)3 0.09 
 
0.067 
 
Microcystis aeruginosa 
 
Amoxicillin 7d 0.008 (Liu et al., 
2012)3 
0.0099 122.98 
Amoxicillin 
 
7d 
 
0.0037 
  
(FASS, 2012)3 0.0099 
 
266.9 
 
Tetracycline  
Tiamulin  
Tylosin  
72h 
72h 
72h 
0.09  
0.003  
0.034  
(Halling-Soren
sen, 2000)2 
0.00017 
0.0033 
0.0035 
0.19 
108.25 
10.42 
Pseudokirchneriella 
subcapitata 
 
Oxytetracyline 
Trimethoprim 
Tylosin 
 
Erythromycin 
Lincomycin 
Oxytetracyline 
 
Amoxicillin 
Chlortetracycline  
Fentanyl 
Tetracycline  
Tiamulin  
Tylosin  
72h 
72h 
72h 
 
72h 
72h 
72h 
 
72h 
72h 
72h 
72h 
72h 
72h 
0.6 
9  
0.0089  
 
0.02  
0.07  
0.17  
 
630 
3.1  
15.1 
2.2  
0.17 
1.38  
(van der 
Grinten et al., 
2010)2 
 
(Isidori et al., 
2005b)3 
 
 
(FASS, 2012)3 
0.00021 
0.49 
0.0035 
 
0.0093 
0.044 
0.00021 
 
0.0099 
0.00016 
5.7E-06 
1.7E-4 
0.0032 
0.0035 
0.035 
5.46 
39.81 
 
46.56 
62.46 
0.12 
 
0.0016 
0.0053 
3.77E-05 
0.0076 
1.97 
0.26 
Scenedesmus 
obliquus 
Enrofloxacin 
 
72h 
 
45.1 
 
(Qin et al., 
2012)3 
2.29E-05 5.09E-05 
Synechococcus 
leopoliensis 
Amoxicillin  
  
96d 
 
0.0022    
 
(FASS, 2012)3 0.0099 
 
444.84 
 
Tetraselmis chuii 
 
Florfenicol  
Oxytetracyline  
96h 
96h 
6.06 
11.18     
(Goncalves et 
al., 2007)3 
0.046 
0.00021 
0.76 
0.0019 
*PNEC= EC50/100 
1 real concentration used; 2 nominal concentration used; 3 unknown 
As the PEC human pharmaceutical calculation relies on API usage data and the PEC 
veterinary pharmaceuticals are calculated by using daily dose and treatment days, as well as 
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other different factors and parameters considered in Equation 2.1 & 2.2, two PEC values are 
obtained. Usually the PEC value calculated for veterinary pharmaceuticals is higher than for 
human pharmaceuticals (e.g. trimethoprim PEChuman 0.00019 mg L
-1 and PECveterinary 0.49 mg 
L-1; amoxicillin PEChuman 0.0022 mg L
-1 and PECveterinary 0.0099 mg L
-1). 
Effluent from the Waste Water Treatment Plants (WWTPs) receiving sewage from 
pharmaceutical manufacturing sites and hospitals are another important source of APIs 
entering the environment. To assess the contribution of APIs emitted from each source and 
their potential risk, a wide range of literature sources were used to identify the measured 
environmental concentrations (MEC) of pharmaceuticals in WWTPs receiving sewage from 
municipal, hospital, manufacture and livestock. APIs with available MEC in effluent from 
different sources and toxicity data to algae were collated and illustrated in Table 2.3 (if more 
than one MEC is available, the highest value is cited). 
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Table 2.3 Risk assessment for pharmaceuticals in WWTP effluent receiving wastewater from municipal, hospital, manufacture and livestock 
Pharmaceuticals EC50* 
(mg L-1) 
Municipal MEC 
(ug L-1) 
Hospital 
MEC 
(ug L-1) 
Manufacture 
(ug L-1) 
Livestock 
(ug L-1) 
Municipal 
RQ 
Hospital RQ Manufacture 
RQ 
Livestock 
RQ 
Trimethoprim 9 0.61 295 9.035 23.65 0.0067 0.32 0.1 0.26 
Carbamazepine 49.4 1.521 3.565 51.75 n.a 0.0031 0.0072 0.1 n.a 
Erythromycin 0.02 0.052 0.946 55 0.15 0.25 4.69 25 0.51 
Ibuprofen 7.1 0.143 0.287 45.876 n.a 0.0019 0.004 0.65 n.a 
Naproxen 31.82 0.352 0.76 505 1.777 0.0011 0.0022 0.16 0.0056 
Diclofenac 10 0.354 0.336 505 0.195 0.0035 0.0033 0.5 0.0019 
Tetracycline 0.09 n.a 0.0896 0.0256 1.137 n.a 0.099 0.028 1.25 
Enrofloxacin 45.1 0.174 0.0265 55 0.595 3.7E-4 5.7E-5 0.011 0.0013 
Chlortetracycline 0.05 n.a 0.225 0.685 2.825 n.a 0.44 1.36 5.64 
Florfenicol 6.06 n.a n.a 55 18.85 n.a n.a 0.083 0.31 
Lincomycin 0.07 n.a 29.85 14.835 6155 n.a 42.57 21.19 878.57 
Penicillin G 0.006 n.a n.a 15 13.55 n.a n.a 16.67 225 
1. (McEneff et al., 2014), Ireland; 2. (Moreno-Gonzalez et al., 2014), Spain; 3. (Ortiz de Garcia et al., 2013), Spain; 4. (Collado et al., 2014), Spain; 5. (Sim et al., 2011), Korea; 6. (Lin and Tsai, 2009), 
Taiwan; 7. (Lin et al., 2008), Taiwan; 
* EC50 is the lowest value of pharmaceuticals derived from Table A1.1 to A1.4, Appendix 1. PNEC= EC50/100 
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Predicted no-effect concentration (PNEC) (for both human and veterinary) is defined as the 
level of concentration at which no negative effects are observed (NOEC), added to an 
assessment factor (AF) (Equation 2.3). Here, NOEC is replaced by EC50 (50% of the tested 
organisms are affected); An AF is used to reduce the level of uncertainty, a default value of 100 
was applied by considering inter-species variations of differences in sensitivity (10) and 
laboratory data to field impact extrapolation (10) (EMEA, 2006). While the OECD 201 
Guidelines are followed by most studies, the statistic toxicity value EC50 still varies due to 
different testing conditions, devices and models used to fit dose-response curves. In this case, 
the lowest EC50 values were used for conservative risk assessment. 
 
PNEC = EC50/AF                                                        Equation 2.3 
 
The environmental risk of pharmaceuticals to algal species is characterised through a risk 
quotient (RQ; equation 2.4; MEC was used to replace PEC to assess risk for other emission 
sources). The results are listed in the Tables A.1 to A.4, Appendix 1). 
 
RQ = PEC/PNEC                                                        Equation 2.4 
 
The RQ value will be compared against a value of one, with a value less than one predicting 
that no toxicity of APIs to algae in aquatic environments is observed (EMEA, 2006, EMEA, 
2008). Those compounds identified as having potential risks were considered to be high 
priority for investigation of their impact on algal species. 
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The ERA results of pharmaceuticals for human use show that the risk characterisation ratios 
(RQ) for clarithromycin, erythromycin and amoxicillin are above one. The high RQ values of 
the first two APIs are due to their high ecotoxicity to the chlorophyte P. subcapitata (EC50 0.002 
mg L-1 and 0.02 mg L-1; (Isidori et al., 2005). The high RQ value for amoxicillin is due to the 
sensitivity of the cyanobacteria M. aeruginosa (EC50 0.008 mg L
-1; (Liu et al., 2012). Tiamulin 
and amoxicillin are the two veterinary pharmaceuticals with the highest RQ values, 108.25 and 
444.84, respectively (Table 2.2), followed by lincomycin (62.46), erythromycin (46.56), tylosin 
(39.81) and trimethoprim (5.46) all with RQ values above one. The RQ values of 
pharmaceuticals for human and veterinary use are synthesised and compared in Table 2.4. 
The high RQ values (>1) are only seen for three human pharmaceuticals; whereas six 
pharmaceuticals for veterinary use show high RQ values (>1), five of which have RQ values 
greater than 10. When comparing RQ values with other published pharmaceutical ranking 
studies, agreement can be found for some pharmaceuticals such as ibuprofen with a PEC: 
PNEC ratio 0.06 (Escher et al., 2011), 0.0018 (this study). However, in some cases large 
discrepancies are observed e.g. clarithromycin 0.035 (Escher et al., 2011) and 12.33 (this 
study). While Escher et al. (2011) used the lowest QSAR-based EC50 values from either fish, 
daphnia or algae for the PNEC calculation, the real environment risk would be vastly 
underestimated due to the predicted toxicity data.  
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Table 2.4 Classification of risk quotients of pharmaceuticals for human and veterinary use 
PEC:PNEC 
ratio range 
Human pharmaceuticals Veterinary pharmaceuticals 
>10 Clarithromycin, Amoxicillin Tylosin, Erythromycin 
Lincomycin, Tiamulin, 
Amoxicillin 
1 - 10 Erythromycin Trimethoprim  
0.1 - 1 Oxytetracycline, Mycophenolate mofetil, Fluoxetine, Propranolol Florfenicol, Oxytetracyline, 
Tetracycline 
0.01 – 0.1 Ibuprofen, Clotrimazole, Diclofenac, Dronedarone, Duac (mixture), 
Tetracycline,   Ketoconazole, Lincomycin, Dipyridamole, 
Paracetamol, Benzoyl peroxide, Duloxetine, Fusidic acid, 
Paracetamol 
 
< 0.01 Minocycline, Metformin, Simvastatin, naproxen, Asasantin Retard, 
Felodipine, Penicillin G, Trimethoprim, Cefradine, Carbamazepine, 
Ceftazidim, Testosterone, ceftazidim, Metoprolol, Alfuzosin, 
Metronidazole, Ranitidine, Bupropion, Mefloquine, Clobetasol, 
Irbesartan, Mometasone, Omeprazol, Ezetimibe, Lamotrigine, 
Risedronic acid, Gluceryl trinitrate, Ofloxacin, Telmisartan, Atenolol, 
Bisoprolol, Sitagliptin, Warfarin, Deferasirox, Tadalafil, Zolpidem, 
Ibandronate, Furosemide, Ramipril, Lidocaine, Fexofenadine,  
Irbesartan, Amiodarone, Sertralin, Eprosartan, Candesartan, 
Econazole, Orlistat, Chloramphenicol, Budesonid, Naproxen, 
Sumatriptan, Lamotrigine, Carvedilol, Trimipramine, Esomeprazole, 
Levofloxacin, Riluzol, Posaconazole, Methylphenidate, 
Butylscopolamine, Etravirine, Fusidic acid, Levofloxacin, 
Noretisteron, Streptomycin, Triclosan, Montelukast, Valaciclovir, 
Loperamide, Leflunomide, Sumatriptan, Risperidone, Olanzapine, 
Captopril, Ropinirole, Zolpidem, Olanzapine, Omeprazole, Ropinirole, 
Fexofenadine, Galantamin, Loratadine, Acyclovir, Midazolam, 
Cefuroxime, Flagyl, Budesonide, Aprepitant, Rivastigmine, 
Furadantin, Pindolol, Mometasone, Valaciclovir, Pindolol, Xyloproct 
(mixture), Lamivudine, Atazanavir, Metronidazole, Terazosin, 
Amiodarone, Risperidone, Qlaira (mixture), Budesonide, Cefuroxime, 
Glimepirid, Symbicort (mixture), Foradil (mixture), Ribavirin, 
Ceftriaxone, Imatinib, Riamet (mixture), Leflunomide, Fentanyl, 
Kivexa (mixture), Itraconazole, Ciclosporin, Naratriptan, Oseltamivir, 
Salmeterol, Nevirapine, Pramipexol, Moxonidine, Lamivudine, 
Abacavir, Darunavir, Yasmin (mixture), Cefuroxime, Terbutaline, 
Paliperidon, Atacand Plus (mixture), Ertapenem, Bambuterol, Telzir, 
Granisetron, Lidocaine, Glimepirid, Granisetron, Paliperidon, 
Moxonidine, Rivastigmine, Entecavir, Tipranavir, Xylocain (mixture), 
Zoledronic acid, Formoterol, Prilocaine, Glibenclamide, Sorafenib, 
Chlortetracycline, 
Enrofloxacin, Fentanyl 
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Nelarabine, Livocabastine, Temozolomide 
The RQ values obtained from four diverse sources using MEC of pharmaceuticals in WWTPs 
effluent receiving sewage from municipal, hospital, manufacture and livestock are synthesised 
and contrasted in Figure 2.3. It can be seen that pharmaceuticals measured in livestock and 
manufacturing, are the two main sources exhibiting high RQ values. For lincomycin and 
penicillin G RQ values are even above 10. In some cases hospital effluent exhibits high RQ 
values (e.g. erythromycin 4.69), no evident difference for hospital and municipal effluent were 
observed.  
pharmaceuticals
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Figure 2.3 risk assessments for pharmaceuticals with available measured concentrations in 
WWTP effluent receiving wastewater from municipal, hospital, manufacturing and livestock. 
Trimethoprim (TMP), carbamazepine (CBZ), erythromycin (ERM), ibuprofen (IBP), naproxen 
(NAP), diclofenac (DIC), tetracycline (TC), enrofloxacin (EFX), chlortetracycline (CTC), 
florfenicol (FFC), lincomycin (LIN), Penicillin G (PEN-G). 
In this section exposure assessment (PEC) for human pharmaceutical is considered using a 
total residue approach. This is a conservative estimation without considering the removal of 
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pharmaceuticals from the system by the individual process of patient metabolism and 
degradation in wastewater treatment plants. Metcalfe et al. (2008) compared the MEC and 
PEC by using ibuprofen as an example. They found that PEC values calculated by this 
approach are always very conservative relative to the MEC data within a factor of less than 
100 from the 90th percentile (Metcalfe et al., 2008). However, a reasonable agreement 
between MEC and PEC data calculated by using the EMEA guidelines (2008) for veterinary 
pharmaceuticals was found for the four environmental compartments (soil, dung, surface and 
sediment; Metcalfe et al., 2008). A wide range of API residues were reported in surface water 
worldwide, especially data available for different classes of antibiotics (e.g. macrolide and 
sulfonamide with maximum ug L-1 levels in the USA; Monteiro and Boxall, 2010). However, to 
enable a better risk assessment, more data covering wider spatial and temporal scales are 
required. Risk assessment methods from different geographical regions, climates, 
demographics, and cultural background should be further developed (Boxall et al., 2012). 
2.7 Comparison of the risks of pharmaceuticals to that of herbicides 
From the previous section it appears that the occurrence of pharmaceuticals in WWTP effluent 
produced by municipal (general human pharmaceutical use), hospital, manufacture and 
livestock use could pose a risk to algal communities. However, an important question is how 
important is the risk posed by pharmaceuticals compared to other stressors in the natural 
environment (Boxall et al., 2012). One group of other chemicals that are known to have high 
potency to algae are the herbicides. Herbicides are the most widely used agricultural 
chemicals. Following their application, herbicide residues can enter the aquatic environment 
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and they have been detected worldwide (Boutin et al., 2014). In the section below, we 
therefore explore the relative risks posed by pharmaceuticals compared to herbicides.  
Data for herbicides and trace organics in surface water were obtained from a wide range of 
literature sources (highest reported data were cited if more than one data was available). EC50 
data for each of the herbicide for algal species were obtained from the Pesticides Properties 
Database (PPDB, 2014). Nineteen herbicides which are currently authorised with available 
monitoring data and toxicity data were screened and targeted. The highest reported monitoring 
data for pharmaceuticals in surface water were collated and these with available toxicity data 
to algal species were targeted. Seventeen pharmaceuticals were therefore selected.  
A simple assessment of risk was then performed by calculating measured environmental 
concentration (MEC): algal EC50 ratios for each herbicide and pharmaceutical (Table A1.5; 
Appendix 1). Herbicides and pharmaceuticals ranked top 10 by MEC: EC50 ratio in each group 
were contrasted and plotted in Figure 2.4. While only 19 herbicides and 17 pharmaceuticals 
were compared, a similar distribution of MEC: EC50 for herbicides and pharmaceuticals was 
observed (herbicides range from 1.5E-5 to 0.14, pharmaceuticals range from 1.6E-5 to 1.2; 
Figure 2.4), and in some cases pharmaceuticals even exhibit higher ratio (e.g. top two items in 
each group, clarithromycin 1.2 and diquat 0.14). This evidence therefore suggests that the risk 
posed by pharmaceuticals at environmentally relevant concentrations to algae is as high as 
that of herbicides. In the following section the current knowledge gaps are discussed and 
recommendations for further research are presented. 
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Figure 2.4 Risk comparisons between selected pharmaceuticals and herbicides. 
Clarithromycin (CLA), diquat (DUT), metazachlor (MTC), amoxicillin (AMOX), triclosan (TRN), 
linuron (LNR), ioxynil (IXN), clozapine (CLO), erythromycin (ERM), dicamba (DIM), bromoxynil 
(BRO), trimethoprim (TMP), chloridazon (CLD), fluoxetine (FLX), carbamazepine (CMZ), 
diclofenac (DIC), glyphosate (GPS), ibuprofen (IBP), naproxen (NAP), mecoprop-P (MCPP), 
2.8. Recommendations for future work 
While a range of toxicity data of pharmaceuticals (around 350) to algae have been published, 
information is still only available for a small proportion of 1500 pharmaceutical active 
ingredients that are currently on market and for a few species. The relationship between 
effects that will occur in the real environment is also unclear. It is therefore very difficult to get a 
real understanding of how pharmaceuticals are impacting primary production. In the future, we 
therefore recommend that research focuses on the following, interrelated areas: 
Identification of APIs of most concern - The large number and variety of pharmaceuticals 
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available mean that it is unlikely that we will be able to monitor and test all the substances and 
all algal groups, so it is sensible to target effects of compounds that are likely to have the 
greatest potential to cause adverse impact on environment. One approach to identify these 
substances is to use prioritisation schemes that bring together information on likely exposure 
alongside mode of action and property information and algal biochemistry (Roos et al., 2012) 
to identify substances of greatest concern. Targeted monitoring and testing of these 
compounds would then be performed.  
Better understanding of emission pathways and amounts - A key data requirement for 
determining the likely impacts is information on the amount of API used in different regions. In 
some countries (e.g. UK), good data are readily available on amounts of pharmaceuticals 
prescribed. However, for some regions these data are not available. Pharmaceuticals can also 
purchase ‘over-the-counter’ at retail outlets and information on amounts distributed via this 
route are typically not available. A better understanding of API use and emission pathways for 
different regions of the world is therefore needed.  
Development of predictive models for effects - Instead of employing a testing approach, 
quantitative structure-activity relationship (QSAR) modelling and read across methods may be 
a valuable tools for screening APIs in terms of ecotoxicity (Sanderson and Thomsen, 2009, 
Cassani et al., 2013). While a handful of research has attempted to use QSAR modelling to 
estimate the environmental effect of chemicals, mainly on fish and daphnia (Yuan et al., 2007, 
Kar and Roy, 2010), an accurate and well-designed QSAR model for predicting the ecotoxicity 
of APIs to algal species is still required (Sanderson et al., 2004).    
Better understanding of sensitivity of different algal species to APIs - Currently most toxicity 
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tests are performed according to the OECD 201 guideline using two freshwater algal species 
(P. subcapitata and D. subspicatus) as representatives for the ecotoxicity test, whereas in 
different cases other non-standard species might be selected (e.g. marine algal species 
should be tested to investigate the potential hazards of APIs to marine and estuarine 
environment) (DeLorenzo and Fleming, 2008). Some endpoints such as physiological 
responses (e.g. effects on photosynthesis) rather than biomass and growth rate may be 
adopted to provide more information on damage processes.  
Understanding why different species respond the way they do - Evolutionary conservation of 
pharmaceuticals targets across species and life stages might explain the sensitivity among 
species. Pharmaceuticals are designed to deliver the desired therapeutic effect in human and 
animals, whereas there is evidence that the same targets and/or pathways may also be 
present in algal species in the natural environment. Exposure to these pharmaceuticals might 
elicit effects in those species (Boxall et al., 2012). Our understanding of target conservation in 
algae is however extremely limited. Efforts should therefore be made to develop gene 
sequences for key algal species and to explore the presence/absence of drug receptors these 
species (e.g. using approaches similar to that of Gunnarsson et al., 2008, JGI, 2014). By 
combining these analyses with targeted ecotoxicological testing it may be possible to develop 
approaches for identifying the vulnerability of different algal species to API exposure. These 
approaches would be invaluable for more intelligent environmental risk assessments. 
Understanding effects of transformation products - In reality before being emitted to the 
environment, although some APIs remain unchanged in humans, a wide range of APIs will be 
transformed and metabolised to corresponding metabolites or transformation products (e.g. 
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atorvastatin is >98% metabolised to ortho-hydroxyatorvastatin and para-hydroxyatorvastatin) 
(Drugbank, 2013). To obtain more realistic exposure concentrations, the predicted PEC should 
be refined by considering the unchanged percentage of pharmaceuticals in human metabolism 
process (Metcalfe et al., 2008). Also for those compounds with a high metabolised percentage, 
the potential risk assessment of corresponding metabolites or transformation products is 
required. A more detailed and complete risk assessment collating current available metabolism 
percentage of APIs is therefore needed.  
Effects of API mixtures - Drug residues detected in the aquatic environment usually occur as 
mixtures and not as single compounds. However, empirical knowledge of the ecotoxicology of 
pharmaceutical mixtures is still limited (Backhaus et al., 2011). This risk assessment has 
considered single pharmaceuticals. However many compounds will have the same mode of 
action and some compounds are known to interact toxicologically in patients (i.e. they are 
contraindicated; (Juurlink et al., 2003). The same mechanisms may occur in algae. A logical 
extension to this assessment exercise would be to consider the potential interactions of high 
priority compounds which have the same mode of action or those which are contraindicated. 
One potential method might be by fitting models. Two concepts have been well developed to 
explain the combination effects of APIs: concentration addition and independent action. 
Concentration addition is suitable for the prediction of the toxicity of mixtures of similarly acting 
chemicals; Independent action mode fits the compounds of a given mixture acting on different 
physiological systems within the exposed organisms (Backhaus et al., 2000, Backhaus et al., 
2011). Application of these two concepts to the toxicity of pharmaceutical mixtures may help to 
identify the interactions between the chosen APIs (synergistic, antagonistic or no interaction). 
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Effects of APIs on communities - In natural aquatic environments algal communities occur 
more frequently than single species (Porsbring et al., 2009), and the sensitivity of communities 
to a range of APIs may vary due to competition between the composition of algal species. 
Instead of using single algal species for ecotoxicity test, evaluation the effects of APIs on 
community level and investigation in structure change might be more realistic methods 
(Backhaus et al., 2011). Currently standard algal tests use cell number as a surrogate to 
identify algal biomass. If multi-species are tested, it is necessary to recognise different cells 
using a microscope with a counting chamber instead of other measurements derived from 
instruments such as spectrometer and fluorimeter.  
2.9. Conclusions 
This review has summarised the ecotoxicological effects of APIs on algal species, and 
synthesised the available toxicity data of APIs to algal species. A risk assessment approach 
has been used together with information on consumption and physico-chemical properties to 
estimate the effects to algal species in the environment. The main conclusions of our review 
are as follows: 
1. Over the past decade, studies investigating the ecotoxicology of APIs to aquatic 
organisms have increased, especially the large amount of data on the direct effects of 
APIs to algal species in the environment. This dataset provides strong evidence that a 
range of algal species are very vulnerable.  
2. Algal species are an essential element of food webs and nutrient-cycling processes in 
natural environment and therefore only impact from APIs to algae might cause damage to 
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the whole ecosystem.  
3. Pharmaceutically active substances can inhibit the algal species by indirectly affecting the 
co-existing system between algae and bacteria. The nutrient produced and supplied by 
bacteria to algae is vital for algae growth. APIs especially antibiotics might disrupt the 
relationship by inhibiting the bacterial activity and structure.  
4. An assessment method applied to rank APIs on the basis of their environment risk, 
identified a series of antibiotics which pose a potential threat to algal species at predicted 
environmental exposure levels. Risk assessment methods adopted by pharmaceuticals for 
veterinary use might obtain higher predicted environmental concentrations (PEC) than 
human pharmaceuticals due to different parameters and factors considered in each 
scenario. A higher risk was therefore observed by using the veterinary pharmaceuticals 
scenario. 
5. A similar environment risk to algal species was observed for APIs and herbicide by using 
the measured occurrence data. Pharmaceuticals, as an emerging contaminant with 
continuous high consumption worldwide, more concerns might be therefore raised on the 
fate and behaviour in the natural environment following their pathways (e.g. WWTPs, 
surface water and terrestrial environment). 
6. While a number of toxicity data are available for single compound, few data on the mixture 
of APIs and their interactions exist. Current studies mainly focus on short-term tests, and 
therefore long-term effects of API residues environmentally relevant concentration levels 
to algal species are still uncertain (e.g. selection of antimicrobial resistant microorganisms, 
resistance development). 
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While a range of antibiotics were shown to be the highly ranked substances that could inhibit 
the growth of algae in Chapter 2, it is still difficult to target the compounds for future 
experimental investigations. The studies in Chapter 2 only considered the APIs with available 
toxicity data of algae. However, these APIs are a small proportion of all the APIs licenced on 
the market. The ranking results in this Chapter cannot guarantee that they are the APIs with 
the highest priority for future algal toxicological studies. Therefore, in the next Chapter, a 
prioritisation method is developed and applied to try to identify which APIs in use are likely to 
pose the greatest risk to the environment. 
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Chapter 3 
Toxicological and ecotoxicological risk based prioritisation of 
pharmaceuticals in the natural environment 
3.1 Introduction 
While a large amount of data has been published in the past decade on different aspects of 
APIs in the environment, information is still only available for a very small proportion of the 
1500 or so active pharmaceutical ingredients that are currently in use. It is possible, therefore, 
that monitoring and effects-based studies are missing substances that could be causing 
adverse impacts in the environment. It would be impossible to experimentally assess the 
hazards and risks for all the pharmaceuticals in use in a timely manner. However, prioritisation 
approaches can be used to focus monitoring, testing and research resources and to identity 
those compounds that are likely to pose the greatest risk in a particular situation. A number of 
prioritisation methods have already been proposed, and applied to, human and veterinary 
APIs (Boxall et al., 2003, Capleton et al., 2006, Roberts and Thomas, 2006, Kostich et al., 
2010, Sanderson et al., 2004). Prioritisation approaches are also available for other classes of 
emerging contaminant such as pesticide metabolites (Sinclair et al., 2006). Many of these 
approaches use exposure and toxicological predictions or information on API potency in 
humans so they can be readily applied to large numbers of compounds. Until now, 
prioritisation methods for APIs have tended to focus on risks of parent compounds in surface 
waters to aquatic organisms and risks to humans via drinking water consumption and tended 
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to focus on single use categories (e.g. prescription or hospital use). Less emphasis has been 
placed on risks to other environmental compartments such as soils, sediments and ground 
waters, risks to top predators or on the risks of metabolites of APIs. 
This Chapter therefore, describe a holistic risk-based prioritisation approach for identifying 
APIs of concern in aquatic and terrestrial systems. The use of the prioritisation approach is 
illustrated using a subset of APIs used in primary and secondary care in the United Kingdom 
as well as those distributed by pharmacists ‘over the counter’ and major metabolites of these. 
The approach considers aquatic and terrestrial exposure routes and acute and chronic effects 
on algae, invertebrates, fish, birds and mammals, including humans. Effects relating to the 
therapeutic mode of action are also considered. The approach is illustrated using 146 active 
ingredients that were either high usage in the UK or where experts indicated that they might be 
of environmental concern. While the approach has been applied to the UK situation, there is 
no reason why it cannot be applied to prioritise APIs in use in other regions of the World. 
3.2 Methods  
The prioritisation approach used risk scores (RS) as the primary parameter to rank the APIs in 
terms of their potential environmental risk (Figure 3.1 A, B). Risk score values were calculated 
by comparing predictions of exposure of APIs in different environmental compartments to 
measures of potential hazard towards different organisms from different trophic levels. The 
prioritisation process considered aquatic and terrestrial organisms as well as humans, acute 
and chronic apical ecotoxicological effects and potential effects related to the mode of action of 
an API (Figure 3.1 A, B). In the next sections we describe how the exposure concentrations 
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and hazard paramaters were derived. Specific equations are provided in the Appendix 2. 
  (A) 
 (B) 
Figure 3.1: The overall approach for prioritisation of activated pharmaceutical ingredients 
(APIs). Risk scores on (A) standard end-point effect; (B) non-standard end-point effects. 
Green: estimated exposure; Orange: estimated effect. PNECAQUATIC: predicted no effect 
concentration for aquatic organisms, including fish, daphnia and algae; PECSW: predicted 
environmental concentration in surface water; PECSOIL: predicted environmental concentration 
in soil; PNECEARTHWORM: predicted no effect concentration in earthworm; FSSPC: fish steady 
state plasma concentration; HTPC: human therapeutic plasma concentration; PECEARTHWORM: 
predicted environmental concentration in earthworm; PECFISH:  predicted environmental 
concentration in fish; ADI: acceptable daily intake for human; PNECMAMMAL: predicted no effect 
concentration in mammal; PNECADULT: predicted no effect concentration for adult; PNECCHILD: 
predicted no effect concentration for child.  
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3.2.1 Identification of substances for prioritisation 
In the United Kingdom (UK), the main ways that pharmaceuticals are made available to 
patients are through the fulfilment of primary care prescriptions by pharmacies and dispensing 
in secondary care (including hospitals). Some can also be purchased ‘over-the-counter’ at 
retail outlets. It would be a mammoth task to determine the usage of all compounds in the UK. 
We therefore, developed a substance list for prioritisation that included the top usage 
compounds in these different categories. To ensure that the list caught compounds of low use 
but very high potency, we also used expert opinion to identify potent compounds that might be 
of concern. Forty international experts from academia, industry and Government agencies 
based in North America, Europe and Asia were contacted via email. These experts were 
selected based on their track record in the area of ecotoxicology and environmental risks of 
pharmaceuticals. Many of them had participated in the Society of Environmental Toxicology 
and Chemistry ‘Big Questions’ exercise on pharmaceuticals and personal care products in the 
environment (Boxall et al., 2012). Their responses were used to collate a list of substances of 
high perceived concern. 
Annual pharmaceutical usage data for the top most prescribed pharmaceuticals in primary 
care (by active ingredient mass) in the UK were collated from Prescription Cost Analysis (PCA) 
data available for England (NHS, 2012), Scotland (Scotland, 2012) and Wales (Welsh, 2011). 
The available PCA data obtained from Northern Ireland was not sufficient to calculate 
pharmaceutical usage. To reduce the time required to collate the data, the usage of all 
pharmaceuticals present on the PCA data for Wales was calculated (approximately 1000 
active ingredients). Usage data were then obtained for England and Scotland for the top 300 
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compounds in use in Wales. These data were then used to generate a list of the top 100 
pharmaceuticals by mass for Great Britain. Twelve substances with high usage but considered 
by the project team to fall outside the scope of this project were excluded from further 
prioritisation. These compounds were aliginic acid compound preparations, calcium carbonate, 
co-magaldrox (magnesium/aluminium hydroxide), ergocalciferol, ferrous fumarate, ferrous 
sulphate, glucose, lithium carbonate, omega-3 marine triglycerides, potassium chloride, 
sodium bicarbonate and sodium valproate.  
Data on pharmaceutical usage in secondary care in 2012 was provided to the project team by 
the British Generic Manufacturers Association (BGMA). Data were provided on the usage, by 
mass, of the top twenty most used pharmaceuticals in secondary care. Three compounds 
(paracetamol, amoxicillin and codeine) that were also present on the primary usage lists had 
their primary and secondary care usage combined. The identity of pharmaceutical active 
ingredients present in pharmaceutical products available over-the-counter were obtained from 
information available on online retailer websites (e.g. the Boots Company website) 
As some compounds will be extensively metabolised in the body, for these substances, the 
environment will be exposed to the metabolite and not the parent compound. Data were 
therefore also obtained on the extent of metabolism of the high use compounds and on the 
identity of the major metabolites. The recent Chemical Investigation Program (CIP) in the UK 
has monitored 12 pharmaceuticals in wastewater treatment plant (WWTP) effluent (Gardner, 
2013). Compounds monitored in CIP but which were not in the top usage compound list or 
which were not identified by the experts were also added to the list for prioritisation. Overall, 
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146 compounds were identified for further quantitative prioritisation. An additional 23 
compounds were identified that are available over-the-counter which were ranked using a 
more simple chemical classification approach due to the absence of quantitative usage data. 
3.2.2 Environmental exposure estimation  
Predicted environmental concentrations of selected pharmaceuticals in surface waters 
(PECSW) and terrestrial systems (PECSOIL) were estimated using standard algorithms that are 
described in existing regulatory guidance documents (Appendix 2, Equations 3.1 – 3.7) (TGD, 
2003). The algorithms assume that pharmaceutical usage by the population is distributed 
evenly both temporally and spatially. The property data for APIs, collated to aid the 
determination of environmental exposure, included the acid dissociation constant (pKa); 
octanol-water partition coefficient (KOW); solid-water distribution coefficient (Kd) and organic 
carbon partition coefficient (KOC).  These data were collated from a number of sources 
including the peer-reviewed literature, grey literature and available online databases (e.g. 
drugbank (Drugbank, 2013)). Where experimentally determined data were unavailable, 
estimation tools, such as Quantitative Structure-Property Relationships (TGD, 2003, Franco 
and Trapp, 2008, Drillia et al., 2005) were used to fill the data gaps. For example, Koc was 
predicted using an estimation model developed for ionisable organic chemicals (Appendix 2, 
Equations 3.8 - 3.11). Default values of pH of soil recommended by the model developers 
(Franco and Trapp, 2008) were used in the Koc estimation (i.e. 5.8 for acids and pH 4.5 for 
bases).  
The fish steady state plasma concentration (FSSPC) resulting from exposure via surface water 
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was predicted based on estimates of the partitioning of an API between the aqueous phase 
and arterial blood in the fish (Pblood :water) (Fick et al., 2010). This partition coefficient was initially 
estimated based on the Log KOW of the API, and this was subsequently combined with the 
PECSW to estimate the FSSPC (Appendix 2, Equations 3.12 – 3.15).  
To estimate concentrations in fish, the Bioconcentration factor for fish (BCFFISH) was estimated 
according to the approach of Fu et al. (Fu et al., 2009) assuming a pH of surface water of 7.0. 
The predicted environmental concentration in fish as food (PECFISH) was then calculated from 
the BCF and the predicted surface water concentration (Appendix 2, Equations 3.16 – 3.20). 
To estimate the concentration of an API in earthworms (PECEARTHWORM), the concentration in 
the earthworms on a wet weight basis (CEARTHWORM) was calculated using an estimate of the 
concentration in porewater (Cporewater) and the BCF for earthworms calculated according to the 
approach in the Technical guideline Document (TGD; Appendix 2, Equations 3.21 – 3.23)  
(TGD, 2003). 
3.2.3 Hazard characterisation  
Predicted no effect concentrations (PNEC) of pharmaceuticals were derived based on either 
experimental or estimated ecotoxicity data, using appropriate safety factors from the Technical 
Guideline Document (TGD) (TGD, 2003) (Appendix 2, Equations 3.24). Where multiple 
ecotoxicological values were available, the most sensitive end-point was used for the 
generation of the PNEC.  
Chronic and acute aquatic and terrestrial ecotoxicity data for standard test taxa (e.g. 
earthworm, green algae, daphnia and fish), together with non-standard taxa and end-points, 
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were collated for the 146 pharmaceuticals (and relevant metabolites) under consideration (e.g. 
from the Fass (Fass.se, 2011) and ECOTOX (EPA, 2015) databases). A number of the 
compounds under consideration had no available experimentally derived ecotoxicological 
aquatic data. Therefore, for these compounds estimation techniques were used to fill the data 
gaps. A read-across approach using the OECD QSAR Toolbox was used for pharmaceuticals, 
and the estimation approach of Escher et al. (Sinclair and Boxall, 2009) was used for 
metabolites. The database present in the OECD QSAR Toolbox was used to identify 
experimental data for molecules deemed ‘similar’ to each of the individual pharmaceutical with 
no data. Then within the software a relationship was built to allow an estimation of the 
ecotoxicological endpoint for the query molecule. The approach adopted for the identification 
of similar compounds was to combine the protein-binding profile with endpoint specific ones, 
as suggested by the Toolbox instruction manual (OECD, 2013). The main procedures in the 
software were as follows: protein binding profile was selected as a group method to define the 
category. Subcategories where then established based on the classification system used by 
ECOSAR (US EPA). The results were then followed by a refinement for structural similarity (70 
- 90% similar). The identified chemicals were then used to read across and estimate 
ecotoxicity data for the query pharmaceutical. Metabolite aquatic ecotoxicty data gaps were 
filled using the estimation approach for pharmaceutical metabolites proposed by Escher et al. 
(Sinclair and Boxall, 2009) which uses the principle of the toxic ratio and parent 
ecotoxicological data to estimate the toxic range for the metabolite. For compounds with no 
experimentally determined earthworm ecotoxicity data, the terrestrial toxicity (14 day LC50 in 
mM kg-1 dry soil) was predicted using the Quantitative structure-activity relationship (QSAR) 
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available in ECOSAR  (US EPA; Appendix 2, Equations 3.25).  
All human plasma therapeutic concentrations (HTPC) were obtained from published work. 
Limited data are available on the toxicology of APIs to birds. Therefore, acceptable daily 
intakes (ADI) for humans and mammalian toxicity data (rat/mouse) were collated as 
surrogates to determine the potential hazards of APIs for top predators (obtained from several 
databases e.g. MEDSAFE (MEDSAFE, 2013), Drugs (Drugs, 2014). A PNEC for mammalian 
data (PNECMAMMAL) was generated from the median lethal dose (LD50) for rat/mouse, by 
dividing by an assessment factor of 100. The potential hazard from drinking water was 
quantified by calculating the predicted no effect concentration of APIs for an adult (PNECADULT) 
and a child (PNECCHILD) based on ADIs for each API using the model of Schwab et al (Schwab 
et al., 2005) (Appendix 2, Equations 3.26). 
3.2.4 Ranking scenarios 
To prioritise substances a risk score was calculated for the different exposure pathway/toxicity 
endpoint combinations by dividing the relevant exposure concentration by the relevant hazard 
concentration (Figure 3.1 A, B). For example, to calculate the risk score for subtle effects on 
fish the FSSPC was divided by the HTPC. Compounds were then ranked based on their risk 
score with substances towards the top of the ranking deemed to be of most interest for that 
particular pathway and endpoint. 
Due to a lack of quantitative usage data, the over-the-counter (OTC) pharmaceuticals were 
classified based on their hazards to the aquatic environment using a classification system 
proposed by European Chemicals Agency (ECHA) (ECHA, 2015). Following these criterion, 
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substances without adequate chronic toxicity data were categorised as either chronic 1, 
chronic 2 and chronic 3, on the basis of the lowest acute aquatic toxicity data from 96 h half 
maximal lethal concentration (LC50) for fish, 48 h half maximal effective concentration (EC50) 
for crustacean or 72/ 96 h EC50 for algae (Table 3.1).  
Table 3.1 Classification categories for chemicals without adequate available chronic aquatic 
toxicity data 
Category Concentration range (mg L-1) 
Chronic 1 <=1 
Chronic 2 >1 to <=10 
Chronic 3 >10 to <=100 
3.3 Results 
3.3.1 Target APIs and collation of pharmaceutical effect data  
Overall 146 compounds were identified for further quantitative prioritisation, these were 
distributed as follows:  88 were used in primary care; 20 were used in secondary care; 12 
were identified as ‘high hazard’ concern, based on expert opinion; 25 major metabolites; and 4 
from the previous Chemical Investigation Program (CIP1; Table 3.2). Twenty three compounds, 
sold as OTC medicines, were also identified in addition to the 146 compounds for quantitative 
prioritisation – these underwent a qualitative assessment. A summary of the available 
experimental toxicological data for 146 study compounds is provided in Table 3.2. Some high 
profile compounds had excellent multi-species/multi-endpoint datasets. However, the majority 
of the compounds under consideration had limited ecotoxicological data available. For the 
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standard aquatic endpoints, 82 compounds had at least one experimentally derived acute or 
chronic ecotoxicity endpoint available. In terms of data on mammalian safety, data were 
available on the toxicity of 65 compounds, 139 had an acceptable daily intake and 113 had a 
human therapeutic plasma concentration (HTPC) (Table 3.2). Toxicological data were not 
available for any of the identified metabolites.   
Table 3.2 Summary of the numbers of compounds selected for prioritisation from each 
compound identification method and availability of experimental ecotoxicological data collated 
for the 146 compounds under consideration 
Prioritisation 
type 
Compound 
identification 
methodology 
Number of 
compounds 
Parameter Number of 
compounds 
Quantitative 
prioritisation 
Primary care 
usage a 
88a 
Acute Fish LC50 89 
 
Secondary care 
usage a 
20a 
 Daphnia EC50 76 
 
High hazard 
concern 
12 
 Algae EC50 74 
 Metabolites 25   
 CIP1 4 Chronic Fish LC50 13 
 TOTAL 146  Daphnia EC50 40 
Qualitative 
prioritisation 
Over-the-counter 23 
  
   
Bioconcentration factor in 
fish 
3 
   
Therapeutic plasma 
concentration 
113 
   Acceptable daily intake 139 
   Mammalian toxicity 65 
a – three compounds, paracetamol, codeine and amoxicillin, identified as high usage in primary and secondary care 
3.3.2 Ranking list development 
The top 20 compounds derived from the different prioritisations for the aquatic and terrestrial 
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environments are provided in Tables 3.3 and 3.4. The prioritisation based on apical acute 
aquatic effects at lower trophic levels indicated that amoxicillin, clarithromycin, ciprofloxacin, 
azithromycin and mesalazine had the highest risk scores (RS>1). For the aquatic apical 
chronic prioritisation process, diclofenac, atorvastatin, estradiol, mesalazine and omeprazole 
demonstrated the greatest risk score (RS>1). The highest ranked compounds based on apical 
acute effects in soil organisms were orlistat, carbamazepine and the carbamazepine 
metabolite, 10,11-epoxycarbamazepine (RS 1-10; Table 3.4). 
When the potential impact of subtle pharmacological effects were considered by comparing 
the human therapeutic concentration in plasma to estimated levels in fish, the atorvastatin 
metabolites ortho-hydroxyatorvastatin and para-hydroxyatorvastatin were ranked highest 
(RS>10) with atorvastatin, estradiol and amitriptyline just below these substances(RS 1-10; 
Table 3.3).  
In the prioritisation based on potential of secondary poisoning in the aquatic environment (i.e. 
fish-eating birds and mammals), diazepam  was ranked the highest (RS between 0.1-1), 
while in terrestrial environments (i.e. earthworm-eating birds and mammals) the highest 
ranked API was orlistat (RS 0.1-1). All other pharmaceuticals had a RS <0.1 (Table 3.4). The 
risk scores of APIs prioritised according to human consumption in drinking water for all 
compounds were less than 1x10-5. The top ranked compounds were phenytoin, metformin and 
simvastatin (Table 3.3). 
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Table 3.3 Top 20 compounds from each prioritisation approach for exposure via water. 
Risk 
Score 
Low trophic levels 
Higher trophic levels 
FSSPC: HTPC 
ratio 
Mammalian predator Human (uptake from drinking water) 
Acute aquatic 
(PECSW/ acute 
PNECAQUATIC) 
Chronic 
aquatic 
(PECSW/ 
chronic 
PNECAQUATIC) 
PECFISH: 
PNECMAMMAL 
PECFISH: ADI Adult 
(PECSW: 
PNECADULT) 
Child 
(PECSW: 
PNECCHILD) 
>10 1 amoxicillin 
 
 
1 diclofenac 
 
n.d. n.d. n.d. n.d. 
1 ortho-hydroxy 
   atorvastatin 
2 para-hydroxy 
   atorvastatin 
1 - 10 2 clarithromycin 
3 ciprofloxacin 
4 azithromycin 
5 metformin 
6 mesalazine 
2 atorvastatin 
3 estradiol 
4 mesalazine 
5 omeprazole 
 
n.d. n.d. n.d. n.d. 
3 atorvastatin 
4 estradiol 
5 amitriptyline 
 
0.1 - 1 7 paracetamol 
8 phenytoin 
9 n-acetyl-5- 
   aminosalicylic 
acid 
10 omeprazole 
11 iminoquinone 
12 mycophenolic 
acid 
13 norsertraline 
14 sulfasalazine 
15 ranitidine 
16 oxytetracycline 
17 homovanillic 
acid 
18 carbocisteine 
19 mebeverine 
20 propanolol 
6 paracetamol 
7 mebeverine 
8 sulfasalazine 
 
1 diazepam 
 
n.d.  n.d. n.d. 
6 tamoxifen 
7 propranolol 
8 norsertraline 
9 terbinafine 
<0.1 
n.d. 
9 codeine 
10 fluoxetine 
11 
azithromycin 
12 diltiazem 
13 mefenamic 
acid 
14 ranitidine 
2 miconazole 
3 paracetamol 
4 propanolol 
5 tramadol 
6 naproxen 
7 quinine 
8 trazodone 
9 diltiazem 
1 miconazole 
2 phenytoin 
3 
ortho-hydroxyatorvas
tatin 
4 estradiol 
5 
para-hydroxyatorvast
1 phenytoin 
2 metformin 
3 simvastatin 
4 estradiol 
5 codeine  
6 omeprazole 
sulfone 
7 lisinopril 
1 phenytoin 
2 metformin 
3 simvastatin 
4 estradiol 
5 codeine  
6 omeprazole 
sulfoned 
7 lisinopril 
10 simvastatin 
11 
ethinylestradiol 
12 amlodipine 
13 diltiazem 
14 fenofibrate 
15 quetiapine 
16 miconazole 
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15 
clarithromycin 
16 terbinafine 
17 metformin 
18 etodolac 
19 
carbocisteine 
20 atenolol 
10 ibuprofen 
11 ranitidine 
12 
cyclophosphamide 
13 
carbamazepine-o-q
uinone 
14 iminoquinone 
15 phenytoin 
16 
2-oxoclopidogrel 
17 lidocaine 
18 
2-hydroxyiminostilb
ene 
19 mycophenolic 
acid 
20 carbamazepine 
diol 
atin 
6 simvastatin 
7 omeprazole sulfone  
8 2-oxoclopidogrel 
9 omeprazole 
10 propanolol 
11 diltiazem 
12 norsertraline 
13 tramadol 
14 irbesartan 
15 terbinafine 
16 quetiapine 
17 tamoxifen 
18 citalopram 
19 5'-o-desmethyl 
omeprazole 
20 codeine 
8 paracetamol 
9 para-hydroxy 
   atorvastatin 
10 citalopram 
11 ortho-hydroxy 
     atorvastatin 
12 5’-o-desmethyl 
     omeprazole 
13 naproxen 
14 gliclazide 
15 3-hydroxy 
     omeprazole 
16 5-hydroxy 
     omeprazole 
17 
2-oxoclopidogrel 
18 omeprazole 
19 pancreatin 
20 diltiazem 
8 paracetamol 
9 para-hydroxy 
   atorvastatin 
10 citalopram 
11 ortho-hydroxy 
     atorvastatin 
12 5’-o-desmethyl 
     omeprazole 
13 naproxen 
14 gliclazide 
15 3-hydroxy 
     omeprazole 
16 5-hydroxy 
     omeprazole 
17 2-oxoclopidogrel 
18 omeprazole 
19 pancreatin 
20 diltiazem 
17 ibuprofen 
18 azithromycin 
19 tramadol 
20 donepezil 
 
n.d. no data 
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Table 3.4 Top 20 compounds from each prioritisation approach considered, according to the 
predicted concentrations in soil (PECsoil) 
Risk score 
Low trophic levels 
Higher trophic levels 
Mammalian predator 
PECSOIL: PNECWORM PECEARTHWORM : PNECMAMMAL PECEARTHWORM : ADI 
>10 n.d. n.d. n.d. 
1 – 10 
1 orlistat 
2 10,11-epoxycarbamazepine 
3 carbamazepine 
n.d. n.d. 
0.1 – 1 
4 venlafaxine 
5 dipyridamole 
6 progesterone 
7 3-hydroxyquinine 
8 2-hydroxyiminostilbene 
9 norsertraline 
10 terbinafine 
n.d. 1 orlistat 
<0.1 
11 cyproterone 
12 norerythromycin 
13 3-hydroxycarbamazepine 
14 2-hydroxycarbamazepine 
15 metoprolol 
16 atorvastatin 
17 levetiracetam 
18 methocarbamol 
19 bisoprolol 
20 amitriptyline 
1 phenytoin 
2 bisoprolol 
3 progesterone 
4 3-hydroxyquinine 
5 diazepam 
6 
10,11-epoxycarbamazepine 
7 carbamazepine 
8 quinine 
9 normorphine 
10 fluoxetine 
11 isosorbide 
12 amitriptyline 
13 miconazole 
14 ranitidine 
15 dipyridamole 
16 3-hydroxyomeprazole 
17 5-hydroxyomeprazole 
18 5'-O-desmethyl 
omeprazole 
19 2-hydroxyiminostilbene 
20 ibuprofen 
2 atorvastatin 
3 ortho-hydroxyatorvastatin 
4 tamoxifen 
5 estradiol 
5 terbinafine 
6 para-hydroxyatorvastatin 
7 bisoprolol 
8 phenytoin 
9 norsertraline 
10 
10,11-epoxycarbamazepine 
11 dipyridamole 
12 fenofibrate 
13 venlafaxine 
14 miconazole 
15 carbamazepine 
16 isosorbide 
17 progesterone 
18 aripiprazole 
19 3-hydroxyomeprazole 
20 5-hydroxyomeprazole 
n.d. no data 
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For over-the-counter (OTC) pharmaceuticals, amorolfine, benzalkonium chloride, 
cetylpyridinium chloride,  dextromethorphan, dimethicone, loratadine and xylometazoline 
hydrochloride were assigned to category chronic 1. The category chronic 2 included cetrimide, 
chlorphenamine maleate, guaifenesin, hexylresorcinol and mepyramine maleate, 
phenylephrine and pseudoephedrine. Beclometasone dipropionate, cetirizine hydrochloride, 
clotrimazole, dexpanthenol, fluticasone propionate, loperamide hydrochloride and pholcodine 
were assigned to category chronic 3 (Table 3.5). Acrivastine and sodium cromoglicate were 
not classified as no toxicity data was available and the estimation approaches did not work for 
these substances. 
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Table 3.5 Classification of over the counter pharmaceuticals based on potential hazard to the 
aquatic environment 
Pharmaceutical 
Acute aquatic ecotoxicity  
(mg L-1) 
Chronic ecotoxicity 
(mg L-1) 
Classification 
Category 
 Algae Daphnia Fish Daphnia Fish  
Acrivastine n.a. n.a. n.a. n.a. n.a. Not classified 
Amorolfine 0.69a 0.68 a >500b n.a. n.a. Chronic 1 
Beclometasone dipropionate n.a. n.a. 23.7 a n.a. n.a. Chronic 3 
Benzalkonium chloride 0.056b 0.037b 0.28b 0.04 b 0.032 b Chronic 1 
Cetirizine hydrochloride 102 a 29.6 a n.a. 15.2 a n.a. Chronic 3 
Cetrimide 1.03 a 1.38 a 4.63 a n.a. n.a. Chronic 2 
Cetylpyridinium chloride 1.26 a 0.0032b 0.11b 0.44 a n.a. Chronic 1 
Chlorphenamine maleate 5.05 a n.a n.a n.a n.a Chronic 2 
Clotrimazole n.a. n.a. 30b n.a. n.a. Chronic 3 
Dexpanthenol n.a. 76.5 a 1220 a n.a. n.a. Chronic 3 
Dextromethorphan  2.6 a 0.95 a 5.81 a 2.04 a n.a. Chronic 1 
Dimethicone n.a. 0.36 a 5.83 a 0.096 a n.a. Chronic 1 
Fluticasone propionate n.a. n.a. 39.4 a n.a. n.a. Chronic 3 
Guaifenesin 9.26 a 292 a n.a. 6.08 a n.a. Chronic 2 
Hexylresorcinol 2.19 a 11.7 a 2.89 a 3.6 a n.a. Chronic 2 
Loperamide hydrochloride >54c >56c >52.3c n.a n.a Chronic 3 
Loratadine 0.7c 0.83c 0.38c n.a n.a Chronic 1 
Mepyramine maleate 8.12 a 181 a 20.4 a 10.7 a n.a Chronic 2 
Phenylephrine 78.1 a 40.8 a 210 a 8.19 a n.a Chronic 2 
Pholcodine 83.4 a 401 a 855 a 54.2 a n.a Chronic 3 
Pseudoephedrine 15.7 a 95.7 a 331 a 7.23 a n.a Chronic 2. 
Sodium cromoglicate n.a n.a n.a n.a n.a Not classified 
Xylometazoline hydrochloride 2.17 a n.a 0.66 a 0.49 a n.a Chronic 1 
a estimated by QSAR toolbox; b EPA ecotox; c FASS.  
3.4 Discussion 
3.4.1 Results comparisons 
A final list of 16 substances including 13 parent compounds (amitriptyline, amoxicillin, 
atorvastatin, azithromycin, carbamazepine, ciprofloxacin, clarithromycin, diclofenac, estradiol, 
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mesalazine, metformin, omeprazole, orlistat) and 3 metabolites (ortho-hydroxyatovastatin, 
para-hydroxyatovastatin and 10,11-epoxycarbamazepine) were identified that had a risk score > 
1 for one or more of the risk comparisons. A substance with RS more than 1 indicates that the 
estimated exposure is higher than the predicted no effect concentration, so more attention 
should be paid as the hazards might occur in the different environment compartments.  
The ranking results for parent compounds agree with some of the previous prioritisation 
studies. Amitriptyline, atorvastatin, carbamazepine, diclofenac, estradiol, mesalazine and 
orlistat were identified as priority substances in use in the Swedish market by Roos et al. 
(Roos et al., 2012), with the ranking at 12th, 22nd, 16th, 5th, 4th, 10th and 11th, respectively. The 
risk score of diclofenac (Ashton et al., 2004) was also reported with a low RS value of 0.01 in a 
UK stream case study. Amoxicillin has been ranked the top in several veterinary medicine 
prioritisation studies, where it was classified as a substance with high hazard to aquatic 
environments in the UK (Boxall et al., 2003, Capleton et al., 2006), Korea (Kim et al., 2008), 
US (Dong et al., 2013) and China (Wang et al., 2014). Azithromycin and metformin were 
identified in a US surface water exercise, being ranked 12th and 5th, respectively (Dong et al., 
2013). Clarithromycin has been identified in a prioritisation study in Germany and ranked 34th 
(Webb et al., 2003). Ciprofloxacin was classified as a substance with a high ranking (8th) in the 
aquatic environment in US (Dong et al., 2013), besides, it was assigned to categories with a 
high and medium toxicity in China (Wang et al., 2014) and Korea (Kim et al., 2008), 
respectively. Omeprazole was considered in the prioritisation studies in the US and Sweden, 
ranking 18th and 22nd, respectively (Roos et al., 2012, Dong et al., 2013).  
Previously published work considering the prioritisation of pharmaceuticals has only focused 
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on parent compounds (Roberts and Thomas, 2006, Roos et al., 2012), whereas in reality 
following consumption by patients, compounds may be metabolised and excreted as 
metabolites, partly or completely (Boxall et al., 2003). This project is the first study that 
considered the impact that metabolism may have on the ranking of APIs. The ranking results 
demonstrated that it is important to consider these compounds, particularly the metabolites of 
atorvastatin (ortho-hydroxyatorvastatin and para-hydroxyatorvastatin) which were highly 
ranked using a number of the prioritisation indices. The classification of ‘over-the-counter’ APIs 
is a novel method applied in a prioritisation exercise, and therefore, no published works are 
available with which to compare our findings. 
3.4.2 Potential risk of highly ranked substances in the environment  
A number of the compounds we identified as high priority are receiving increasing regulatory 
scrutiny. For example, as part of Directive 2013/39/EU) (EC, 2013), which relates to priority 
substances in water, three APIs: diclofenac and two hormones 17-beta-estradiol (E2) and 
17-alpha-ethinylestradiol (EE2) have been added to EU’s pollutant watch list, two of these 
(diclofenac and E2) appear in our top 16 list. While EE2 did not fall in the top 16, it was still 
ranked highly using the plasma therapeutic concentration approach (number 11), even though 
the amounts of this compound used in the UK are small. Side effects of diclofenac on the fish 
kidneys (histopathological damages) have been documented (Schwaiger et al., 2004, 
Triebskorn et al., 2004). Diclofenac is also considered to have threatened some sensitive 
organisms (e.g. vultures from the Gyps genus) through secondary poisoning (SCHER, 2011). 
E2 and EE2 are the two APIs for which the toxicity have been determined at environmental 
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relevant concentrations. E2 is a natural estrogen with endocrine disrupting properties. Potent 
effects of E2 on gamete quality and maturation in two salmonid species (rainbow trout 
Oncorhynchus mykiss and grayling Thymallus thymallus) have been reported, even at ng L-1 
exposure concentration levels (Lahnsteiner et al., 2006). 17-alpha-ethinylestradiol (EE2) has 
been ranked in the top 20 list (Table 3.3). There is widespread evidence that exposure of male 
fish to EE2 at ng L-1 levels can result in feminzation of male fish (Zha et al., 2008) and that 
chronic exposure of fish (i.e. fathead minnow Pimephales promelas) to EE2 could ultimately 
result in a the collapse of fathead minnow populations in surface waters (Kidd et al., 2007).  
The watch list has been further developed in the European Environmental Quality Standards 
Directive (JRC, 2015), where four antibiotics including erythromycin, clarithromycin, 
azithromycin and ciprofloxacin have been added. The inclusion of antibiotics in the watch list is 
mainly due to their potential toxic effects to algal species. Three of these antibiotics 
(clarithromycin, azithromycin and ciprofloxacin) were identified as top priority in the current 
study. The 72/96 h acute EC50 values with growth as the endpoint for these free antibiotics are 
0.002 mg L-1 (Pseudokirchneriella subcapitata) (Santos et al., 2010), 0.001 ug L-1 (unreported 
blue-green algae) (Fass.se, 2011) and 0.005 mg L-1 (Microcystis aeruginosa) 
(Halling-Sorensen, 2000), respectively. 
The occurrence of some of the highly ranked parent APIs in aquatic the environment has been 
reported with concentrations at ng L-1 in surface waters and at up to µg L-1 levels in WWTP 
effluents (Monteiro and Boxall, 2010). Amitriptyline was reported to inhibit the growth of the 
macrophyte Lemna minor with 7 d EC50 1.69 mg L-1 (Agerstrand and Ruden, 2010) and cause 
inhibition of crustacea Daphnia magna with an EC50 of 5 mg L-1 (NCCOS, 2013). Atorvastatin 
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and metformin were reported to inhibit the growth of a wide range of organisms such as 
macrophyte (e.g. lemna) and vertebrate (e.g. fish), where the lowest 14 d NOEC 0.013 ug L-1 
of atorvastatin with genetic endpoint was documented for Zebrafish (Danio rerio) (EPA, 2015) 
and 48 h LC50 1.35  mg L-1 of metformin for a crustacea Daphnia magna (Crane et al., 2006). 
While currently no experimental toxicity data were recorded for mesalazine and omeprazole, in 
the present study a read-cross approach was used to predict their hazards to aquatic 
organisms. The lowest predictive chronic toxicity data of mesalazine and omeprazole each 
was 0.031 mg L-1 and 0.009 mg L-1, both of these being for crustacea Daphnia magna. 
Hazards of five classified OTC APIs to three aquatic trophic levels have been illustrated in 
Table 3.5. Of the three highly ranked metabolites, only the occurrence of 
10,11-epoxycarbamazepine has been reported, with a mean value of 19.1 ng L-1 in the WWTP 
effluent (Monteiro and Boxall, 2010).  
Except for the impacts of prioritised APIs on organism and population levels of non-target 
organisms in the environment, side effects of some targeted APIs (Table 3.6) on the cellular 
and genomic levels have also been documented. Hepatocyte cytotoxicity of the antibiotic 
amoxicillin has been reported in rainbow trout (Oncorhynchus mykiss) with a 24 h 
EC50 >182.7 mg L-1 (Laville et al., 2004). Detrimental effects of carbamazepine on the liver 
and kidney cytopathology of rainbow trout (Oncorhynchus mykiss) has been observed with 
LOECs >0.1 and 0.001 mg L-1, respectively (Triebskorn et al., 2007). Carbamazepine and 
diclofenac have been reported to significantly affect the genomic template stability in Zebrafish, 
at concentrations of 310 ng L-1 and 810 ng L-1, respectively (Rocco et al., 2013). Niemuth et al. 
(Niemuth et al., 2015) found that 4 wk metformin exposure at the concentration of 40 ng L-1 
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causes potential endocrine disruption in adult male fathead minnows (Pimephales promelas), 
through inducing significant up-regulation of messenger ribonucleic acid (mRNA) encoding the 
protein vitellogenin.    
Table 3.6 Data gaps for the highly ranked substances 
Compound Priority scheme Comments 
Amitriptyline, Subtle pharmacological effect Predicted FSSPC 
Amoxicillin, Acute aquatic low trophic level Predicted KOC, 
Atorvastatin, Chronic aquatic low trophic level Predicted KOC 
 Subtle pharmacological effect Predicted FSSPC 
Azithromycin, Acute aquatic low trophic level Predicted KOC 
Carbamazepine, Terrestrial low trophic level Predicted KOC, LC50 earthworm 
Ciprofloxacin, Acute aquatic low trophic level Predicted KOC 
Clarithromycin, Acute aquatic low trophic level Predicted KOC 
Diclofenac, Chronic aquatic low trophic level Predicted KOC, 
Estradiol Subtle pharmacological effect Predicted FSSPC 
Metformin, Acute aquatic low trophic level Predicted KOC, 
Mesalazine Acute aquatic low trophic level Predicted KOC, acute daphnia LC50 
 Chronic aquatic low trophic level 
Predicted KOC, chronic daphnia 
NOEC 
Omeprazole, Chronic aquatic low trophic level 
Predicted KOC, chronic daphnia 
NOEC 
Orlistat Terrestrial low trophic level Predicted KOC, LC50 earthworm 
In terrestrial environments, the antiepileptic carbamazepine and antiobesity orlistat were the 
two highest ranked substances. The occurrence of carbamazepine in soil was reported at 
concentrations up to 6.85 x 10-3 mg kg-1, and the QSAR based 14 d LC50 toxicity to earthworm 
was 1060 mg kg-1. While the detection of orlistat in the terrestrial environment has not been 
reported, a relatively high experimental BCF of 51.1 for the orlistat treated earthworm has 
been documented (Carter et al., 2014) and the predictive 14 d LC50 toxicity to earthworm was 
28.28 mg kg-1. It should be recognised that prioritisation of several substances was based on 
the predicted properties and/ or toxicity data (Table 3.6), especially for KOC values that were 
absent for all compounds. For some prioritised substances selected from subtle 
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pharmacological effect scenario, exposures (FSSPC) were all estimated from log KOW on the 
basis of QSAR.  
3.4.3 Limitation of methods and future improvement 
Approaches for exposure estimations of APIs used in the present study rely heavily on the 
annual usage information for individual pharmaceutical active ingredients. However it is well 
recognised that as well as the primary and secondary care pharmaceutical usage, for a limited 
number of compounds ‘over-the-counter’ sales through retail outlets such as supermarkets 
and pharmacies may add a significant contribution to the overall usage (Cooper, 2013). 
Attempts were made to obtain quantitative usage data for OTC compounds during the present 
study but these were unsuccessful. A previous study has estimated that in Germany OTC 
usage can contribute up to 50% of the total usage of some pharmaceuticals. However, this can 
vary on a compound by compound basis, and usage through this route could not be included 
in the quantitative risk score based element of this project. An accurate quantification 
approach of OTC usage should be further established. 
The exposure of APIs in the terrestrial environment was estimated by only considering a 
simple input pathway: APIs adsorbed to sludge in WWTP and a this sludge was then applied 
to the land (CHMP, 2006). Experimentally determined biodegradation data of APIs were not 
available. PECs and therefore, the risk scores of APIs that were susceptible to biodegradation 
during wastewater treatment will therefore have been significantly overestimated. Limited 
information on experimental physical-chemical properties such as soil-water partition 
coefficients (Koc) was available for some listed APIs. To fill in the data gaps, an empirical 
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estimation model developed by Franco and Trapp (2008) was used to estimate adsorption 
during wastewater treatment. This model was developed for soils and its applicability to 
estimating sorption in sludge is not known. The model also omits selected sorption processes, 
such as complexation, which may be important for some pharmaceuticals (Franco and Trapp, 
2008). 
In the secondary poisoning assessment of APIs in the terrestrial compartment, as very limited 
experimental data was available on bioconcentration factors for worms (BCFworm), this 
parameter was predicted using the regression equation outlined in TGD (TGD, 2003). This 
regression can well describe uptake by worms kept in water. However, evaulation of the model 
against real data indicate that the estimated BCFworm in the soil are usually higher than the 
experimental BCFs (TGD, 2003). Higher PECORAL, PREDATOR(earthworm) values than those that 
occur in reality could therefore have been obtained in the current study, and secondary 
poisoning effects of APIs in terrestrial environments on earthworm-eating birds may well be 
overestimated. Therefore, an improvement in the accuracy of BCFworm estimation in soil 
warrants further consideration. 
To target the metabolites for prioritisation, metabolic rates and metabolites of a wide range of 
APIs in human have been identified from the literature (e.g. Drugbank 2013). However for 
substances without metabolism information, we assumed that no biodegradation and 
biotransformation occurred in the body to implement a conservative risk score estimation (Kim 
et al., 2008). In this case, the exposures of these parent compounds in aquatic and terrestrial 
compartments may have been overestimated, and their metabolites will have been missed in 
our prioritisation list. For the highly ranked compounds without available metabolism data, it is 
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recommended that information on the properties such as the excretion rate of parent 
compounds and the properties and toxicities of related metabolites should be produced. 
3.5 Conclusions 
A holistic methodology has been developed and implemented to prioritise pharmaceuticals of 
concern that are released into the environment through wastewater. Pharmaceutical usage 
data in the UK has been used, together with information on the physical-chemical properties, 
patient metabolism and wastewater treatment removal to estimate concentrations in the 
aquatic and terrestrial environments. To rank the APIs, these concentrations have been 
compared to a range of hazard end-points. A series of end-points have been considered, 
including traditional risk assessment PEC/PNEC ratios for the aquatic and terrestrial 
compartments as well as non-standard endpoints such as the potential for subtle 
pharmacological effects and the impact on animals consuming fish and earthworms.   
Sixteen substances, including parent compounds from the therapeutic classes of antibiotic, 
antidiabetic, anti-inflammatory, antidepressant, antiobesity, antisecretory, lipid modifying 
agents, antiepileptics, estrogens and three metabolites have been highly ranked. Due to 
significant data gaps, the rankings of some compounds were based on data generated from 
predictive methods. A targeted monitoring study for these compounds, therefore, needs to be 
performed at a few treatment works to identify whether or not these high priority substances do 
occur in wastewater effluents and sludge.  
While, the approach has been illustrated for the UK, there is no reason why the concept cannot 
be applied to identify APIs of priority in other regions of the World. In doing this, the risk 
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ranking algorithms may need to be refined to reflect regionally relevant pathways of exposure. 
We believe that the broader application of the approach would be highly beneficial in focusing 
monitoring and testing on substances that really matter which should ultimately result in better 
protection of the natural environment and of human health. 
In this Chapter, based on the ecotoxicological data of algae, compounds identified with high 
priorities were all antibiotics. This result agreed with the findings in Chapter 2. Taking into 
account the higher estimated exposure for APIs in veterinary usage in surface water compared 
to human usage, and their high ranking (Table 2.4; Chapter 2), three veterinary antibiotics 
tylosin, lincomycin and trimethoprim were identified for further laboratory investigation. The 
effects of three antibiotics on the growth and physiology of a range of algal species including 
chlorophyte, cyanobacteria and diatoms were then systematically evaluated (Chapter 4 & 5), 
and these toxicological data were used to assess the risk of a mixture including three 
compounds in European Community (EC, Chapter 6).   
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Chapter 4 
Comparing the sensitivity of chlorophytes, cyanobacteria and 
diatoms to major use antibiotics 
4.1 Introduction 
Of all the Active Pharmaceutical Ingredients (API) considered in Chapter 2 & 3, algae were 
found to be particularly sensitive to antibiotic exposure. Available data on toxicity of antibiotics 
to chlorophytes (primarily P. subcapitata and D. subspicatus) show EC50 values generally 
occur at the mg L-1 level (Guo et al., 2015).  Effects of antibiotics on cyanobacteria have also 
been reported and these organisms have been found to be particularly sensitive to antibiotics 
with EC50 values reported at the µg L
-1 level (Guo et al., 2015). A limited amount of data are 
also available on toxicity of antibiotics to diatoms with reported EC50 values in the mg L
-1 range. 
As a consequence of the observed high sensitivity of cyanobacteria to antibiotics, blue green 
algal species are recommended as one of the test species that should be used in the 
environmental risk assessment of antibiotics as part of the marketing authorisation process 
(EMEA, 2008).  
In instances where data are available on the toxicity of a single antibiotic to a range of algal 
and cyanobacterial species, large differences can be observed in the EC50 values for the 
different species tested. These differences could be attributed to four potential reasons: 1) 
differences in antibiotic bioavailability, which is related to the pKa of the chemical and pH 
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values in the test medium during the test period (Halling-Sorensen, 2000); 2) the 
characteristics of binding sites in the primary targets, where highly conserved antibiotic 
ligand-binding pockets in some algal species may result in a higher sensitivity (McRobb et al., 
2014); 3) Elimination process (enzymatic inactivation) in the various algal species that could 
reduce the impacts of different antibiotics by direct degradation or modification of their 
structure (Wright, 2005); or 4) the presence of efflux pumps, which are the transport proteins 
used to extrude intracellular toxic substrates, including antbiotics. Differences in efflux pumps 
present in the various algal species could contribute to their different responses to antibiotic 
exposures (Webber and Piddock, 2003).  
While the differences in sensitivity of algae to antibiotics are recognised, our understanding of 
these differences is limited with data being available for only a handful of species and groups 
(Halling-Sorensen, 2000, Luetzhoft et al., 1999, Eguchi et al., 2004, DeLorenzo and Fleming, 
2008). There is therefore a need for investigations examining the sensitivity of a battery of 
algal species, from a range of groups (e.g. chlorophytes, cyanobacteria and diatoms) to a 
range of antibiotics. Data from these types of studies could be invaluable in informing the 
development of more intelligent environmental risk assessment strategies for antibiotic 
compounds. 
In this study, therefore we present the results of a systematic study into the sensitivity of algal/ 
cyanobacterial species to three major-use antibiotics, tylosin, lincomycin and trimethoprim, 
with contrasting mechanisms of action. These substances have been highly ranked in a recent 
prioritisation study of pharmaceuticals in the natural environment where they all demonstrated 
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risk scores greater than one, based on ecotoxicity to algae (Guo et al., 2015). Tylosin is an 
antibiotic administrated as a veterinary prophylactic (intestinal and respiration infections) and 
growth enhancer (Hagenbuch and Pinckney, 2012, De Liguoro et al., 2003). The primary 
mode of action is inhibiting bacterial protein synthesis by binding to the 50S ribosome. 
Lincomycin is a veterinary lincosamide antibiotic and its side effect on algae is thought to occur 
through the inhibition of the synthesis of the D1 protein in photosystem Ⅱ, which handles the 
algal recovery ability from light-inhibition (Hagenbuch and Pinckney, 2012). Trimethoprim is 
used for the treatment of urinary tract infections, uncomplicated pyelonephritis and mild acute 
prostatitis (Drugbank, 2013). It is a dihydrofolate reductace inhibitor, binding to susceptible 
bacteria and influencing folate synthesis (Table 1.1). The three antibiotics have beendetected 
in the surface waters of the US and elsewhere with concentrations ranging from 0.05 to 0.7 µg 
L-1 (Table 1.1).  
Six algal species recommended in the OECD 201 guideline (OECD, 2011) including 
chlorophytes (Pseudokirchneriella subcapitata, Desmodesmus subspicatus and Chlorella 
vulgaris), cyanobacteria (Synechococcus leopoliensis and Anabaena flos-aquae) and a 
diatom (Navicula pelliculosaand  Phaeodactylum tricornutum) were chosen for use in the 
ecotoxicity studies. All these seven species are ecologically relevant and their distribution have 
been widely reported in five continents (Asia, Europe, Africa, North America and Oceania) (AB, 
2015). The hypothesis for this study was that cyanobacteria would be more sensitive than 
chlorophytes and diatoms, and that the two cyanobacterial species would exhibit similar 
sensitivities. 
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4.2. Materials and methods 
4.2.1. Chemicals 
Tylosin tartrate (referred to as tylosin, 86.4%) (CAS-no. 1405-54-5), lincomycin hydrochloride 
(referred to as lincomycin, ≥95%) (CAS-no. 859-18-7), trimethoprim (≥98%) (CAS-no. 
738-70-5) and potassium dichromate (≥99.8%; used as reference substance) were purchased 
from Sigma-Aldrich. Ammonium acetate and formic acid (≥95%) as analytical reagent grade 
were purchased from Fisher Scientific UK and Sigma-Aldrich, respectively. Acetonitrile, 
methanol and water (HPLC Gradient grade) were purchased from Fisher Scientific UK.  
4.2.2 Algal cultures 
Algal toxicity tests were conducted using three chlorophytes: P. subcapitata (CCAP 278/4), D. 
subspicatus (CCAP 258/137) and C. vulgaris (CCAP 211/11b); two cyanobacteria: 
S. leopoliensis (CCAP 1405/1) and A. flos-aquae (CCAP 1403/13A); two diatoms N. 
pelliculosa (CCAP 1050/9) and P. tricornutum (CCAP 1052/1b) obtained from the Institute of 
Freshwater Ecology (Culture Collection of Algae and Protozoa, UK). P. subcapitata, D. 
subspicatus and C. vulgaris were cultured in Kuhl medium, pH 6.8 (Kuhl and Lorenzen, 1964); 
S. leopoliensis and A. flos-aquae were grown in Jaworski’s Medium (JM), pH 7.8 (CCAP, 
2014); N. pelliculosa and P. tricornutum were grown in Enriched Seawater-Artificial Water 
(ESAW) plus f/2 medium, pH 8.2 (Berges et al., 2004).  
Cultures of algae were grown at 20 °C under gentle and continuous shaking (100 cycles per 
minute (cpm)) in a culture chamber, with a controlled temperature (20 ± 2 °C) and a constant 
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illumination (76 µmol m-2s-1). Triplicate cultures were prepared in conical flasks (250ml) 
containing 100 ml of medium and 1 ml algal cells. To avoid contamination, the flasks were 
washed in Decon, rinsed with hydrochloric acid (50mM) and then autoclaved (at 121 °C for 30 
min) before use. The algal numbers for the cultivation phase were counted daily with a 
hemacytometer under a microscope, and growth curves (cell numbers over time) were plotted 
to identify the logarithmic phases (usually over 2-4 days cultivation). The algal stocks were 
subcultured on a weekly basis. 
4.2.3 Procedures for the growth inhibition test 
Growth inhibition tests were undertaken following the OECD 201 Guideline for freshwater alga 
and cyanobacteria, growth inhibition tests (OECD, 2011) for the study antibiotics and the 
reference toxicant (potassium dichromate). The inhibition experiments were conducted in two 
steps: range-finding and EC50 determination. Range-finding was used to estimate the EC50, 
and then at least six selected concentrations ((maximum 93.79, 225.73 and 344.45 µmol L-1 
for tylosin, lincomycin and trimethoprim, respectively) of samples (triplicates each) around the 
predicted EC50 in geometric series were used for the definitive EC50 test. The 
concentration-response curve based on growth (cell density) over t days (t=1, 2, 3, 4) was then 
generated based on the definitive data. 
Prior to use, all glassware and stoppers used in the tests were autoclaved at 121 °C for 30 min. 
The antibiotics in the media were prepared and filtered into a 25 ml vial, using a 0.2 µm 
sterilized syringe filter. The pre-cultured algal inocula, taken from logarithmic growing cultures, 
were diluted to 15 ml with the prepared antibiotic solutions in a 25 ml vial. The initial algal 
concentrations for P. subcapitata and D. subspicatus were set at 5000 cells ml-1, 2× 104 cells 
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ml-1 for C. vulgaris and A. flos-aquae, 1× 104 cells ml-1 for N. pelliculosa and P. tricornutum and 
5× 105 cells ml-1 for S. leopoliensis. The test vials were then capped with air-permeable 
stoppers made of cotton and muslin. All the operations were performed on a sterilized bench. 
The prepared vials were put in the culture chamber under the same conditions as used for the 
culturing. Bioassays lasted for 96 h, and the cell numbers were measured every 24 h using 
UV-Vis spectrophotometry. Cell density was calculated from a calibration curve of known cell 
density counted by a haemocytometer against adsorption (turbidity) measured by an ultraviolet 
and visible (UV-Vis) spectrophotometry for each species (R2>0.999).Measurement of turbidity 
(adsorption) using a spectrophotometer with an appropriate selected wavelength is a reliable 
method to determine cell density (ABO, 2013). Each algal culture was diluted and scanned 
between the 600-800 nm ranges. The wavelengths with the highest absorbance were selected 
for experiments. The wavelength for absorption measurement was 750 nm for P. subcapitata, 
720 nm for C. vulgaris, 682 nm for D. subspicatus, N. pelliculosa, P. tricornutum, A. flos-aquae 
and S. leopoliensis. 
The prepared concentration of tested samples before the test was confirmed by chemical 
analysis. Samples with the highest and lowest concentrations were analysed again after the 
test to determine the antibiotic stability. In several algal toxicity tests, the recoveries of 
antibiotics in the highest and lowest test concentrations were less than 80% after 4d test. In 
these cases, the first-order degradation reaction (Equation 4.1) was used to estimate a 
dissipation rate constant (k). The k was then applied in Equation 4.2 to estimate the 
time-weighted average concentration (TWAC) over t days (where t=1, 2, 3, 4). By comparing 
the TWAC with the nominal concentration, a correction factor was then obtained for use in the 
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concentration response analyses. Observations from the low concentration recovery tests 
were used for correcting the three lowest concentrations used in the ecotoxicity study while 
concentrations for the high concentration recovery were used for correction of the three 
highest concentrations. 
Ct = C0 X e
-kt                                                                                             Equation 4.1 
Cavet = C0 X (1- e
-kt) / kt                                                    Equation 4.2 
Where C0: initial concentration (µmol L
-1); Ct: concentration at the t day (µmol L-1); Cavet: 
average concentration over t days (µmol L-1); k: rate constant (day-1); t: time (day) (Boesten et 
al., 1997). 
4.2.4 Antibiotic analyses 
Samples were analysed by High Performance Liquid Chromatography (HPLC) using an 
Agilent 1100 with C18 Supelco Discovery column (15 cm × 4.6 mm × 5 µm). Tylosin and 
trimethoprim were analysed using a 24 min gradient method. The mobile phase consisted of 
methanol (A) and a buffer (B) (50 mM ammonium acetate plus 0.01% formic acid, pH 6.5 
adjusted with 2.5% ammonium solution). The gradient was as follows: 5 minute equilibration at 
a 10:90 ratio (A:B); 2 minutes at 50:50; 20 minutes at 90:10; and 2 minutes at 10:90. A 
retention time of 13 min with a flow rate of 1 ml min-1 and detection wavelength of 280 nm was 
used for tylosin and 6.4 min, 1 ml min-1, 238 nm was used for trimethoprim. Lincomycin was 
analysed by an isocratic method using 0.1% formic acid plus acetonitrile at a ratio 75:25 with a 
retention time of 4 min, flow rate of 1.2 ml min-1 and a detection wavelength of 196 nm. A range 
of antibiotic standards was prepared to derive calibration curves for each of the analytical 
methods. A linear relationship between concentrations and peak areas was obtained for each 
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analyte (R2> 0.999); the mean recovery was more than 98% for tylosin and trimethoprim and 
95% for lincomycin. The limit of detection (LOD) of tylosin, trimethoprim and lincomycin in the 
nutrient medium were 0.44, 0.55 and 1.15 µmol L-1, respectively. The limit of quantification 
(LOQ) value of three above antibiotics was each 1.41, 1.86 and 3.86 µmol L-1.  
For measuring low concentration solutions (less than 0.28 µmol L-1) of tylosin and lincomycin 
(less than 0.68 µmol L-1) for the cynobacterial tests, solid phase extract (SPE) was used to 
concentrate the samples prior to analysis. Oasis HLC 3cc extraction cartridges were used 
purchased from Waters (UK). The SPE procedures were as follows: cartridge conditioning was 
undertaken by adding 6 ml methanol followed by 6 ml water. The sample (100 ml) was then 
loaded onto the SPE. The cartridges were then rinsed with 6 ml water and eluted using 6 ml 
methanol. Eluates were then concentrated, by evaporation with nitrogen in a fume hood, to 
dryness before being taken up in 1 ml methanol. The mean SPE recovery for tylosin and 
lincomycin were 119% and 138%, respectively.    
4.2.5 Statistical methods 
The data were analysed with Sigma-plot software. The concentration response curve was 
obtained by fitting regression analysis of sigmoidal functions (sigmoid, logistic, weibull, 
gompertz, hill and chapman equations) embedded in the Sigma plot software version 12.0. 
The best fitting model (highest coefficient of determination (R2)) was used for EC50, EC10 and 
EC5 calculation. Significant differences between inhibition percentages calculated based on 
the cell density in treatments and controls were determined using the Dunnett test with a p 
value <0.05 taken as being statistically significant. NOEC, LOEC values were derived from this 
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statistic analysis. 
To explore whether pH in the three different algal media (Kuhl, 6.8; JM, 7.8; ESAW+f/2, 8.2) 
were significantly different, pH values of controls (n=3) in each algal test were compared using 
Tukey’s test (p value <0.05). 
4.3 Results and discussion 
4.3.1 Chemical analyses 
At the high test concentrations, decreases in antibiotic levels over the 4 d study period were 
observed for tylosin (C. vulgaris 74.4%, A. flos-aquae 74.8%, S. leopoliensis 53.14%) and 
trimethoprim (P. subcapitata 37%). Measured concentrations of unaltered antibiotics for most 
other antibiotic/algal combinations remained within 80 - 120% of the initial concentration 
(Figure 4.1). For the low test levels, decreases in concentration were observed for tylosin (A. 
flos-aquae 27.2%, S. leopoliensis 15.54%), lincomycin (N. pelliculosa 66.86%, P. tricornutum 
64.18%) and trimethoprim (P. subcapitata 48.11%, A. flos-aquae 43.55%, S. leopoliensis 
42.83%; Figure 4.1). The reductions in concentrations could be due to a range of processes 
including abiotic (photolysis, hydrolysis) or biotic (i.e. metabolism by the algae) degradation or 
due to sorption or uptake to/into the algal cells.  
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Figure 4.1: The residual percentage (%) of the three antibiotics in growth inhibition cultures of 
the seven algal species (samples in lowest and highest concentration for each biotest). Data 
represent mean ± standard deviation (n=3). PS, P. subcapitata; DS, D. subspicatus; CV, C. 
vulgaris; NP, N. pelliculosa; PT, P. tricornutum; AF, A. flos-aquae; SL, S. leopoliensis. LIN, 
lincomycin; TYN, tylosin; TMP, trimethoprim. 
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The three study compounds are known to be hydrolytically stable (Lam et al., 2004, Loftin et al., 
2008, Mitchell et al., 2015). However, the photolysis of the three antibiotics has demonstrated 
previously. The photolysis of tylosin under simulated sunlight has been reported by Werner et 
al. (Werner et al., 2007), where tylosin underwent a rapid decrease in the first 4 min of the 
study followed by photochemical loss at a slower time scale over 120 min. Tylosin equilibrated 
to approximately one-half of the original concentration for over 48 h and importantly, 
photochemical equilibrium was independent of initial concentration and pH value. In a 
photolysis study of trimethoprim in two matrices (distilled water and sea water) under 
simulated sunlight, 50% of the original trimethoprim concentration disappeared after 780 min 
of exposure (Sirtori et al., 2010). However, a longer half-life was observed in the sea water 
solution due to the influence of salt content (Sirtori et al., 2010). Direct photolysis of lincomycin 
has been studied by Paola et al. (Di Paola et al., 2006), They found that parent compound with 
initial concentration 49.2 µmol L-1 dropped 40% after 5h exposure to UV light. This evidence 
indicated that photolysis of antibiotics may occur in algal tests during the 4d study period but 
this degradation is dependent on media type and the concentration of the antibiotic. 
While studies on biodegradation of three antibiotics in algal species are rare, information on 
their biodegradation in activated sludge have been well established. All three antibiotics show 
a high resistance to biodegradation in activated sludge in several studies, and they were 
classified as non-biodegradable compounds (Prado et al., 2009, Kim et al., 2013, 
Halling-Sorensen et al., 2000). The losses of antibiotics in our studies were therefore unlikely 
due to biodegradation in algae. 
While no significant difference in pH values in JM’s (7.8) and ESAW+f/2 (8.2) media used for 
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culturing cyanobacteria and diatoms was found, the pH in Kuhl medium used for culturing 
chlorophytes (6.8) was significantly different from others. The pH of the exposure medium for 
all the treatments varied slightly over the study period (Figure 4.2). For chlorophytes D. 
subspicatus and C. vulgaris the rise of pH was within 1 unit and for diatoms N. pelliculosa and 
P. tricornutum the variation of pH values were within 0.9 units. These variances were within the 
scope of OECD 201 guideline. However, no evident pH increases were observed for the tests 
on P. subcapitata, A. flos-aquae and S. leopoliensis with changes < 0.2 units. The low pH 
increases for these species is believed to be due to their relative low growth rates compared to 
other species (Luetzhoft et al., 1999). The pH variations agreed with published work e.g. 
Halling-Sorensen et al. (Halling-Sorensen, 2000) investigated the effects of eight antibiotics 
including tylosin on the growh of cyanobacteria Microcystis aeruginosa with a initial pH 8.1–8.3, 
where almost no increase in pH was observed for M. aeruginosa due to a lower growth rate. 
Kolar et al. (Kolar et al., 2014) explored the influence of trimethoprim on chlorophyte P. 
subcapitata and cyanobacteria A. flos-aquae, where the pH values were in the range of 7.6-8.3 
and 7.1-7.4, respectively.  
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Figure 4.2 Changes in pH during 4 days of exposure to antibiotics. Data represent mean ± 
standard deviation (n=21). PS, P. subcapitata; DS, D. subspicatus; CV, C. vulgaris; NP, N. 
pelliculosa; PT, P. tricornutum; AF, A. flos-aquae; SL, S. leopoliensis. LIN, lincomycin; TYN, 
tylosin; TMP, trimethoprim. 
The reference substance, potassium dichromate, has previously been tested on the three 
chlorophytes with the EC50 values in the range of 1.33-4.86 µmol L
-1 for D. subspicatus 
(Pattard, 2009), 0.54-2 µmol L-1 for C. vulgaris (ECB, 2005) and 1.29-8.87 µmol L-1 for P. 
subcapitata (Pattard, 2009). In this study, EC50 values for D. subspicatus and P. subcapitata 
were 4.59 and 5.23 µmol L-1 respectively. For C. vulgaris a higher EC50 value 8.29 µmol L
-1 
was obtained, the discrepancy might be due to the differences in the selection of algal strain. 
No toxicity data of potassium dichromate on cyanobacteria and diatoms have been reported 
with which to compare our data. In this study EC50s were found within the range from 15.94 to 
33.99 µmol L-1 and greater than 33.99 µmol L-1 for cyanobacteria and diatom species, 
respectively. 
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4.3.2 Toxicity tests analysis  
All three antibiotics were found to inhibit the growth of selected algal species after 4 day 
exposure (Table 4.1; Figure 4.3). Lincomycin inhibited the growth of all seven test species with 
EC50 values ranging from 0.095 to 225.73 µmol L
-1; Tylosin inhibited the growth of selected 
species with EC50 values ranging from 0.09 to 81.2 µmol L
-1; The EC50 values of seven species 
exposed to trimethoprim ranged from 7.36 to 344.45 µmol L-1 (Table 4.1). Here a wide range of 
algal toxicity values (as much as 4 orders of magnitude) was found for these compounds. 
While clear stimulation effects (hormesis) in the lower range of test concentrations were 
observed in some algal tests such as N. pelliculosa/ tylosin and P. triconutum for trimethoprim, 
most of the negative growth inhibition observed in this study were around 20% or less. Low 
dose stimulation effects were therefore ignored in EC50 calculation (OECD, 2011). 
Table 4.1: Summary of the effects of tested antibiotics in 4d ecotoxicological biotests. Toxicity 
data derived from testing (A) lincomycin and potassium dichromate; (B) tylosin; (C) 
trimethoprim. All toxicity values are in µmol L-1 (values in brackets are the range of 95% 
confidence limits). Seven algal species are P. subcapitata (PS), D. subspicatus (DS), C. 
vulgaris (CV), N. pelliculosa (NP), P. tricornutum (PT), A. flos-aquae (AF) and S. leopoliensis 
(SL) 
(A) 
Spe. Lincomycin Potassium 
dichromate 
EC50 
 
EC10 EC5 NOEC LOEC Slope 
(EC50/EC5) 
Model, R2 Neutral 
fraction (%) 
EC50 
PS 7.36 
(4.88-11.98) 
0.88 0.57 1.35 4.06 12.91 Weibull, 
0.93 
86.32 5.23 
(3.37-n.a.) 
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DS 16.07 
(11.2-23.72) 
0.19 
(n.a.-0.77) 
0.13 <1.35 1.35 123.62 Weibull 
0.93 
86.32 4.59 
(3.84-5.88) 
CV >225.73 n.a n.a 225.7
3 
>225.7
3 
n.a. n.a. 86.32 8.29 
(n.a.-12.92) 
NP >225.73 35.66 
(13.77-66.78) 
16.07 
(n.a-41.43) 
121.8
9 
180.59 14.05 Gompertz 
0.64 
20.08 >34 
PT >225.73 n.a. n.a 121.9 180.59 n.a. n.a 20.08 >34 
AF 0.13 
(0.11-0.15) 
0.03 0.017 0.045 0.14 7.65 Weibull 
0.971 
38.69 15.94  
(13.05-19.61) 
SL 0.095 
(0.076-0.13) 
0.02 0.013 <0.14 0.14 7.31 Hill 
0.93 
38.69 >34 
n.a. not available; Spe., species. 
(B) 
Spe. Tylosin 
EC50 EC10 EC5 NOEC LOEC Slope 
(EC50/EC5) 
model Neutral fraction 
(%) 
PS 4.14 
(3.4-5.06) 
0.91 
(0.45-1.37) 
0.4 0.56 1.69 10.35 Gompertz 
0.963 
89.49 
DS 12.19 
(10.57-15.42) 
4.05 
(1.95.-7.33) 
3 <9.38 9.38 4.06 Chapman 
0.955 
89.49 
CV >81.2 n.a. n.a >81.2 >81.2 n.a n.a. 89.49 
NP 1.33 
(1.14-1.76) 
0.83 
(0.6-1.06) 
0.75 0.56 1.13 1.77 Chapman 
0.916 
25.31 
PT 5.7 
(3.67-9.6) 
0.21 
(n.a-0.43) 
0.08 0.28 0.56 71.25 Hill 
0.89 
25.31 
AF 0.092 
(0.073-0.12) 
0.02 0.012 0.037 0.074 7.67 Hill 
0.96 
45.98 
SL 0.09 
(0.068-0.13) 
0.011 0.005 0.009 0.026 18 Chapman 
0.95 
45.98 
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n.a. not available; Spe., species. 
(C) 
Spe. Trimethoprim 
EC50 EC10 EC5 NOEC LOEC Slope 
(EC50/EC5) 
model Neutral 
fraction (%) 
PS >218.28 n.a n.a 218.28 >218.28 n.a n.a. 32.37 
DS >344.45 n.a n.a >344.45 >344.45 n.a n.a. 32.37 
CV >344.45 n.a n.a >344.45 >344.45 n.a n.a. 32.37 
NP 7.36 
(6.74-8.28) 
4.55 
(3.65-5.5) 
4 4.13 6.89 1.84 Chapman 
0.96 
92.32 
PT 74.61 
(55.47-105.23) 
17.19 
(7.62-30.59) 
11.44 20.67 62 6.52 Chapman 
0.894 
92.32 
AF 315.78 
(285.16-n.a.) 
63.13 32.5 46.79 137.78 9.72 logistic 
0.9 
82.72 
SL >344.45 97.58 28.67 206.67 275.56 12 Sigmoid 
0.74 
82.72 
n.a. not available 
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Figure 4.3: The 4d concentration-response curves for seven algal species towards single 
exposure 
Slopes of the concentration-effect curves are of importance in algal tests. It is assumed that 
chemicals with the same “mode of action” have a comparable slope for a particular species 
(Smit et al., 2001). While no universal measure for slope of a concentration-response curve 
exists, it can be defined as a ratio between two EC values (e.g. the EC50/EC05 ratio), which 
has been reported in a range of literatures (Brosche and Backhaus, 2010). Most of the 
EC50/EC05 ratios in this study ranged from 1.77 to 18, which agreed with the average value 
(7.2) in bioassay of algae (Smit et al., 2001). However, no clear trend in slope variance was 
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observed for chlorophytes, cyanobacteria and diatoms (Table 4.1).The toxicological effects of 
the test antibiotics on selected algal species have been reported previously (Table 4.2). For 
tylosin, three studies have been reported on P. subcapitata with 72h EC50 ranging from 0.0083 
to 1.51 µmol L-1 (Halling-Sorensen, 2000, van der Grinten et al., 2010). EC50 values for two of 
the studies are within an order of magnitude of the EC50 of 4.14 µmol L
-1 we obtained for 
tylosin. The EC50 of 0.0083 µmol L
-1 reported by van den Grinten et al. (van der Grinten et al., 
2010) is surprisingly low in comparison to our study. Halling-Sorensen (Halling-Sorensen, 
2000) reported the effects of tylosin on the cyanobacteria Microcystis aeruginosa with a 72h 
EC50 value of 0.037 µmol L
-1 (Table 4.2). This value is lower than the EC50s for A. flos-aquae 
and S. leopoliensis in the current study of 0.092and 0.09 µmol L-1 respectively.  
For lincomycin, 72h EC50 previously reported EC50s for P. subspicata are within an order of 
magnitude of the value we obtained (Table 4.2). Data are also available for toxicity to 
S. leopoliensis and a diatom species (Andreozzi et al., 2006). Our 96h EC50 0.095 µmol L
-1 for 
S. leopoliensis was around a factor of 4 lower than the previously reported value. For diatoms 
we saw no inhibition effects for either diatom species (EC50 >225.73 µmol L
-1), for N. 
pelliculosa and P. tricornutum) whereas Andreozzi et al. (Andreozzi et al., 2006), obtained an 
EC50 of 4 µmol L
-1 although it is important to recognize this was a different species Cyclotella 
meneghiniana than we used.  
For trimethoprim previously reported EC50s for chlorophytes ranged from > 31 to 444.34 µmol 
L-1 (Table 4.2), whereas we obtained an EC50 >344.45 µmol L
-1. For blue green algae, our 
lowest 96h EC50 value was 315.78 µmol L
-1 for A. flos-aquae which is similar to a previously 
reported value for this species of 871.45 µmol L-1. 
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Toxicity data for three earlier time points are summarized in Tables A3.2-3.4 (Appendix 3). In 
most cases no evident algal toxicities were observed at the maximum test concentration over 
the first 2 days of the exposure. While the toxicity effects of antibiotics to algal species were 
continuously increasing from 3d to 4d exposure, the EC50 values were very similar. For 
example, over 3d and 4d exposure of N. pelliculosa to trimethoprim, EC50 values only 
decreased from 9.4 to 7.36 µmol L-1 (Figure 4.4). 
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Figure 4.4: Toxicity comparison (EC50 µmol L
-1) of three antibiotics to selected algal species 
based on 3 day and 4 day measurement. PS, P. subcapitata; DS, D. subspicatus; NP, N. 
pelliculosa; PT, P. tricornutum; AF, A. flos-aquae; SL, S. leopoliensis. LIN, lincomycin; TYN, 
tylosin; TMP, trimethoprim. 
Hypothesis-based no effect concentration (NOEC) and low effect concentration (LOEC) are 
common statistical approaches used to summarize ecotoxicological effects. However, the use 
of NOEC data has been criticized as experiments conducted using poor laboratory practice 
would report larger variability (Warne SJ and Van Dam, 2008). Therefore, the difference 
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between the control and treatments would have to be larger in order to be significant different. 
Instead of using NOEC, a range of studies have called for using regression-based effect 
concentration (ECx) value as an alternative (e,g. EC10) (Iwasaki et al., 2015). In this study 
therefore, in addition to determining the NOEC and LOEC values, we also have derived the 
EC10 value for each algal test (Table 4.1). Most of the NOEC and EC10 data are within an 
order of magnitude of each other.  
Table 4.2: Ecotoxicity data of tested antibiotics to algal growth in literature 
Species Test duration EC50 (µmol L
-1) Reference 
Lincomycin    
P. subcapitata 4 d 3.71 (Andreozzi et al., 
2006)  
Cyclotella meneghiniana 4 d 4 (Andreozzi et al., 
2006)  
S. leopoliensis 4 d 0.49 (Andreozzi et al., 
2006)  
Tylosin    
P. subcapitata 3 d 0.0083 (van der Grinten et 
al., 2010)  
P. subcapitata 3 d 1.51 (Halling-Sorensen, 
2000)   
P. subcapitata 3 d 0.38 (Eguchi et al., 
2004)  
Microcystis aeruginosa 3 d 0.037 (Halling-Sorensen, 
2000)  
Trimethoprim    
P. subcapitata 3 d >31 (van der Grinten et 
al., 2010)  
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P. subcapitata 3 d 276.59 (Eguchi et al., 
2004)  
P. subcapitata 3 d 444.34 (Kolar et al., 2014)  
A. flos-aquae 3 d 871.45 (Kolar et al., 2014)  
4.3.3 Species sensitivity comparisons towards antibiotics at EC50 level  
Sensitivities of the seven algal species exposed to the three antibiotics at EC50 level were 
assessed. For the three chlorophytes, P. subcapitata was slightly more sensitive to tylosin and 
lincomycin exposure than D. subspicatus, while C. vulgaris was not sensitive at the highest 
concentrations tested (Table 4.1). For the cyanobacteria, while A. flos-aquae was slightly more 
sensitive to trimethoprim exposure than S. leopoliensis, sensitivities of the two cyanobacteria 
to tylosin and lincomycin exposures based on EC50 values were of the same order of 
magnitude (Table 4.1). The two diatom species were not affected by lincomycin at the highest 
concentration tested. But based on data for tylosin and trimethoprim, N. pelliculosa was more 
sensitive than P. tricornutum (Table 4.1).  
In general, cyanobacteria were more sensitive than chlorophytes to lincomycin with the EC50 
ranging from 0.095 to 0.13 µmol L-1. No effects of lincomycin were seen on diatoms (Table 4.1). 
The result of sensitivity across algal classes agreed with the literature. For example, Andreozzi 
et al. (Andreozzi et al., 2006) found the 4d EC50 value of lincomycin on the growth of 
cyanobacteria S. leopoliensis were around eight times lower than that for P. subcapitata.  
Cyanobacteria were also found to be most sensitive algae tested to tylosin with EC50 values 
ranging from 0.09 to 0.092 µmol L-1 which was more than 5 times lower than EC50 values for 
chlorophytes and diatoms (Table 4.1). The sensitivities of chlorophytes and diatoms towards 
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tylosin were similar (Table 4.1). These results are consistent with the findings of 
Halling-Sorensen (Halling-Sorensen, 2000), who observed that the cyanobacteria M. 
aeruginosa was ten times more sensitive to tylosin than the chlorophyte P. subcapitata.  
For trimethoprim, no effects were seen on the growth of chlorophyte and cyanobacteria 
species at the maximum test concentration (344.45 µmol L-1) whereas the diatom species 
were found to be much more sensitive to trimethoprim exposure with EC50 values ranging from 
7.36 to 74.61 µmol L-1.  
The differences in the sensitivities within and across algal classes to the antibiotics tested 
might be attributed to a number of explanations, including: differences in antibiotic uptake; 
differences in the binding pockets in the primary targets; differences in antibiotic elimination; 
and differences in active efflux pumps. These are discussed below. 
In this study, the tests were performed in different media with different pH values. It has long 
been recognised that the pH of a system can affect the toxicity of ionisable compounds such 
as the study antibiotics. The initial pH values of culture media for chlorophyte, cyanobacteria 
and diatom species were different:  6.82 (Kuhl medium for chlorophyte), 7.8 (JM medium for 
cyanobacteria) and 8.2 (ESAW+f/2 medium for diatoms), respectively. For acidic antibiotics 
such as tylosin and lincomycin, which have pKa values ranging from 7 to 8 (Table 1.1), media 
with higher pH values would promote ionisation of the antibiotics which would reduce uptake 
into the cells (Halling-Sorensen, 2000). Species tested in lower pH media might therefore be 
expected to accumulate more antibiotic than higher pH media and hence toxicity, expressed 
based on the concentration of the antibiotic in water, would be increased. In instances where 
the pH of the test system changes significantly over time, this will also affect uptake. Based on 
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the pH of the test media, uptake of tylosin and lincomycin by chlorophyte would be expected to 
be greater than by cyanobacteria and diatoms based on the proportion of substance present in 
the neutral form (Table 4.1). As the chlorophyte were never the most sensitive group to 
lincomycin and tylosin, it seems that the observed differences in toxicity are not explained by 
differences in uptake alone. For the weak base trimethoprim, a higher pH would increase the 
percentage of neutral compound. The neutral percentage of trimethoprim increased from 
32.37% in Kuhl medium to 82.72% in JM medium, and reached 92.32% in ESAW+f/2 medium. 
The higher neutral percentage of trimethoprim in ESAW+f/2 medium may therefore contribute 
to a higher toxicity observed for the diatom species (Table 4.1). 
The toxicity of antibiotics in the non-target organisms is most frequently due to interactions 
with the specific drug target (Gunnarsson et al., 2008). While orthologous drug targets (protein) 
are evolutionarily conserved in different species, they are likely to bind to the same exogenous 
chemicals by binding the same or similar endogenous ligands (McRobb et al., 2014). 
Well-conserved targets in a given species might, therefore, increase the risk of 
pharmacological effects in aquatic organisms after exposure to pharmaceuticals (Gunnarsson 
et al., 2008). Though currently no studies have reported the conservation of pharmaceutical 
ligand-binding sites in the algal species, the pockets of endocrine disrupting chemicals (EDCs) 
have already been found to be highly conserved in aquatic toxicity testing organisms such as 
amphibians and fish (McRobb et al., 2014). 
The sensitivity of algal species to antibiotics may also be attributed to differences in antibiotic 
elimination (enzymatic inactivation) by direct degradation or modification of compounds 
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(Wright, 2005). Some organisms (e.g. bacteria) could produce enzymes that degrade the 
antibiotics and further inactivate them. A wide range of antibiotics have hydrolytically 
susceptible chemical bonds (e.g. esters and amides), the integrity of which are important for 
biochemicalactivity. However, for some compounds such as beta-lactam antibiotics (e.g. 
penicillin), the beta-lactam ring could be cleaved by beta-lactamases. Macrolide esterase 
hydrolyses the macrolide antibiotic (e.g. erythromycin) by opening the ring (Wright, 2005). 
Other antibiotic resistant enzymes are the group transferases, which impair target binding by 
structural alteration. A wide range of enzymes such as chloramphenicol acetyltransferases 
and streptogramin acetyltransferases inactivate antibiotics by this pathway (Wright, 2005). 
While the above antibiotic elimination has been only reported in bacteria, the potential 
occurrence in the algal species may result in different sensitivities towards antibiotics.  
The different sensitivity of algal species towards antibiotics may be due to differences in active 
efflux pumps. Efflux pumps are transport proteins used to extrude intracellular toxic substrates 
including antibiotics to the extracellular environment (Webber and Piddock, 2003). Several 
efflux pumps covering a variety of substrates were found in prokaryotic bacteria, and they are 
believed to lead to acquired bacterial antibiotic resistance due to the broad variety of 
substrates they recongnise (Webber and Piddock, 2003). In eukaryotic cells, some efflux 
pumps were found to modulate the accumulation of antibiotics in phagocytic cells (Van 
Bambeke et al., 2000). As efflux pumps are specific for one substrate or multiple classes of 
antibiotics, differences in efflux pumps included in each organism might explain their 
sensitivities towards antibiotic exposures (Webber and Piddock, 2003). Though no antibiotic 
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efflux studies have been reported in the algae, the potential appearance of different efflux 
pumps in the algal species may determine their sensitivities to antibiotic exposure. 
The observations of differences in species sensitivity seen in this study are probably due to a 
combination of these factors. We would therefore advocate that more work be done to assess 
the toxicokinetics and toxicodynamics of antibiotics in different algal species, and other 
pharmaceuticals, in order to provide a better understanding of the key drivers of species 
sensitivity. 
4.3.4 Implication for environment risk assessment  
As can be seen from Table 4.2, previously reported toxicity data for antibiotics for algal species 
have been predominately available for chlorophytes and cyanobacteria. The observed 
sensitivity of cyanobacteria to antibiotics has resulted in these organisms being recommended 
for use in assessing the environmental risks of antibiotics as part of the Market Authorisation 
process for new antibiotics (EMEA, 2006). This conclusion is partly supported by our present 
toxicity results for lincomycin and tylosin. However, trimethoprim appears to be significantly 
more toxic to diatoms than the chlorophytes and cyanobacteria (Table 4.1) so the assumption 
that cyanobacteria are the most sensitive species does not seem to hold true for all antibiotics. 
The current EMEA regulation (EMEA, 2006) on the risk assessment of antibiotics by only 
considering chlorophyte and cyanobacteria as indicators might, therefore, underestimate the 
influence on diatoms. For the purpose of risk assessment of antibiotics on the algal species in 
the aquatic environment and based on the OECD 201 guideline, we recommend that the 
inhibition effects of antibiotics on the growh of at least three species, one from each algal class, 
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be investigated. It would make sense that these tests are done on the species from each class 
that appear to be consistently most sensitive to antibiotic exposure i.e. P. subcapitata, A. 
flos-aquae and N. pelliculosa. It is also important to recognise that we have only worked with a 
selection of indicator species from three classes. Further work on other antibiotic classes and 
other species is warranted to better inform the development of risk assessment approaches. 
4.4 Conclusions 
This study explored the effects of lincomycin, tylosin and trimethoprim on a battery of algal 
species using a standard test procedure. The results showed that algal sensitivity to antibiotics 
varied with EC50 values ranging from < 1 µmol L
-1 level to > 344.45 µmol L-1 for three 
antibiotics. For lincomycin, cyanobacteria were found to be the most sensitive group followed 
by chlorophytes and then diatoms. For tylosin, cyanobacteria were found to be the most 
sensitive group, but diatoms were more sensitive than chlorophytes. Chlorophytes and 
cyanobacteria were not sensitive to trimethoprim at the top concentration tested (344.45 µmol 
L-1) but diatoms were found to be sensitive with EC50 values ranging from 7.36 to 74.61 µmol 
L-1. It is concluded that the ecotoxicological information of antibiotics on model algal species 
(e.g. P. subcapitata and D. subspicatus) may not generalize to other algal groups in light of 
variations in species sensitivity. We would, therefore, recommend that future risk assessment 
of antibiotics in the aquatic compartment should include at least three species from different 
algal classes. 
There are several mechanisms that might be responsible for the inhibition of antibiotics on the 
growth of algae. Reduction in growth could be due to the interference of antibiotics on the algal 
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photosynthetic pigment synthesis such as the light-harvesting pigment chlorophyll a, b and 
carotenoid. As photosynthesis is the primary process for algae to produce biomass, a study 
investigating the effects of antibiotics on the algal photosynthesis would be valuable for 
understanding the toxic mechanism. In the next Chapter, the impacts of the study antibiotics 
on photosynthetic related endpoints are therefore explored. 
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Chapter 5 
Effects of veterinary antibiotics on the growth and physiology 
of chlorophytes, cyanobacteria and a diatom species 
5.1 Introduction 
While it was evident that algae especially cyanobacteria were particularly sensitive to some 
antibiotic exposure (Guo et al., 2015), limited information is currently available concerning the 
underlying toxic mechanism of antibiotics to algae. For eukaryotes such as chlorophytes, 
available evidence indicates that antibiotics are thought to inhibit photosynthetic pathways and 
associated protein synthesis (Liu et al., 2011) which then results in disruption of cell growth. 
For example, Sandmann and Peter Boger (1981) reported that amphotericin B inhibited the 
photosynthetic electron transport of chlorophyte Dunaliella parva (Sandmann and Boger, 1981) 
and Liu et al. (2011) found that erythromycin, ciprofloxacin and sulfamethoxazole could 
significantly inhibit the physiological progress including primary photochemistry, electron 
transport, photophosphorylation and carbon assimilation(Sandmann and Boger, 1981, Liu et 
al., 2011). Effects of antibiotics on prokaryote cyanobacteria are thought to be primarily due to 
interference of protein synthesis (e.g. as seen for chloramphenicol) and DNA replication (e.g. 
as seen for quinolones) (Sandmann and Boger, 1981), although a range of studies have 
reported that antibiotics could also interfere with the photosynthesis process in cyanobacteria. 
For example, Pan et al. (2009) found that the antibiotic levofloxacin inhibited electron transport 
and decreased the density of the active photosynthetic reaction centre in the cyanobacteria 
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Synechocystis sp (Pan et al., 2009).  
At present little is known about the direct effects of antibiotics on light-harvesting pigment 
synthesis and light utilization efficiency, though they are the prerequisites for proceeding 
photosynthesis metabolism in algae and cyanobacteria. The energy of sunlight is captured by 
the light-harvesting pigments such as chlorophyll and carotenoids in the wavelength range of 
700 nm to 400 nm. While light utilization efficiency involves a variety of complex processes, it 
could be readily investigated by exploring the relationship between the irradiance and 
photosynthetic rate (Bahrs et al., 2013). 
While photosynthetic endpoints such as short-term oxygen evolution rate and pigment 
synthesis (i.e. chlorophyll a content) have been used in a range of studies investigating the 
effects of external stressors on algal photosynthetic process, researchers have primarily 
focused on the impacts of stressors such as herbicides. For example, Xia et al. (2005) 
compared the endpoint sensitivity of chlorophyll a, growth and oxygen evolution rate of the 
cyanobacterium Nostoc sphaeroides after 12 d exposure to 38.79 µmol L-1 of the herbicide 
thiobencarb (Xia, 2005). Significant inhibition effects were only found on the endpoints of 
oxygen evolution rate and growth, where oxygen evolution rate exhibited higher sensitivity 
(42.1% inhibition) than growth (33.3% inhibition). Wong (2000) investigated the effects of the 
herbicides glyohosate and paraquat on the growth, photosynthesis and pigment synthesis in 
the chlorophyte Scenedesmus quadricauda. At a concentrations of 11.83 µmol L-1 of 
glyphosate, growth was found to be the most sensitive endpoint (64.3% inhibition), followed by 
photosynthetic rate (48.3% inhibition) and chlorophyll a (33.3% inhibition) (Wong, 2000). While 
growth was still the most sensitive endpoint (85.7% inhibition) after exposure to 0.78 µmol L-1 
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paraquat, chlorophyll a showed higher sensitivity (66.7% inhibition) than the photosynthetic 
rate (38.6% inhibition). Only a handful of publications has explored the inhibition effects of 
antibiotics including erythromycin and chloramphenicol on the photosynthesis of chlorophytes 
Pseudokirchneriella subcapitata and Chlamydomonas reinhardis. Both substances were 
proved to signifcantly inhibit algal oxygen evolution rate and the degree of inhibition was 
enhanced at the higher exposures (Liu et al., 2011, Hudock et al., 1964). However, no 
attempts were made to compare the sensitivity of photosynthesis related endpoints and growth 
(i.e. cell counts). For the effect assessment of antibiotics on algal species, an understanding of 
the endpoint sensitivity for a battery of species from the chlorophyte, cyanobacteria and 
diatom groups would be valuable in understanding the potential impacts of antibiotics on 
ecosystems and also to provide information to help understand the mechanisms of action of 
antibiotics in different algal species. 
The objectives of the work described in this Chapter were, therefore: 1) to compare the 
sensitivity of photosynthesis related endpoints (i.e. oxygen evolution rate) and growth (i.e. cell 
counts) following 4d exposure to antibiotics; 2) to obtain information on the underlying toxic 
mechanisms of the antibiotics regarding light-harvesting pigment synthesis and utilization 
efficiency. The work focused on the three antibiotics studied in the work described in the 
previous Chapter and the four species Pseudokirchneriella subcapitata, Desmodesmus 
subspicatus, Anabaena flos-aquae and Navicula pelliculosa, which were shown to be the 
sensitive organisms of the seven species studies in Chapter 4. 
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5.2 Method 
5.2.1 Chemicals 
The sources and purities of the test chemicals are described in Chapter 4 (Section 4.2.1). 
5.2.2 Algae culture 
Algal species P. subcapitata (CCAP 278/4), D. subspicatus (CCAP 258/137), A. flos-aquae 
(CCAP 1403/13A) and N. pelliculosa (CCAP 1050/9) were supplied by the Institute of 
Freshwater Ecology (Culture Collection of Algae and Protozoa, UK). For detailed culture 
methods refer to Section 4.2.2. 
5.2.3 Effects on growth 
The effects of the study antibiotics on algal growth were explored over 4 d using OECD 
Guideline 201. Initial range-finding studies were used to estimate the EC50 range based on the 
growth (cell density) inhibition tests. Triplicates of six concentrations (maximum 93.79, 225.73 
and 344.45 µmol L-1 for tylosin, lincomycin and trimethoprim, respectively) around the 
estimated EC50 in geometric series were then selected for use in the definitive study.  
All glassware and stoppers used in the tests were autoclaved at 121 °C for 30 min prior to use. 
Each concentration of antibiotic was prepared in the corresponding culture medium. After 
addition of the antibiotic solution, samples were filtered to a 25 ml vial using a 0.2 µm sterilized 
syringe filter. The algal solution grown in the logarithmic phase was then inoculated into the 
vial to obtain 15 ml solution with an initial density 5 X 105 cells mL-1. Following the inoculation, 
these vials were caped with air-permeable stoppers made of cotton and muslin. All the 
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operations were undertaken in a sterilized chamber, and the vials were then incubated for 4 d 
under the same conditions as the cultures. 
Cell density in each sample was measured at 24 h intervals using UV-Visible 
spectrophotometry. Cell density was calculated from a calibration curve of known cell density 
counted by a haemocytometer against adsorption measured by an ultraviolet and visible 
(UV-Vis) spectrophotometry (R2>0.999) for each test species. Measurement of turbidity 
(adsorption) using a spectrophotometer set at a selected wavelength is a reliable method to 
determine cell density (ABO, 2013). Each algal culture was diluted and scanned over the 
600-800 nm range. The wavelengths with the highest absorbance were selected for 
experiments. P. subcapitata was detected at a wavelength of 750 nm and D. subspicatus, A. 
flos-aquae, N. pelliculosa at a wavelength 682 nm.  
The prepared concentration of tested samples before the test was confirmed by chemical 
analysis. Samples with the highest and lowest concentrations were analysed again after the 
test to determine the antibiotic stability. In several algal toxicity tests, the recoveries of 
antibiotics in the highest and lowest test concentrations were less than 80% after 4d test. In 
these cases, the first-order degradation reaction (Equation 5.1) was used to estimate a 
dissipation rate constant (k). The k was then applied in Equation 5.2 to estimate the 
time-weighted average concentration (TWAC) over t days (where t=1, 2, 3, 4). By comparing 
the TWAC with the nominal concentration, a correction factor was then obtained for use in the 
concentration response analyses. Observations from the low concentration recovery tests 
were used for correcting the three lowest concentrations used in the ecotoxicity study while 
concentrations for the high concentration recovery were used for correction of the three 
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highest concentrations. 
Ct = C0 X e
-kt                                                                                             Equation 5.1 
Cavet = C0 X (1- e
-kt) / kt                                                    Equation 5.2 
Where C0: initial concentration (µmol L
-1); Ct: concentration at the t day (µmol L-1); Cavet: 
average concentration over t days (µmol L-1); k: rate constant (day-1); t: time (day) (Boesten et 
al., 1997). 
5.2.4 Photosynthetic oxygen evolution 
After 4 d exposure to the antibiotics, algae from the growth studies were taken and the oxygen 
evolution rate was determined using a DW2 Oxygen Electrode Chamber (Hansatech 
Instruments Limited, UK). The measurement was firstly performed for 10 min under dark 
conditions at 20 °C to give the respiration rate (R). A 15 min measurement under illumination of 
76 µmol m-2 s-1 actinic light intensity was then performed to give the photosynthesis rate (Pn). 
The gross photosynthesis rate (Pg) was the sum of these two processes.  
5.2.5 Photosynthetic pigment content 
After 4 d exposure in the growth studies, 5 ml of each treated sample was firstly filtered using a 
25 mm fibre filter (Pall Corporation, UK). Afterwards, the filter was put into a vial with 5 ml 
methanol, and kept for 24h in a spark-free fridge to extract photosynthetic pigment content. 
Chlorophyll a and b were estimated using the Wellburn coefficient equation (Equation 5.3 & 
5.4) (Wellburn, 1994) and the total carotenoid (carotene and xanthophyll) were estimated 
using the Lichtenthaler equation (Equation 5.5) (Henriques et al., 2007). Absorbance was 
measured by UV - Vis spectrophotometry at 470 nm, 653 nm and 666 nm. For each 
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experimental measurement, the result was corrected for cell density.  
Chlorophyll a (mg L-1) = 15.65 A666 - 7.34 A653                                         Equation 5.3 
Chlorophyll b (mg L-1) = 27.05 A653 - 11.21 A666                               Equation 5.4 
Total carotenoids (mg L-1) = (1000 A470 - 44.76 A666) / 221                      Equation 5.5 
5.2.6 Irradiance-Photosynthesis (I- P) relationship measurement 
To investigate the potential effects of antibiotics on the algal light utilization efficiency, algae 
were exposed, in triplicate, to the EC50 of each antibiotic based on photosynthesis endpoint for 
4 d after which photosynthesis of the samples was measured under 5 different light intensities: 
76, 150, 300, 450 and 600 µmol m-2 s-2. Bar charts of gross photosynthesis rate (Pg) versus 
light intensity were plotted to analyse the effects of antibiotics on the algal light utilisation 
efficiency. 
5.2.7 Chemical analysis procedures 
Concentrations of the study antibiotics in the test solutions were confirmed analytically using 
the methodologies described in Section 4.2.4. 
5.2.8 Statistical methods 
The inhibition data were analysed using Sigma-plot software. Dose-response curves were 
fitted using sigmoid curve regression analysis. Significant differences between treatments and 
controls were identified using the One way ANOVA Dunnett test with a p value <0.05. A Two 
way ANOVA Tukey test was used in Irradiance-photosynthesis relationship study, where all 
data passed the test for normality.  
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5.3 Results and discussion 
5.3.1 Analysis of chemical stability, pH variation and reference substance  
While SPE was performed to concentrate the exposure solutions for the tests on A. flos-aquae 
prior to the chemical analysis, the volume of solution in the test vial was less than 15 ml so it 
was not possible to conduct SPE again. While no stability data of the antibiotics for studies 
with A. flos-aquae during the 4d period are available, stability data of lincomycin and tylosin 
obtained in Chapter 4 were applied to extrapolate to the intermediate concentration.  The 
mean recovery of tylosin, lincomycin and trimethoprim before the test on A. flos-aquae were 
120.13%, 120.28% and 84.7%, respectively. 
Data on the stability of the study compounds during the tests on the two chlorophytes and the 
diatom are presented in Figure 5.1 and Appendix 4. Stability varied depending on test 
concentration and species. For tylosin, concentrations at the end of the study ranged from 
40.96% (N. pelliculosa exposed to a concentration of 7.25 µmol L-1) to 129% (P. subcapitata 
exposed to 0.4 µmol L-1) of the starting concentration. For lincomycin, the range of was 33% (N. 
pelliculosa exposed to a concentration of 225.73 µmol L-1) to 131.1% (D. subspicatus exposed 
to 18.87 µmol L-1). For trimethoprim the range was 12.75% (P. subcapitata exposed to 30.69 
µmol L-1) to 105.08% (N. pelliculosa exposed to 146.32 µmol L-1). The disappearance of 
antibiotics might be due to photolysis and metabolism to algae. The potential occurrences and 
effects of two factors on algal tests have been thoroughly discussed in Chapter 4 and will 
therefore not be repeated here.  
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Figure 5.1: The amount (expressed as a % of the starting concentration) of the three study 
antibiotics remaining in the exposure media used in the growth samples (data are shown for 
the lowest and highest test concentration for each study). Data represent mean ± standard 
deviation (n=3). DS, D. subspicatus; PS, P. subcapitata; NP, N. pelliculosa. 
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For most studies, there was no significant difference between the pH of the medium at the start 
and the end of the study (Figure 5.2). The exceptions were tests with trimethoprim on P. 
subcapitata, N. pelliculosa and A. flos-aquae, lincomycin on N. pelliculosa and tylosin on P. 
subcapitata where a maximum increase of 0.8 units was observed - this value is within the 
variation considered acceptable by the OECD 201 guideline (less than 1.5 units). An 
explanation is that CO2 mass transfer from the surrounding air could not fulfil the growth of 
algae due to the carbon demand of algal growth. CO2 was then derived from biocarbonate in 
the medium resulting in an increase in pH (Luetzhoft et al., 1999). This result agreed with 
published work e.g. in previous tests of trimethoprim on the chlorophyte P. subcapitata and 
cyanobacteria A. flos-aquae, the pH values were within the range of 7.1-8.3 (Kolar et al., 2014). 
The pH values of the different algal media (6.8—8.2) would promote the ionisation of the 
tested antibiotics in solutions, which resulted in the neutral fractions ranging from 20.08% to 
92.32% (Table 5.1). Effects of antibiotic ionisation on algal toxicity and sensitivity have been 
discussed in Chapter 4 and therefore will not be repeated here.   
EC50 values for the reference toxicant, potassium dichromate on two chlorophytes D. 
subspicatus and P. subcapitata were 4.59 and 5.23 µmol L-1, respectively. These results are 
consistent with previously reported data where the EC50 for the substance was found to range 
from 1.33 to 4.86 µmol L-1 for D. subspicatus and 1.29-8.89 µmol L-1 for P. subcapitata (Pattard, 
2009). The EC50 found for diatom N. pelliculosa and A. flos-aquae were > 33.99 and 
15.94µmol L-1, respectively. However, no information on the toxicity of potassium dichromate 
to these two species is available in the literature for comparison purposes. 
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Figure 5.2: Changes in pH during 4 days of exposure to antibiotics. Data represent mean ± 
standard deviation (n=21). PS, P. subcapitata; DS, D. subspicatus; NP, N. pelliculosa; AF, A. 
flos-aquae; LIN, lincomycin; TYN, tylosin; TMP, trimethoprim. 
5.3.2 Endpoint sensitivity comparison 
All the exposure concentrations used for plotting concentration-response curves have been 
revised using modified chemical recoveries (Table 5.2). While this study characterised the 
inhibition effects of antibiotics on the pigment synthesis, the results of pigment content 
(chlorophyll a, b and carotenoid) after 4d exposure could not be fitted to dose-response curves. 
Therefore, it was only possible to derive dose-response curves based on effects on growth 
and oxygen evolution rate to derive EC50 values. These data are described in the next section 
along with a discussion of the sensitivity of the different endpoints. 
5.3.2.1 Toxicity test analysis based on growth 
Studies into the effects of the three study antibiotics on the growth of a selection of algal 
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species have been reported previously. In our study the 96 h EC50 for tylosin for growth 
inhibition of P. subcapitata was 4.8 µmol L-1 (Table 5.1), which agrees with the previous studies 
where 72h EC50 values have been reported to range from from 0.0083 to 1.51 µmol L
-1 
(Halling-Sorensen, 2000, van der Grinten et al., 2010, Eguchi et al., 2004). For A. flos-aquae, 
we obtained a 96h EC50 of 0.06 µmol L
-1, which is at the order of magnitude of a published 
EC50 of 0.037 µmol L
-1 which was reported for another cyanobacterial species, Microcystis 
aeruginosa, after 72h exposure to tylosin (Halling-Sorensen, 2000). The 96 h EC50 for 
lincomycin for A. flos-aquae growth inhibition was 1.2 µmol L-1, this is not dissimilar to the 96h 
EC50 value reported for the cyanobacteria Synechococcus leopoliensis of 0.49 µmol L
-1  
(Andreozzi et al., 2006). The 96 h EC50 for lincomycin to the chlorophyte P. subcapitata was 
24.14 µmol L-1 (Table 5.1), which is higher than previously reported values for the same 
species 0.16 µmol L-1 [72 h EC50] (Isidori et al., 2005) and 3.71 µmol L
-1 [96 h EC50] (Andreozzi 
et al., 2006). There are numerous explanations for variations between our data and previous 
studies including: differences test conditions (e.g. in initial inoculation cell number) or 
differences in the sensitivities of individual species within an algal class. As suggested by 
OECD 201 guideline (OECD, 2011), low cell numbers ranging from 5 X 103 to 5 X 104 cells 
mL-1 were usually used for pure toxicity tests (van der Grinten et al., 2010, Andreozzi et al., 
2006, Isidori et al., 2005). In this study, the inoculated cell number was set at 5 X 105 cells mL-1 
to allow the pigments to be extracted and analysed after the 4 day exposure. The pigment 
extraction could be favoured by a higher initial biomass to obtain measurable pigment content. 
A higher initial cell density could lead to less toxicant content bonding to the cells (both 
intercellular and extracellular), and further lead to less toxicant uptake and lowering of toxicity 
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(Franklin et al., 2002). This trend has been reported in tests with copper on the chlorophyte P. 
subcapitata, where significantly more extra- and intracellular copper was accumulated at algal 
initial cell density at 103 cells ml-1 compared to 104 and 105 cells ml-1 for the medium with the 
same copper concentration. The toxicity at 72h EC50 level in terms of growth rate significantly 
decreased from 97.56 to 118.02 and 267.51 µmol L-1 as cell density increased (Franklin et al., 
2002). Despite previous studies showing lincomycin to affect the diatom Cyclotella 
meneghiniana with a reported at 96 h EC50 of 4 µmol L
-1 (Andreozzi et al., 2006), in the current 
study, no effect was found for the diatom N. pelliculosa at the top test concentration of 153.91 
µmol L-1. It was inferred to the difference in species sensitivity. Potential effects of trimethoprim 
were recorded for the chlorophyte P. subcapitata (72h EC50 276.59 – 444.34 µmol L
-1) (Kolar et 
al., 2014, Eguchi et al., 2004) and cyanobacteria A. flos-aquae (72h EC50 871.45 µmol L
-1) 
(Kolar et al., 2014), which agreed with the results of this study (> 307 µmol L-1). The 96h EC50 
for trimethoprim for the diatom N. pelliculosa was 70.48 µmol L-1, this compound does not 
appear to have been tested previously on diatoms.  
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Table 5.1 Summary of EC50 (µmol L-1) data based on two endpoints (growth and gross photosynthesis) for three antibiotics on four algal species over 4 d 
exposures (Numbers in parenthese indicate 95% confidence limits). 
 Tylosin Trimethoprim Lincomycin 
 Growth Photosynthesis pH range Neutral 
fraction 
(%) 
Growth Photosynthesis pH range Neutral 
fraction 
(%) 
Growth Photosynthesis pH range Neutral 
fraction 
(%) 
DS 38.27 
(30.23-47.08) 
17.6 
(10.13-13.39) 
6.65-7.76 89.49 >272.7 >272.7 5.99-6.31 32.37 >188.71 79.41 
 (60.27-103.3) 
7.38-7.8 86.32 
PS 4.8 
(4.26-5.47) 
2.1 
(n.a.) 
6.69-6.86 89.49 >307 >307 6.77-7.03 32.37 24.14 
(21.84-27.6) 
12 
(n.a.-20.68) 
5.92-6.06 86.32 
AF 0.06 
(n.a.-0.068) 
0.33 
(0.21-0.52) 
6.99-8.04 45.98 >341.69 >341.69 7.21-7.85 82.72 1.2 
(1.04-1.51) 
4.75 
(0.49-n.a.) 
7.28-7.78 38.69 
NP 4.4 
(3.66-5.05) 
7.35 
(0.44-17.49) 
7.75-8.36 25,31 70.48 
(57.79-96.03) 
136.36 
(95.34-n.a.) 
8.54-9.1 92.32 >153.91 >153.91 8.81-9.07 20.08 
n.a. not available;  
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5.3.2.2 Toxicity test analysis based on photosynthesis and endpoint sensitivity comparison 
For the two chlorophytes, photosynthesis was found to be a more sensitive endpoint than 
growth. After 4d exposure to tylosin, the EC50 values for the two chlorophytes D. subspicatus 
and P. Subcapitata, based on photosynthesis as an endpoint, were 17.6 and 2.1 µmol L-1, 
respectively. Similar results were also observed for two chlorophytes exposed to lincomycin 
(Table 5.1). However, for cyanobacteria A. flos-aquae and diatom N. pelliculosa, the situation 
was reversed and growth appeared to be a more sensitive endpoint than photosynthesis 
(Table 5.1). For example, after 4d exposure of A. flos-aquae to lincomycin, the EC50 derived 
based on growth was 1.2 µmol L-1 (Table 5.1), which was nearly one third of that derived based 
on photosynthesis. While no explanation for the sensitivity behaviour of both endpoints was 
available, the results of this study indicate that when testing antibiotics on chlorophytes for the 
environmental risk assessment purpose, oxygen evolution rate measurements might be an 
additional endpoint that could be included which, in some cases, may be more sensitive as 
well a being ecologically relevant as photosynthesis is such an important process for 
ecosystem functioning. 
5.3.3 Analysis of the toxic effects on the algal physiology 
5.3.3.1 Toxic effects on the oxygen evolution rate 
All three antibiotics significantly inhibited the oxygen evolution rate of gross photosynthesis 
(Table 5.2). The inhibition effects were strengthened with the increasing concentrations of 
antibiotics. However, not all tested antibiotics (e.g. trimethoprim on N. pelliculosa and 
lincomycin on A. flos-aquae) affected pigment synthesis (e.g. chlorophyll a). The effects of 
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these antibiotics on algal photosynthetic reaction (i.e. oxygen evolution rate) may be due to the 
damage on structural development of the chloroplast, where it was not correlated with a factor 
directly related to chlorophyll synthesis/ content (Hudock et al., 1964). Similar results were 
reported in the study of Hudock et al. (1964) who investigated the effects of the antibiotic 
chloramphenicol on a strain of the chlorophyte Chlamydomonas reinhardi. Algal cultures were 
kept in the dark for 96h where this strain could neither form a normal chloroplast nor 
synthesize chlorophyll. The cells were then returned to the light to ensure that the chlorophyll 
and chloroplasts were newly synthesised and formed (called regreening; Hudock et al., 1964). 
It was found that algal cultures treated with 61.89 µmol L-1 chloramphenicol during the first 
three hours of regreening would inhibit the oxygen evolution rate but had no effect on 
chlorophyll synthesis rate/content.  
5.3.3.2 Toxic effects on the pigment synthesis  
The pigment contents of algal cells were not significantly affected by the three antibiotics for D. 
subspicatus. However, in some cases, pigment contents were significantly increased for P. 
subcapitata, N. pelliculosa and A. flos-aquae at the concentrations affecting growth (Table 5.2). 
For example, after 4d exposure to tylosin at 18.23 µmol L-1, the chlorophyll a and carotenoid 
contents per cell of P. subcapitata increased by 45% and 165% compared to that in control. 
Similar stimulation effects have been reported by study testing other toxicant (polyamidoamine 
(PAMAM) 1,4-diaminobutane core, G2), where total chlorophyll content increased by 121% 
compared to the control at a concentration of 0.76 µmol L-1  (Petit et al., 2010). However, not 
all the antibiotics could promote the synthesis of chlorophyll and carotenoids. Liu et al. (2011) 
reported that erythromycin at the concentration of 0.41 µmol L-1 could lead to a reduction in the 
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chlorophyll content of P. subcapitata to 0.4 mg g-1 fresh weight compared to 0.95 mg g-1 in the 
control. A few of studies only present the measured pigment contents in the unit of mg L-1, 
without correction for cell density or weight. For example, the carotenoid content of the 
prokaryote Sarcina lutea was reduced from 63 mg L-1 in the control to 38 mg L-1 over 24 h 
exposure to 14.24 µmol L-1 chloramphenicol (Portoles et al., 1970), In this case, the reduction 
in pigment might be attributed to less algae exisitng in the solution due to reduced growth. 
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Table 5.2 Values of net photosynthesis, respiration, gross photosynthesis rate, chlorophyll a, b and total carotenoid content per cell of Desmodesmus 
subspicatus (D.S.), Pseudokirchneriella subcapitata, (P.S.) Navicula pelliculosa (N.P.) and Anabaena flos-aquae (A.F.) over 4 d antibiotic exposures for three 
antibiotics: tylosin (TLN), trimethoprim (TMP) and lincomycin (LIN) (n.a not available as chlorophyll b only occurred in chlorophyte; Data are presented as Mean 
values ± standard deviation (n=3); asterisks indicate significant difference; Data are shown for the control, the lowest and highest test concentration for each 
study).  
Algae Pharma 4d TWAC 
 (µmol L
-1
) 
net 
photosynthesis/cells 
(umol O2  h-1 
cell-1106) 
respiration/cells 
(umol O2  h-1 
cell-1106) 
gross 
photosynthesis/cells 
(umol O2  h-1 cell-1 
106) 
chloro a/cell (109 
mg L-1 cell-1) 
chloro b/cell (109 
mg L-1 cell-1) 
total chloro/cell 
(109 mg L-1 cell-1) 
total carotenoid/ 
cells (109 mg L-1 
cell-1) 
D.S. TLN control 0.233±0.108 -0.27±0.077 0.507±0.045 0.98±0.11 1.41±0.19 2.4±0.31 0.59±0.073 
  6.49 0.282±0.067 -0.16±0.083 0.44±0.027 0.91±0.3 1.42±0.65 2.32±0.95 0.56±0.204 
  12.99 0.339±0.028 -0.11±0.011* 0.45±0.018 0.97±0.104 1.41±0.18 2.38±0.29 0.60±0.066 
  25.97 0.092±0.022 -0.0058±0.018* 0.097±0.016* 1.12±0.37 1.77±0.64 2.88±1.01 0.72±0.202 
  42.94 0.074±0.037* -0.051±0.033* 0.125±0.039* 0.72±0.071 1.1±0.096 1.82±0.17 0.49±0.042 
  57.26 0.093±0.091* -0.093±0.077* 0.185±0.12* 0.65±0.14 1.02±0.31 1.67±0.45 0.45±0.107 
  71.56 0.076±0.0085* -0.045±0.039* 0.12±0.048* 0.86±0.089 1.51±0.18 2.37±0.27 0.61±0.07 
 LIN Control 0.38±0.031 -0.076±0.024 0.46±0.055 1.24±0.14 1.76±0.3 3±0.44 0.71±0.1 
  18.87 0.25±0.031* -0.092±0.0068 0.34±0.035* 1.17±0.07 1.78±0.21 2.95±0.25 0.72±0.063 
  37.74 0.19±0.047* -0.112±0.016 0.304±0.034* 1.44±0.18 2.12±0.31 3.56±0.49 0.88±0.12 
  75.49 0.11±0.054* -0.11±0.0072 0.22±0.053* 1.03±0.16 1.42±0.35 2.45±0.52 0.63±0.12 
  113.23 0.07±0.05* -0.13±0.014* 0.2±0.041* 1.12±0.058 1.6±0.13 2.72±0.19 0.69±0.037 
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  150.97 0.027±0.015* -0.14±0.035* 0.17±0.023* 1.2±0.098 1.85±0.15 3.05±0.24 0.78±0.07 
  188.71 0.02±0.018* -0.11±0.015 0.13±0.0046* 1±0.1 1.5±0.12 2.5±0.22 0.64±0.067 
 TMP control 0.23±0.11 -0.19±0.01 0.43±0.1 1.25±0.052 1.77±0.12 3.02±0.17 0.72±0.039 
  27.25 0.2±0.16 -0.14±0.0063 0.34±0.16 0.99±0.13 1.31±0.19 2.3±0.32 0.57±0.069 
  54.53 0.25±0.13 -0.18±0.034 0.43±0.16 1.05±0.1 1.36±0.13 2.41±0.24 0.59±0.045 
  109.09 0.24±0.13 -0.2±0.019 0.44±0.14 1.14±0.15 1.51±0.31 2.65±0.46 0.65±0.089 
  163.61 0.31±0.11 -0.18±0.033 0.49±0.13 0.99±0.34 1.65±0.44 2.64±0.63 0.66±0.15 
  218.14 0.3±0.088 -0.15±0.053 0.45±0.13 1.22±0.21 1.66±0.33 2.88±0.54 0.703±0.12 
  272.7 0.36±0.033 -0.15±0.033 0.51±0.066 0.98±0.057 1.27±0.13 2.25±0.18 0.56±0.051 
P.S. TLN Control 0.086±0.055 -0.11±0.023 0.2±0.046 0.49±0.068 0.25±0.12 0.745±0.18 0.2±0.042 
  0.4 0.098±0.045 -0.095±0.013 0.19±0.052 0.5±0.07 0.246±0.083 0.746±0.15 0.21±0.03 
  1.2 0.1±0.038 -0.098±0.012 0.2±0.045 0.52±0.054 0.23±0.031 0.749±0.081 0.205±0.024 
  3.61 -0.08±0.006* -0.13±0.027 0.052±0.03* 0.53±0.015 0.29±0.061 0.82±0.063 0.23±0.026 
  9.12 -0.2±0.045* -0.22±0.04 0.023±0.006* 0.6±0.097 0.63±0.072* 1.24±0.16 0.307±0.041 
  18.23 -0.3±0.095* -0.32±0.092* 0.012±0.006* 0.89±0.044* 1.22±0.089* 2.12±0.13* 0.53±0.036* 
  27.35 -0.32±0.083* -0.33±0.083* 0.008±0.006* 0.43±0.038 0.38±0.14 0.81±0.17* 0.19±0.068* 
 LIN Control 0.073±0.036 -0.063±0.0078 0.136±0.039 0.29±0.036 0.15±0.015 0.44±0.049 0.14±0.014 
  17 -0.029±0.022* -0.082±0.023 0.053±0.007 0.31±0.078 0.203±0.14 0.51±0.204 0.18±0.069 
  34 -0.055±0.01* -0.096±0.037 0.041±0.044 0.28±0.083 0.3±0.14 0.58±0.22 0.19±0.056 
  68 -0.078±0.014* -0.089±0.014 0.0107±0.002 0.33±0.092 0.45±0.204 0.78±0.3 0.23±0.069 
  125 -0.104±0.032* -0.11±0.032 0.0073±0.002* 0.29±0.1 0.405±0.18 0.7±0.28 0.214±0.071 
  166.61 -0.124±0.039* -0.13±0.035* 0.0069±0.005* 0.17±0.074 0.19±0.14 0.36±0.21 0.12±0.05 
  208.28 -0.131±0.014* -0.14±0.016* 0.0052±0.002* 0.34±0.31 0.52±0.55 0.85±0.86 0.23±0.18 
 TMP Control 0.044±0.022 -0.073±0.0205 0.117±0.034 0.52±0.035 0.35±0.095 0.88±0.13 0.26±0.03 
  13.2 0.058±0.038 -0.059±0.014 0.017±0.04 0.45±0.018 0.26±0.037 0.707±0.054 0.208±0.013 
  26.42 0.059±0.036 -0.063±0.023 0.12±0.046 0.54±0.054 0.37±0.098 0.908±0.15 0.26±0.038 
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  52.83 0.058±0.014 -0.073±0.015 0.13±0.024 0.56±0.048 0.41±0.082 0.97±0.13 0.28±0.025 
  103.29 0.05±0.015 -0.07±0.018 0.12±0.023 0.5±0.0104 0.32±0.03 0.818±0.039 0.24±0.002 
  137.73 0.043±0.01 -0.068±0.022 0.11±0.025 0.52±0.018 0.408±0.081 0.928±0.086 0.27±0.013 
  172.15 0.033±0.006 -0.072±0.019 0.1±0.022 0.45±0.044 0.35±0.0503 0.801±0.093 0.23±0.023 
N.P. TLN control 0.071±0.016 -0.081±0.013 0.15±0.014 0.74±0.053 n.a. n.a. 0.502±0.041 
  4.88 -0.01±0.012* -0.1±0.061 0.086±0.051* 0.86±0.1 n.a. n.a. 0.64±0.067 
  9.77 -0.04±0.009* -0.11±0.013 0.07±0.012* 1.05±0.12 n.a. n.a. 0.8±0.089 
  19.53 -0.06±0.019* -0.11±0.011 0.051±0.017* 1.1±0.2 n.a. n.a. 0.85±0.19 
  41.72 -0.06±0.007* -0.096±0.02 0.032±0.021* 1.05±0.34 n.a. n.a. 0.8±0.28 
  59.6 -0.06±0.02* -0.099±0.04 0.036±0.03* 1.24±0.4 n.a. n.a. 0.95±0.32 
  77.4 -0.06±0.014* -0.12±0.022 0.054±0.023* 1.34±0.17 n.a. n.a. 1.06±0.13* 
 LIN Control 0.02±0.023 -0.12±0.025 0.14±0.037 0.76±0.18 n.a. n.a. 0.56±0.14 
  21.44 0.031±0.022 -0.089±0.004 0.12±0.021 0.56±0.024 n.a. n.a. 0.42±0.023 
  42.88 0.035±0.023 -0.09±0.031 0.13±0.051 0.73±0.24 n.a. n.a. 0.5±0.13 
  64.33 0.026±0.014 -0.1±0.027 0.13±0.041 0.77±0.19 n.a. n.a. 0.58±0.14 
  82.03 0.048±0.007 -0.1±0.031 0.15±0.038 0.64±0.1 n.a. n.a. 0.38±0.1 
  102.61 0.05±0.009 -0.095±0.022 0.15±0.031 1.03±0.34 n.a. n.a. 0.77±0.24 
  153.91 0.053±0.027 -0.093±0.007 0.15±0.033 0.78±0.2 n.a. n.a. 0.58±0.17 
 TMP control 0.026±0.016 -0.17±0.047 0.19±0.032 0.57±0.096 n.a. n.a. 0.43±0.077 
  10.85 0.035±0.009 -0.16±0.02 0.19±0.013 0.66±0.038 n.a. n.a. 0.49±0.031 
  16.26 0.026±0.004 -0.16±0.03 0.19±0.034 0.6±0.053 n.a. n.a. 0.45±0.031 
  32.52 0.059±0.012 -0.16±0.04 0.22±0.042 0.7±0.04 n.a. n.a. 0.51±0.039 
  48.77 -0.01±0.016 -0.18±0.085 0.17±0.075 0.63±0.048 n.a. n.a. 0.49±0.033 
  97.55 -0.15±0.061* -0.29±0.101 0.14±0.041 1.68±0.6* n.a. n.a. 1.4±0.48* 
  146.32 -0.19±0.068* -0.27±0.051 0.086±0.023* 1.14±0.2* n.a. n.a. 0.97±0.17* 
A.F. TLN control 0.058±0.041 -0.1±0.0093 0.16±0.05 0.26±0.032 n.a. n.a. 0.194±0.034 
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  0.032 0.07±0.039 -0.097±0.17 0.17±0.051 0.24±0.062 n.a. n.a. 0.166±0.052 
  0.064 0.03±0.014 -0.074±0.033 0.1±0.019 0.27±0.033 n.a. n.a. 0.215±0.024 
  0.19 -0.1±0.026* -0.19±0.031 0.092±0.034 0.24±0.002 n.a. n.a. 0.191±0.007 
  0.5 -0.18±0.084* -0.21±0.065 0.034±0.054* 0.4±0.064 n.a. n.a. 0.332±0.045 
  1.06 -0.18±0.091* -0.18±0.051 -0.0032±0.042* 0.47±0.178* n.a. n.a. 0.366±0.137* 
  2.11 -0.2±0.073* -0.2±0.095 -0.0071±0.022* 0.49±0.048* n.a. n.a. 0.384±0.038* 
 LIN control 0.028±0.025 -0.13±0.023 0.16±0.026 0.35±0.137 n.a. n.a. 0.25±0.095 
  0.12 -0.01±0.034 -0.14±0.013 0.13±0.034 0.56±0.267 n.a. n.a. 0.363±0.14 
  0.23 -0.04±0.007 -0.144±0.016 0.104±0.021 0.31±0.112 n.a. n.a. 0.227±0.074 
  1.38 -0.11±0.042* -0.21±0.078 0.101±0.054 0.47±0.146 n.a. n.a. 0.35±0.091 
  2.93 -0.17±0.054* -0.25±0.087 0.079±0.034* 0.83±0.176* n.a. n.a. 0.57±0.113* 
  5.87 -0.17±0.065* -0.25±0.08 0.08±0.02* 0.6±0.05 n.a. n.a. 0.43±0.035 
 TMP control 0.091±0.019 -0.066±0.034 0.16±0.035 0.27±0.046 n.a. n.a. 0.18±0.032 
  23.21 0.094±0.055 -0.064±0.027 0.16±0.03 0.22±0.016 n.a. n.a. 0.14±0.008 
  46.42 0.056±0.056 -0.078±0.0098 0.13±0.065 0.22±0.015 n.a. n.a. 0.13±0.008* 
  92.83 0.085±0.034 -0.067±0.023 0.15±0.052 0.22±0.041 n.a. n.a. 0.12±0.029* 
  205.02 0.084±0.057 -0.067±0.021 0.15±0.073 0.27±0.029 n.a. n.a. 0.17±0.02 
  273.35 0.101±0.025 -0.067±0.018 0.168±0.041 0.23±0.025 n.a. n.a. 0.14±0.017 
  341.69 0.069±0.019 -0.064±0.017 0.13±0.035 0.24±0.041 n.a. n.a. 0.15±0.013 
Chapter 5                                Antibiotic effects on algal growth and physiology               
140 
 
5.3.3.3 Toxic effects on the Irradiance - Photosynthesis relationship 
The gross oxygen evolution rate in the control cultures of D. subspicatus, P. subcapitata and N. 
pelliculosa measured at increasing irradiance levels increased and the trend followed a typical 
irradiance – photosynthesis (I-P) curve (Figure 5.3),where significant differences between 
controls and treated samples were observed for these species. While the oxygen evolution 
rate in the treated samples exhibited a similar increasing trend, each evolution rate was still 
lower than that of the control (except for A. flos-aquae). The gap of gross oxygen evolution rate 
between control and treated samples was enlarged with higher irradiance. However, in the 
cyanobacteria A. flos-aquae, no significant differences between controls and treated samples 
were observed, though EC50s of lincomycin and tylosin based on photosynthesis were applied. 
The reason might be due to that the EC50 derived was not significantly different. For example, 
after 4d exposure to tylosin, EC50 derived from concentration-response curve (gross oxygen 
evolution rate) was 0.33 µmol L-1, which was lower than the lowest-observed-effect- 
concentration (LOEC, 0.5 µmol L-1; Table 5.2). No increasing trend of oxygen evolution rate 
was shown with increasing irradiance as light has already achieved saturation or higher 
(Figure 5.3). These findings agreed with other published work e.g. Bahrs et al. (2013) found 
significant differences in P – I relationship could be observed for the chlorophyte 
Desmodesmus armatus and the cyanobacteria Synechocystis sp. between the control and 
samples treated with polyphenol p - benzoquinone at the EC90 level based on growth. In 
particular, the maximum gross oxygen production of Synechocystis sp. in treated sample was 
five times lower than that in the control. However, no significant effects of p - benzoquinone 
were found on the P - I relation of cyanobacteria Microcystis aeruginosa. The light - saturation 
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photosynthesis rate was determined by the light acclimation state and the nutrient conditions 
(Blache et al., 2011). As the nutrients in control and treated samples in this study were the 
same, a reduction in light - saturation photosynthesis rate might be due to antibiotic interacting 
with algal acclimation state via the disruption of the photosynthesis process. 
D. subspicatus to LIN
Irradiance (umol photon m-2 s-1)
100 200 300 400 500 600 700
G
ro
ss
 p
ho
to
sy
nt
he
si
s 
/ c
e
lls
 
(u
m
o
l O
2
 h
-1
 c
e
lls
-1
 *
 1
0
6
)
0.0
.1
.2
.3
.4
.5
a
ab
ab
ab
b
c c
c
c
c
control 
79.41 umol L-1
D. subspicatus to TYN
Irradiance (umol photon m-2 s-1)
100 200 300 400 500 600 700
G
ro
ss
 p
ho
to
sy
nt
he
si
s 
/ c
e
lls
 
(u
m
o
l O
2
 h
-1
 c
e
lls
-1
 *
 1
0
6
)
0.0
.1
.2
.3
.4
.5
a
ac
ad
bcd
b
e
e
e e
e
control 
17.6 umol L-1
 
P. subcapitata to LIN
Irradiance (umol photon m-2 s-1)
100 200 300 400 500 600 700
G
ro
ss
 p
ho
to
sy
nt
he
si
s 
/ c
e
lls
 
(u
m
o
l O
2
 h
-1
 c
e
lls
-1
 *
 1
0
6
)
0.0
.1
.2
.3
c c
c
c
c
a
ab
ab ab
b
control 
12 umol L-1
P. subcapitata to TYN
Irradiance (umol photon m-2 s-1)
100 200 300 400 500 600 700
G
ro
ss
 p
ho
to
sy
nt
he
si
s 
/ c
e
lls
 
(u
m
o
l O
2
 h
-1
 c
e
lls
-1
 *
 1
0
6
)
0.0
.1
.2
.3
a
a
a
a a
b b
b b
b
control 
2.1 umol L-1
 
N. pelliculosa to TMP
Irradiance (umol photon m-2 s-1)
100 200 300 400 500 600 700
G
ro
ss
 p
ho
to
sy
nt
he
si
s 
/ c
e
lls
 
(u
m
o
l O
2
 h
-1
 c
e
lls
-1
 *
 1
0
6
)
0.00
.05
.10
.15
.20
ac
abc
ab ab
b
c c c c c
control 
136.36 umol L-1
N. pelliculosa to TYN
Irradiance (umol photon m-2 s-1)
100 200 300 400 500 600 700
G
ro
ss
 p
ho
to
sy
nt
he
si
s 
/ c
e
lls
 
(u
m
o
l O
2
 h
-1
 c
e
lls
-1
 *
 1
0
6
)
0.00
.05
.10
.15
.20
.25
.30
ae
ace ade
bcde
b
e e
e
e e
control 
7.35 umol L-1
 
Chapter 5                                Antibiotic effects on algal growth and physiology               
142 
 
A. flos-aquae to LIN
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Figure 5.3 Responses of the gross photosynthetic rate on irradiance for algal species with 
evident photosynthesis inhibition effect from antibiotics. Data represent mean ± standard 
deviation (n=3). Bars sharing the same letter code are not significantly different; LIN, 
lincomycin; TYN, tylosin; TMP, trimethoprim.  
5.3.3.4 Toxic mechanism analysis 
While antibiotics are designed to interact with receptors in pathogenic bacteria, the fact that 
similar receptors and/or pathways might also be conserved in algal species means that the 
exposure of antibiotics in the culture medium could pose potential threat to the growth of algae. 
For tylosin and lincomycin, the mode of action is by interference with bacterial protein 
synthesis by binding to the 50s ribosomal subunit (Drugbank, 2013, Sigma-Aldrich, 2015). 50s 
is the larger subunit of the 70s ribosome of prokaryotes (PDB, 2010). In the eukaryote 60s is 
the larger subunit of the 80s ribosome (Wilson and Cate, 2012). An antibiotic (e.g. 
erythromycin) with a similar mode of action is entirely selective for 70s ribosomes and does not 
affect 80s ribosomes (Scholar and Pratt, 2000). This evidence could explain why a high 
sensitivity to tylosin and lincomycin was observed for the cyanobacteria. However, tylosin and 
lincomycin could inhibit the growth of eukaryotic species by interfering with the protein and 
enzyme synthesis involved in the photosynthesis process (Liu et al., 2011). For example, 
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approximately 30 proteins of cytochrome bf complex, which are the important component for 
the membrane in the thylakoid of algae, are involved in photosynthesis Ⅰ and Ⅱ. The 
macrolide erythromycin has been found to reduce the membrane content by interfering with 
the electron transport from PS Ⅱ to PS Ⅰand reducing the size of the receptor- side of PS 
Ⅱ (Liu et al., 2011). Ribulose bisphosphate carboxylase (Rubisco) is an essential enzyme to 
catalyse the addition of CO2 to ribulose-1,5-bisphosphate (RuBPCase) during the Calvin Cycle 
in the algal photosynthesis (Cooper, 2000). Macrolides could adversely influence the activity of 
rubisco and further inhibit the synthesis and activity of the RuBPCase in algae i.e. 
erythromycin could inhibit the synthesis of RuBPCase in P. subcapitata, and the inhibitory 
degree enhanced with higher exposure concentration (Liu et al., 2011).  
For trimethoprim, the mode of action is to interact with dihydrofolate reductase (FolA) 
(Drugbank, 2013). However, for prokaryotic species such as Nostoc sp. and Synechocystis sp., 
FolA is not included as these enzymes seem not to be essential in their folate metabolism 
(Myllykallio et al., 2003). This may indicate why trimethoprim did not affect the chlorophyll 
synthesis in cyanobacteria. For eukaryotes, information on the toxic mechanism of 
trimethoprim is still lacking. 
5.4 Conclusions 
This study indicated that after 4d exposure to antibiotics tylosin, lincomycin and trimethoprim, 
the photosynthesis related endpoint (oxygen evolution rate) exhibited higher sensitivity than 
the growth endpoint in the test with chlorophytes. The situation was reversed when testing 
antibiotics on cyanobacteria and diatoms. It is recommended that more species from each 
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class should be involved in testing antibiotics to confirm this conclusion. Once the verdict has 
been confirmed, the endpoint of oxygen evolution rate might be an endpoint that could be used 
in regulatory ecotoxicity studies in the future in addition to growth.  
This study revealed that antibiotics might promote the pigment synthesis in some algal species 
(P. subcapitata, N. pelliculosa and A. flos-aquae). Despite the light utilization efficiency of 
eukaryote chlorophytes and diatom being reduced after exposure to the antibiotics that 
affecting growth, no significant inhibition effect on prokaryote cyanobacteria was observed. 
While Chapters 2 - 5 have attempted to understand and characterise the potential risk and 
effects of antibiotics on a wide range of algal species in surface waters, results from these 
studies were obtained based on single compound tests. However, surface waters are more 
likely to be exposed to antibiotic mixtures than single substances so the combination effects 
and potential risks of antibiotic mixtures warrant further consideration. The next Chapter 
therefore explores the risks arising from combined exposure to the three study compounds. 
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Chapter 6 
Risks of mixtures of major-use veterinary antibiotics to 
blue-green algae 
6.1 Introduction 
The work described in the previous Chapters (Chapter 4 & 5) investigated the effects of the 
three study antibiotics on the growth and physiology of algal species. The studies worked with 
single compounds. The results indicated that algal species, especially cyanobacteria, are 
more likely to be affected by antibiotics than other aquatic organisms. However, agricultural 
surface waters are unlikely to be exposed to single antibiotics (Backhaus et al., 2011). The 
reason being that some antibiotic products contain mixtures of antibacterially active 
substances (e.g. sulfonamides and trimethoprim are often used in combination) (Kienzler et al., 
2014) and a number of different antibiotics are likely to be in use in a catchment at any one 
time (Kienzler et al., 2014). When assessing the risks of antibiotics, it is therefore important to 
consider the potential combined effects of antibiotics. A number of studies have explored the 
effects of pharmaceutical mixtures on aquatic organisms. For examples, Cleuver (2003) 
assessed the joint toxicity of clofibric acid and carbamazepine on the green algae 
Desmodesmus subspicatus, and showed that the mixture toxicity could be predicted by the 
concept of independent action (IA). Christensen et al. (2007) investigated the effects of binary 
mixtures of citalopram, fluoxetine, fluvoxamine, paroxetine and sertraline on algae and 
daphnids, and also showed that the combined toxicity of the compounds could be predicted by 
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concentration addition (CA).  
Methods for assessing the risks of mixtures of chemicals to the natural environment have been 
proposed (Kienzler et al., 2014). For example REACH (Regulation No 1907/2006) presents a 
tiered approach for assessment of industrial chemical mixtures (EC, 2006). At tier 1, a 
conservative approach based on concentration addition (CA) is applied. Risk quotients (RQ) 
for individual mixture components are determined from PECs and PNECs and then summed 
to determine the RQ of the mixture (RQmix) (Kienzler et al., 2014). A similar approach could be 
used to evaluate the risks of antibiotic mixture.  
This Chapter describes a study to assess the risks of the three study antibiotics to the 
cyanobacterial species Anabaena flos-aquae. A. flos-aquae was selected for use in the 
mixture studies as the studies described in Chapter 4 demonstrated that this species was the 
most sensitive to tylosin and lincomycin with the 4d EC50 being 0.13 µmol L
-1 and 0.14 µmol L-1, 
respectively, while the 4d EC50 for trimethoprim was 285.75 µmol L
-1.  
Initially, an experimental investigation into the effects of a mixture of the study antibibiotics was 
performed and the results used to evaluate the performance of two commonly used mixture 
effect models, the concentration addition (CA) and independent action (IA) models. One of the 
validated models was then used alongside surface water exposure models, proposed by the 
Forum for Pesticide Fate Models and their Use (FOCUS) (FOCUS, 2011), to assess the 
combined risks of the use of the three compounds, resulting from use as veterinary medicines, 
to European surface waters.  
6.2 Methods  
6.2.1 Chemicals 
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The sources and purities of the test antibiotics are described in Section 4.2.1. 
6.2.2 Algae culture 
Algal culturing procedures for Anabaena flos-aquae are described in Section 4.2.2. 
6.2.3 Ecotoxicity studies  
Exposure models described in the CVMP Guidance Document (EMEA, 2008) were used to 
define relative concentrations, on a molar basis, of the three study compounds for use in the 
experimental mixture toxicity study. Based on this modelling (see Equation 6.1, Appendix 5), a 
ratio of 1 part tylosin to 4.31 parts trimethoprim and 4.18 parts lincomycin was selected for 
mixture toxicity testing. The 96 h EC50 values for the single study compounds were determined 
in the work described in Chapter 4. Therefore, the EC50 determination for the mixture was 
conducted without the range-finding step. Thirteen concentrations of the mixture in a 
geometric series around the lowest EC50 of the study compounds (i.e. tylosin) were used in the 
definitive EC50 test. The dose-response curve based on growth (cell density) was then 
generated based on the definitive data. 
Prior to use in the ecotoxicity studies, all glassware and stoppers used in the tests were 
autoclaved at 121°C for 30 min. The antibiotics in the media were prepared and filtered into a 
25 ml vial using a 0.2 µm sterilized syringe filter. The precultured algal inocula, taken from 
logarithmic growing precultures, were diluted into 15 ml of the prepared antibiotic solutions in 
the vials. The initial cell density was set at 2× 104 cells ml-1. The test vials were capped with 
air-permeable stoppers made of cotton and muslin. All the operations were performed on a 
sterilized bench. Afterwards, the prepared vials were put in the culturing incubator with the 
same shaking and physical conditions.  
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Bioassays lasted for 96 h, and the cell numbers were measured every 24 h using UV-Vis 
spectrophotometry. Cell numbers were estimated using a calibration curve of absorption 
determined by an ultraviolet and visible (UV-Vis) spectrophotometry and cell density. The 
wavelength for absorption measurement was 682 nm for A. flos-aquae. The pH values of 
thirteen tested exposure solutions were measured at the start and the end of the exposures. 
Analytical confirmation of exposure concentrations was also performed for the thirteen 
exposure solutions.
6.2.4 Concentration - response curve analysis
The data were analysed using Sigma-plot software. The experimental concentration - 
response curve was obtained by fitting experimental result to a sigmoidal regression, where x-
axe was the molar sum of each component (µmol L-1) and y-axe was growth inhibition (%). 
Two computational models concentration addition (CA) and independent action (IA) were 
introduced to predict the concentration – response curves. Concentration addition is defined 
as toxicants acting on the same biological site by the same mode of action (Equation 6.2):
 = 1                                                             Equation 6.2∑
𝑛
𝑖= 1 𝐶𝑖𝐸𝐶𝑥𝑖
Where Ci is the individual concentration of the ith substance present in a mixture with a total 
effect of x%, and ECxi is the concentration of ith substance that causes the same x% effect by 
single exposure (Backhaus et al., 2000, Cleuvers, 2003). With the known mixture ratio (tylosin: 
trimethoprim: lincomycin, 1: 4.31: 4.18), the total concentration can be expressed as a 
function of the concentration of each component. To calculate the effect concentrations 
predicted by the concentration addition (CA), Equation 6.2 can be rewritten as Equation 6.3:
ECxmix = ( )-1                                                      Equation 6.3
∑𝑛𝑖= 1 𝑃𝑖𝐸𝐶𝑥𝑖
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Where ECxmix is the total concentration of the mixture causing x% effect and pi is the molar 
fraction of components in the mixture (Backhaus et al., 2000). By using all the available effect, 
the total concentration was calculated (Equation 6.3) and a predicted concentration-response 
curve was plotted by fitting total concentration/ effect pairs to sigmoid regression. The dose – 
response curve of A. flos-aquae exposed to each single antibiotic was obtained from pervious 
study (Chapter 4).
The alternative concept is independent action defined by the effects of toxicants on different 
modes of toxic action (Equation 6.4): 
E (cmix) = 1-                                                 Equation 6.4
∏𝑛𝑖 (1 ‒ 𝐸(𝑐𝑖))
Where E (ci) is the effect of an individual single component and E (cmix) is the total effect of 
the mixture of total concentration. Equation 6.4 was used to estimate the mixture effects 
based on independent action (IA), and the total concentration is the sum of each component 
(Equation 6.5). The total concentration/ effect pairs were plotted and fitted to sigmoid 
regression to get the concentration-response relationship (Backhaus et al., 2000).
Cmix =                                                            Equation 6.5
∑𝑛𝑖= 1𝐶𝑖
6.2.5 Mixture model evaluation
The 5% effective concentration values (EC05) and the median effective concentration values 
(EC50) with approximate 95% confidence intervals were calculated for the experimental 
mixture concentration – response curves as well as the CA and IA predictive curves. 
EC50/EC05 ratio provides a measure of slope. These parameters were used to evaluate the 
predictive capability of the two models.
6.2.6 Antibiotic analysis
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Concentrations of the antibiotics in the exposure solutions were confirmed using analytical 
methodologies described in Section 4.2.4.  
6.2.7 Estimation of PECs based on FOCUS model 
Concentrations of the study antibiotics in representative surface waters in agricultural areas in 
Europe were estimated using models and scenarios recommended by the Forum for Pesticide 
Fate Models and their Use (FOCUS) (FOCUS, 2011). The application rate, which is a required 
input for the models, was estimated based on recommended dosages and treatment 
frequencies and durations for each antibiotic, obtained from Compendium of Data Sheets for 
Animal Medicines 2012 (NOAH, 2011), using the approach recommended by the European 
Medicines Agency (EMEA, 2008). For each antibiotic, the maximum application rate (Amax), the 
average application rate (Aave) and the minimum application rate (Aave) of all products and 
indications were used for the FOCUS modeling. The medical products used to derive the 
maximum application rates were Synutrim (trimethoprim) and Pharmasin (tylosin) used for the 
treatment of broilers, and Lino-spectin 100 (lincomycin) for treating pigs (NOAH, 2011). The 
medical products used to derive the minimum application rates were Trimacare injection 
(trimethoprim) and TYLAN 200 (tylosin) used for the treatment of cattle, and Lincocin Premix 
(lincomycin) for pig treatment.  
Modeling of the eight scenarios (five covering systems with soil drainage: D1, D2, D4, D5, D6; 
and three systems that are vulnerable to runoff: R1, R3, R4) covering drainage and runoff 
inputs to different watercourses (ditch, pond and stream) was performed using the winter 
cereal scenario. The ground incorporation method of application was selected and inputs from 
spray drift were set at zero. No uptake by plants was assumed (EMEA, 2008). 
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Physico-chemical properties of the antibiotics, needed for the modeling, were derived from a 
variety of sources and are given in Table 6.1. Estimation procedures can be found in the 
FOCUS model manual. The 4 d time-weighted averaged exposure concentrations (TWAEC) in 
the water layer for each scenario and antibiotic were obtained and used in the risk 
characterization work, as the PNEC in this study was based on 4 d EC50 derived from the 
effects of antibiotics on a cyanobacteria A. flos-aquae.  
Table 6.1: Input parameters for the three antibiotics used in the FOCUS modelling 
 Trimethoprim Tylosin Lincomycin 
Molecular weight (g mol-1) 290.32 916.12 406.53 
Log Kow 0.911 1.632 0.561 
DT50water (d) 29.1
3 9.54 37.55 
DT50soil (d) 110
6 547 4.58 
DT50sediment (d) 542
5 10005 337.55 
VP (pa) 1.32 x 10-6 9  2.65 x 10-32 5 1.79 x 10-15 5  
Water solubility (mg L-1) 40010 511 2930010  
Enthalpy of vaporization (J mol-1)12 95000  95000 95000 
Molar enthalpy of dissolution (J mol-1) 12 27000  27000 27000 
Amax (kg ha
-1) 6.652 8.448 0.456 
Aave (kg ha
-1) 0.711 1.194 0.257 
Amin (kg ha
-1) 0.0273 0.0656 0.0652 
Koc 16809  55313  596  
1 (Drugbank, 2013); 2 (Loke et al., 2002); 3 (Giang et al., 2015); 4 (Brain et al., 2005); 5 Data predicted 
by EPI Suite (EPA, 2013); 6 (Boxall et al., 2005); 7 (Boxall et al., 2006); 8 (Kummerer, 2004); 9 (straub, 
2013); 10 (Drugbank, 2013); 11 (EPA, 2013); 12 (EMEA, 2008); 13 (Rabolle and Spliid, 2000) 
6.2.8 Mixture risk assessment for the three antibiotics 
Concentration addition was used as the basis for the risk characterization for the mixtures of 
the three antibiotics for each of the FOCUS scenarios. Initially, a risk quotient (PEC/PNEC) for 
each veterinary antibiotic was calculated based on the concentration estimated for the 
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antibiotic in each scenario. The risk quotient for the mixture (RQmix) of antibiotics for a scenario 
was then obtained by summing up the PEC/PNEC ratios for the individual antibiotics (Kienzler 
et al., 2014). If the RQmix was lower than one then the risk of the mixture to algae was deemed 
to be acceptable. 
6.3 Results and discussion 
6.3.1 Chemical analysis and pH variation 
With an increase in the exposure concentration, the pH in the antibiotic mixture studies 
decreased gradually from 7.99 to 6.96. While a pH variation (1 unit) was observed, it was 
within the scope of OECD 201 guideline (less than 1.5 units). A drift in pH can be caused by 
CO2 mass transfer from the surrounding air to the test solution (OECD, 2011). The variation in 
pH was consistent with a previous study (Chapter 4). The chemical recoveries for tylosin, 
lincomycin and trimethoprim were 122±16% (mean± standard deviation), 191±37% and 
80±24%, respectively. As the chemical recovery of lincomycin was far above 100%, this 
measured concentration of lincomycin was used to modify the mixture ratio (tylosin: 
trimethoprim: lincomycin, 1: 4.31: 6.65) 
6.3.2 Mixture toxicity analysis and model evaluation 
Dose-response curves based on the experiments with cyanobacteria A. flos-aquae as well as 
CA and IA predictions are shown in Figure 6.1. The mixture had an observed 4d EC50 of 0.248 
µmol L-1 (trimethoprim 0.089 tylosin 0.021 and lincomycin 0.138 µmol L-1) (Table 6.2). While 
both the CA and IA concepts provided good estimations of the combined effects of the different 
mixtures of tylosin, lincomycin and trimethoprim (Table 6.2; Figure 6.1), a more accurate 
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predictability by CA of the joint toxicity of the mixture was observed. The IA predicted an EC50 
of 0.34 µmol L-1 which was 37.1% higher than the observed EC50. While CA predicted a slightly 
higher toxicity (EC50 0.21 µmol L
-1) which was only 15.3 % lower than the observed EC50. This 
finding was consistent with other publications investigating combination effects of 
pharmaceuticals. For examples, Cleuvers (2003) reported that the toxic effect of a binary 
mixture of pharmaceuticals ibuprofen and diclofenac, both belonging to the nonsteroidal 
anti-inflammatory drugs (NSAID), on chlorophyte D. subspicatus could be predicted well using 
the CA concept yet the IA predicted a lower combination effect. The binary mixture toxicity of 
three selective serotonin reuptake inhibitors (SSRIs) citalopram, fluoxetine and sertraline to 
freshwater algae P. subcapitata was predictable by CA model (Christensen et al., 2007). 
The fact that the CA model works well is probably explained by the modes of action of the 
three antibiotics as well as the relative concentrations. Trimethoprim acts by inhibiting 
dihydrofolate reductase (DHFR) (Drugbank, 2013), while tylosin and lincomycin act by 
inhibiting bacterial protein synthesis by binding to 50s ribosome (Drugbank, 2013, 
Sigma-Aldrich, 2015). The relative concentrations mean that tylosin and lincomycin, which act 
by the same mode of action, are the two components within the mixture that dominant toxicity 
in this mixture (both EC50s are 1000 times lower than that of trimethoprim; Table 6.2). 
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Table 6.2 Concentration - response models, EC05, EC50 and EC50/EC05 ratio of the tested 
antibiotics and the mixture 
Substance Model EC05 (µmol L-1) EC50 (µmol L-1) EC50/EC05 
Trimethoprim Three-parameter 
sigmoid 
<1.56 285.95 (246.88- n.a.) 183 
Tylosin Three-parameter hill  0.025 0.13 (0.09-0.18) 5.2 
Lincomycin Three-parameter hill  0.036  0.14 (0.11-0.15) 3.89 
Mixture Three-parameter hill 0.05 0.248 (0.22-0.29) 5 
CA Calculated <0.061 0.21 3.44 
IA Calculated <0.12 0.34 2.83 
Steepness is important in determining the predictability of CA and IA models for a mixture at 
EC50 level. While no universal measure for slope of a concentration-response curve exists, it 
can be defined as a ratio between two EC values (e.g. the EC50/EC05 ratio), which has been 
reported in a range of literatures [47]. Brosche and Backhaus (2010) reported that with an 
EC50/EC05 ratio of 13.5, CA and IA models will predict quantitatively identical toxicity despite 
their mutually exclusive conceptual ideas. CA will predict a lower EC50 (higher toxicity) for the 
mixture than IA if the ratio for the concentration – response curve of the mixture is lower. In this 
study the EC50/EC05 ratio (5) indicated a high steepness of the observed concentration – 
response curve for the mixture (Table 6.2; Figure 6.1) (Brosche and Backhaus, 2010). The 
steepness of the mixture curve was within the range of slope for each single component, e.g. 
the ratio of EC50/EC05 ranged from 3.89 for tylosin up to 183 for trimethoprim. The CA model 
predicted a more accurate steepness with a factor of 0.31 lower than the experimental value 
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(Table 6.2), despite only a lower factor of 0.43 was observed in the steepness of IA predicted 
curve. Smit et al. (2001) found average value for the EC50/EC05 ratio of 7.2 for typical 
bioassay with algae, which is in line with finding for our single and mixture studies (Table 6.2). 
Typical EC50/EC05 ratios for algal test were substantially smaller than the critical threshold of 
13.5 (Smit et al., 2001). The application of CA to a mixture tested on algae would therefore 
result in a slight overestimation of the mixture toxicity and IA predicted higher toxicity value, 
which agreed with the current study (Table 6.2). In conclusion, CA predicted more accurately 
the combined effect of three antibiotics on A. flos-aquae than IA. Therefore, risk assessment 
for the antibiotic mixture was performed based on the CA model. 
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Figure 6.1: Predicted and observed mixture toxicity. Solid line (blue) = prediction according to 
concentration addition (CA); dashed line (dark yellow) = prediction according to independent 
action (IA); dashed-dotted line (red) = fit to the experimental mixture data; Solid line (green) = 
95% confidence band; solid symbols= treated samples. X axis (Cmix) is the sum concentrations 
of three antibiotics. Molar rate of tylosin: trimethoprim: lincomycin = 1: 4.31: 6.65. 
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6.3.3 Estimation of exposure concentrations 
The maximum occurrence of three substances were found in scenario R3 for stream systems 
(Table 6.3). R3 is a southern Europen scenario considering the superficial loading from run-off 
to surface water, where run-off is determined by annual rainfall and slope. The R3 stream 
scenario had a higher annual rainfall (800-1000 mm) than R1 & 4 scenarios (600-800 mm), 
and a slope of 4-10% in comparison with the intermediate case 2-4% of R1 (FOCUS, 2011).  
The occurrence of three antibiotics has been reported worldwide. The concentration of 
trimethoprim ranged from less than 3.4 x 10-5 µmol L-1 in UK surfacewaters (Ashton et al., 2004) 
to 0.0061 µmol L-1 (US) (Kolpin et al., 2002) in US. These reported concentrations of 
trimethorpim were within the range of the predicted concentrations obtained using the FOCUS 
models. While very limited information on the occurrence of tylosin and lincomycin in surface 
waters was available, the presensce of lincomycin in surfacewater has been recorded from 
less than 2.46 x 10-6 to 0.0018 µmol L-1 (US) (Monteiro and Boxall, 2010). The maximum 
occurrence of tylosin was found at 5.46 x 10-5 µmol L-1 in the downstream of agricultural land in 
US (Boxall et al., 2011). All these reported concentrations for both antibiotic bases were within 
the range of the predicted concentrations in this study (Table 6.3) which gives some 
confidence in the model predictions. It should be noted that only 4 d TWAEC was extracted 
here (Table 6.3), whereas in reality the concentration of each antibiotic can be further reduced 
by other factors such as degradation and dilution over time. 
Table 6.3 Estimation of exposure concentrations and single-substance risk quotients for three 
antibiotics. 4 d TWAEC: 4 d time weighted average exposure concentration. The value range 
indicates the lowest and highest TWAECs and risk quotients obtained for target waterbody 
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type. Values in parentheses are predicted based on medium application rate. D: drainage 
scenario; R: runoff scenario. 
Chemical Waterbody 
type 
Highest 
scenario 
4 d TWAEC (µmol L-1) Risk quotient 
Trimethoprim Pond R1 4.72x10-6 - 0.016 
(0.0017) 
1.65x10-6  - 0.0054 
(0.00058) 
 Ditch D1 1.22 x10-5 - 0.026 
(0.0028) 
4.26x10-6  - 0.0092 
(0.00098) 
 Stream R3 4.82 x10-6 - 0.084 
(0.009) 
1.69 x10-6 - 0.029 
(0.0031) 
Tylosin  Pond R1 9 x10-6 - 0.0061 
(0.00086) 
0.0069 – 4.61 (0.65) 
 Ditch D2 1.98 x10-5 - 0.011 
(0.0016) 
0.015– 8.45 (1.19) 
 Stream R3 8.27 x10-6 - 0.073 
(0.01) 
0.0063 – 55.83 (7.89) 
Lincomycin 
 
Pond R1 1.25 x 10-5 - 0.0004 
(0.00022) 
0.0089 - 0.28 (0.16) 
 Ditch D2 1.01 x 10-5 - 0.00075 
(0.00042) 
0.0072 - 0.53 (0.3) 
 Stream R3 6.74 x 10-6  - 0.011 
(0.0063) 
0.0048 – 8.01 (4.51) 
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6.3.4 Risk assessment for single antibiotics and antibiotic mixtures 
In terms of single substances, it can be concluded that a potential environment risk for 
trimethoprim was unlikely even using maximum application rate for the exposure estimation, 
as the maximum risk quotient (RQ) reached 0.029 in the R3 stream scenario (Table 6.3). With 
the estimation of medium exposures, RQs of tylosin and lincomycin exceeded a value of one 
for streams (Table 6.3). The maximum RQ values for both substances were 55.83 and 8.01, 
respectively (Table 6.3). These data indicate a high potential risk for tylosin and lincomycin in 
the European aquatic environment. These risk characterisation reuslts for single antibiotics 
agreed with other risk assessments or risk based prioritisation studies. For example, the max 
RQ of trimethoprim was 0.15 in Norway (Grung et al., 2008). Both tylosin and lincomycin were 
classified as high priority based on the potential risk in the UK environment (Boxall et al., 2003). 
Risk quotients for mixtures, estimated based on maximum application rates, exceeded one for 
most exposure scenarios i.e. D1, D2, D5, D6, R1, R3 and R4. The RQ values of the antibiotic 
mixture estimated based on the three application rate scenarios ranged from 0.016 to 63.86 
(Figure 6.2). While these values indicated a high potential risk of this antibiotic mixture to the 
aquatic environment, the risk was dominated by tylosin.  
In this risk assessment exercise cyanobacteria A. flos-aquae was targeted for hazard 
assessment. A range of studies have demonstrated that cyanobacteria exhibit higher 
sensitivity towards anitbiotics than fish, daphnia and other algal species, despite there were 
some exceptions i.e. diatom Navicula pelliculosa was found to be more sensitive to 
trimthoprim (4 d EC50 21.01 µmol L
-1) than A. flos-aquae by a factor of 10 (Guo et al., 
submitted). However, N. pelliculosa was not sensitive to lincomycin with 4 d EC50 > 225.7 µmol 
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L-1, which was more than 1000 times higher than that of A. flos-aquae (4 d EC50 0.13 µmol L
-1). 
The 4 d EC50 of tylosin to N. pelliculosa (1.33 µmol L
-1) was also ten times higher than that of A. 
flos-aquae (0.13 µmol L-1; Chapter 4). Therefore, risk characterisation on cyanobacteria A. 
flos-aquae will likely protect the broader environment from exposure to an antibiotic mixture of 
trimethoprim, tylosin and lincomycin. 
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Figure 6.2: Risk quotients (PEC/PNEC) for a mixture of three antibiotics calculated based on 
maximum, medium and minimum application rate. d, ditch; s, stream and p, pond. 
6.4 Conclusions 
This study explored the combined effect of mixtures of three major use veterinary antibiotics to 
cyanobacteria A. flos-aquae, followed by an evaluation on the predictability of concentration 
addition (CA) and independent action (IA) models. With the estimation of antibiotic exposures, 
concentration addition was used as the basis for the risk characterization for the mixture. The 
results showed that while CA slightly overestimated the combined toxicity, this model 
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performed better than the IA model. When the CA model was used alongside exposure 
assessment models, an unacceptable risk was observed for the mixture of the three antibiotics 
for surface water scenarios covering different regions of Europe, primarily due to the effects 
from tylosin and lincomycin. We advocate that target monitoring of these antibiotics in the 
European surface water should be performed to gather data for a more realistic risk 
assessment and that biological monitoring be performed to see whether effects on algae are 
occurring in reality. 
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Chapter 7 
General discussion and recommendations 
 
In the last decades much research has focused on the fate of APIs in the environment and the 
potential effects on a wide range of organisms. Several studies have investigated the 
ecotoxicological effects of APIs on algal species with the EC50 ranging from ug L
-1 to mg L-1 
levels (Chapter 2). While differences in the sensitivity of algae to antibiotics have been 
recognised, the available data is limited to very few species and groups. Fewer studies have 
investigated the sensitivity of algal species to antibiotics. As the current environment risk 
assessment (ERA) regulations (e.g. EMEA 2006 & 2008) on antibiotics heavily rely on the 
algal test results to perform hazard assessment, studies exploring the sensitivity of algal 
species to antibiotic exposures and the underlying toxic mechanisms are justified.   
Studying the response of algal species towards APIs in the aquatic environment is important 
because algae, sitting at the base of the food web, act as an essential element in the nutrient - 
cycling processes in the environment, so impacts of APIs on algae might threaten entire 
ecosystems (Chapter 2). In contrast to Daphnia and fish, algae are known to be particularly 
sensitive to APIs with antimicrobial properties.  
The research in this thesis initially prioritised the APIs for experimental investigation, based on 
the potential risk in the UK environment (Chapter 3). An approach was developed for 
prioritising pharmaceuticals in the environment in terms of risks to aquatic and soil organisms, 
Chapter 7                                             Conclusions & Recommendation                                                                     
162 
 
avian and mammalian wildlife and humans. Compared to other prioritisation studies that have 
tended to focus on single use categories (e.g. prescription or hospital use), the developed 
approach is more complete as it includes assessment of parent compounds with high primary 
and secondary care usage, associated metabolites, over the counter (OTC) drugs, APIs 
suggested by environmental experts and substance detected in a recent chemical monitoring 
program (Gardner, 2013).  
A summary of the highly ranked APIs, identified based on the ecotoxicological data for algae in 
Chapters 2 & 3 are presented in Table 7.1. The chemicals with RQ > 1 (i.e. those that are likely 
to occur at concentrations above effects concentrations) are all antibiotics. The antibiotics 
identified as a priority in the two Chapters were also slightly different (Table 7.1). The 
differences in priorities between the two Chapters are explained by differences in the exposure 
assessment methodologies used. In Chapter 2, a total residue method that only relied on the 
usage data in England was used, whereas the usage data considered in Chapter 3 included 
England, Scotland and Wales and the exposure assessment considered metabolism and 
removal in Waste Water Treatment Plants (WWTP). In this case the compound that is 
extensively metabolised after oral administration and easily to be adsorbed to sludge would be 
removed from the priority list (Chapter 3), but the primary metabolite would be added i.e. After 
oral administration, less than 5% of the administered dose of erythromycin can be recovered in 
the active form in the urine (Drugbank, 2013). This fact resulted in the low ranking of 
erythromycin. However, its main metabolite norerythromycin appeared 11th in the final list with 
a risk score in the range 0.1-1 (Chapter 3). In contrast with the research in Chapter 2, the 
priority compounds identified in Chapter 3 are more likely to occur in the environment due to 
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the realistic exposure assessment approach (Metcalfe et al., 2008) and a wide range of 
toxicological data characterised in the hazard assessment. Dissimilar ranking results for 
veterinary and human APIs in Chapter 2 are due to different exposure estimation approaches. 
Unlike exposure for human APIs that rely on total residue, the PECsurfacewater for veterinary APIs 
is dependent on the daily dose and number of days of treatment (EMEA, 2008). Furthermore, 
only a small proportion of veterinary APIs have available toxicological data to algae (Chapter 
2). The priority substances for veterinary APIs are therefore not comparable to that for human 
APIs.  
While this research (Chapter 2 & 3) only focuses on the UK environment, several studies 
(Roos et al., 2012, Kim et al., 2008) indicated that a variety of highly prioritised compounds 
identified in this study also showed high usage in other nations. The prioritisation approach for 
APIs also be transferred to other countries for the purpose of designing monitoring program, 
setting priorities and developing environmental risk management plans (Boxall et al., 2003). 
For example, risk scores (RQ) obtained for three veterinary antibiotics tylosin, lincomycin and 
trimethoprim identified for laboratory study (Table 7.1) were comparable to prioritisation 
studies based on RQ in other countries i.e. In a prioritisation exercise of veterinary APIs in 
China, tylosin and trimethoprim were classified as high priority, and lincomycin was classified 
as medium priority (Wang et al., 2014). 
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Table 7.1 Summary of priority compounds derived in Chapter 2 & 3, based on the 
ecotoxicological data to algal species 
Risk score Human APIs 
Chapter 2 
Veterinary APIs 
Chapter 2 
Human APIs 
Chapter 3 
>10 clarithromycin 
amoxicillin 
tylosin 
erythromycin 
lincomycin 
tiamulin  
amoxicillin 
Amoxicillin 
1-10 erythromycin trimethoprim clarithromycin 
azithromycin 
ciprofloxacin 
0.1-1 oxytetracycline 
mycophenolate mofetil 
fluoxetine 
propranolol 
florfenicol 
oxytetracycline 
tetracycline 
mycophenolic acid 
oxytetracycline 
The research then systematically evaluated the sensitivity of different algal species from 
chlorophytes, cyanobacteria and diatoms to three antibiotics by deriving a dose-response 
relationship for each species/antibiotic combination (Chapter 4). This was followed by 
evaluating the sensitivity between cell density and photosynthetic related endpoints that 
directly link to viable cells such as the oxygen evolution rate in the standard algal bioassays 
(Chapter 5). A summary of the ecotoxicological data generated from the experiments detailed 
in this thesis can be found in Table 7.2. In the tests with P. subcapitata, D. subspicatus, A. 
flos-aquae and N. pelliculosa, it is important to recognise that the EC50s based on the growth 
endpoint in Chapter 4 are always lower than that in Chapter 5. For example, in the test of 
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lincomycin on P. subcapitata, the EC50 ranged from 7.36 µmol L
-1 with initial cell density 5X103 
cells L-1 to 24.14 µmol L-1 with 5X105 cells L-1. The discrepancy in the EC50s is likely due to the 
difference in the initial cell density, 5X103 - 2X104 cells mL-1 recorded in Chapter 4 and 5X105 
cells mL-1 in Chapter 5, respectively. A higher initial cell density could lead to less toxicant 
content bonding to the cells (both intercellular and extracellular), and further lead to less 
toxicant uptake and the lowering of toxicity (Franklin et al., 2002). A report studying the effects 
of copper on the chlorophyte P. subcapitata, where the initial cell density ranging from 103 to 
105 showed that increasing cell number decreased the toxicity from 97.56 to 267.51 µmol L-1 
based on EC50 values (Franklin et al., 2002).  
The research presented in this thesis demonstrates that oxygen evolution rate is a more 
senstivie endpoint than growth for chlorophytes P. subcapitata and D. subspicatus. While the 
toxic mechanisms determining the effects of antibiotics on algal growth are still uncertain, this 
research indicates that antibiotics could affect biomass synthesis by interfering with the algal 
photosynthesis process such as light-harvesting pigment synthesis and light utilisation 
efficiency (Chapter 5).  
The research generated knowledge on the effect and risk assessment of major use antibiotic 
mixtures based on the toxicological data to the cyanobacterial species A. flos-aquae, where 
the CA model was found to perform best in describing the combination effects of the antibiotic 
mixture (Chapter 6). While the FOCUS models have been proposed for the exposure 
assessment of veterinary medicines in the EMEA (2008) guideline, the research documented 
in Chapter 6 was the first attempt to estimate exposures of major use veterinary antibiotics in 
European surface water and use these data to assess mixture risks. The results indicated that 
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a potential risk of the antibiotic mixtures to the environment was likely in the regions of Europe, 
primarily due to the effects from tylosin and lincomycin. 
While algal toxicity testing is required for environmental hazard evaluation as recommended 
by the Organization for Economic Cooperation and Development (OECD), these studies are 
often conducted as a screening toxicity tests rather than for predicting environmental impact 
(Rand, 2003). The ecological relevance of results from algal toxicity tests is still unknown. For 
example, the results from the standard 4 day tests using single-species may not be predictive 
of effects on natural algal communities exposed to the same compound (Calow, 1998). 
Available data indicate that, in general, laboratory-based algal studies are more sensitive to 
chemical exposure than natural algal communities (Calow, 1998). Potential reasons for this 
include that there is considerable interspecific variation in response of algae to a chemical, that 
unrealistic experimental conditions are used in laboratory tests, and that natural communities 
are able to adapt to tolerate exposure to a pollutant (Ogilvie and Grant, 2008), The ability of 
algal toxicity tests using single species to predict ecosystem effects therefore is still unclear 
(Rand, 2003). 
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Table 7.2 Summary of the EC50 values for tested antibiotics obtained in ecotoxicological studies. All toxicity values are in µmol L-1 (values in brackets are the 
range of 95% confidence limits). Initial cell densities (cell no.) are in cells mL-1. Seven algal species are P. subcapitata (PS), D. subspicatus (DS), C. vulgaris 
(CV), N. pelliculosa (NP), P. tricornutum (PT), A. flos-aquae (AF) and S. leopoliensis (SL). Three antibiotics are lincomycin (LIN), tylosin (TYN) and trimethoprim 
(TMP). n.a. not available. 
 LIN     TYN     TMP     
 Cell 
no. 
EC50 growth Cell 
no. 
EC50 growth EC50 
photosynthesis 
Cell 
no. 
EC50 growth Cell 
no. 
EC50 growth EC50 
photosynthesis 
Cell 
no.. 
EC50 growth Cell 
no.. 
EC50 growth EC50 
photosynthesis 
P.S. 5X103 7.36 
(4.88-11.98) 
5X105 24.14 
(21.84-27.6) 
12 
(n.a.-20.68) 
5X103 4.14 
(3.4-5.06) 
5X105 4.8 
(4.26-5.47) 
2.1 
(n.a.) 
5X103 >218.28 5X 
105 
>306.9 >306.9 
D.S. 5X103 16.07 
(11.2-23.72) 
5X105 >188.71 79.41 
 (60.27-103.3) 
5X103 12.19 
(10.57-15.42) 
5X105 38.27 
(30.23-47.08) 
17.6 
(10.13-13.39) 
5X103 >344.45 5X 
105 
>272.7 >272.7 
C.V. 2× 
104 
>225.7 n.a. n.a n.a 2× 
104 
>81.2 n.a n.a n.a 2× 
104 
>344.45 n.a n.a n.a 
N.P. 1× 
104 
>225.7 5X105 >153.91 >153.91 1× 
104 
1.33 
(1.14-1.76) 
5X105 4.4 
(3.66-5.05) 
7.35  
(0.44-17.49) 
1× 
104 
7.36 
(6.74-8.28) 
5X 
105 
70.48 
(57.79-96.03) 
136.36 
(95.34-n.a.) 
P.T. 1× 
104 
>225.7 n.a n.a n.a 1× 
104 
5.7 
(3.67-9.6) 
n.a n.a n.a 1× 
104 
74.61 
(55.47-105.23) 
n.a n.a n.a 
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A.F. 2× 
104 
0.13 
(0.11-0.15) 
5X105 1.2 
(1.04-1.51) 
4.75 
(0.49-n.a.) 
2× 
104 
0.092 
(0.073-0.12) 
5X105 0.06  
(n.a-0.068) 
0.33  
(0.21-0.52) 
2× 
104 
315.78 
(285.16-n.a.) 
5X 
105 
>341.69 >341.69 
S.L 5× 
105 
0.095 
(0.076 - 
0.13) 
n.a n.a n.a 5× 
105 
0.09 
(0.068-0.13) 
n.a n.a n.a 5× 
105 
>344.45 n.a n.a n.a 
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7.1 Implications for Environmental Risk Assessment 
7.1.1 Multi - species involved in the APl risk assessment 
Cyanobacteria have previously been shown to demonstrate high sensitivity to a wide range of 
antibiotics and have therefore been recommended for use in assessing the environment risks 
of antibiotics as part of the Market Authorisation process for new antibiotics (EMEA, 2008). 
While our toxicity study results for tylosin and lincomycin partly support this approach, the 
study found that trimethoprim only influences the growth of the diatom species rather than 
chlorophytes and cyanobacteria. This evidence indicates the assumption that cyanobacteria 
are the most sensitive species does not hold for all antibiotics. Therefore, to avoid the 
underestimation of environmental hazards to algae, this research suggests that the future risk 
assessment should consider inhibitiory effects of antibiotics on the growth of at least three 
species, one from each algal class. It would make sense that these tests are done on the 
species from each class that appear to be consistently most sensitive to antibiotic exposure i.e. 
P. subcapitata, A. flos-aquae and N. pelliculosa. It is also important to recognise that this 
research has only used a selection of indicator species from three classes. Further work on 
other antibiotic classes and other species is warranted to better inform the development of risk 
assessment approaches. 
7.1.2 Mixtures in pharmaceutical risk assessment 
As a broad range of substances are used as human and veterinary pharmaceuticals, the 
occurrence of APIs in the aquatic environment is more likely to be a multi-component mixture 
instead of a pure substance. Concerns about the mixture effects have been raised due to the 
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facts that: 1. the ecotoxicity of a mixture is almost always higher than that of single substance; 
and 2. a mixture could cause considerable ecotoxicological effects even when all the 
components are below the low observed effect concentrations (LOEC) (Backhaus et al., 2008). 
In view of these facts, current environmental risk assessment of antibiotics regulations (e.g. 
EMEA 2006 & 2008) only using individual substances may therefore underestimate the 
potential risk. This study demonstrates that environmental risk assessment of chemical 
mixtures based on the CA concept could be applied in the assessment for antibiotic mixture. In 
this approach PNECs of the individual substances are calculated first, and then extrapolation 
from a single substance to a mixture is undertaken by adding the PEC/PNEC ratios (risk 
characterisation ratios for the individual compounds). This approach makes optimum use of 
the existing individual compound assessments and it could be applied as a cautious step for 
mixture assessment (Backhaus and Faust, 2012). 
7.1.3 The use of algal photosynthesis as an additional endpoint 
Standardised algal ecotoxicological tests (e.g. OECD 201 guideline) do not consider important 
physiological endpoints such as algal photosynthesis, in which alteration could affect the 
ecological balance (Petit et al., 2010). Effects of external chemical stressors on algal 
photosynthetic activity are widely studied by the direct measurements of short-term oxygen 
evolution rate (Petit et al., 2010, Liu et al., 2011). In this study the sensitivity between two 
endpoints, oxygen evolution rate and growth, was compared. The results demonstrated that 
photosynthesis was a more vulnerable endpoint than growth for two chlorophytes, whereas 
higher sensitivities on the growth of cyanobacteria and the diatom species were observed. For 
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example, the effect of tylosin on the photosynthesis of D. subspicatus at EC50 level was 21.67 
µmol L-1, which was nearly half of that calculated based on growth (43.24 µmol L-1); after 4d 
exposure to lincomycin, the photosynthesis based EC50 value of P. subcapitata was 8.8 µmol 
L-1, which was approximately three times lower than that calculated based on growth (32.62 
µmol L-1). While the reason for this particular observation is still unclear, the endpoint of 
oxygen evolution rate might be an endpoint that could be used in the future in addition to 
growth. It is important to recognise that this comparison work only focused on a selection of 
indicator species, more antibiotics and algal species from three classes need to be involved in 
further research to confirm this finding. 
7.2 Conclusion 
This research has prioritised the APIs based on their risk in the UK environment, followed by 
systematically evaluating the sensitivity of a battery of species from chlorophytes, 
cyanobacteria and diatom to antibiotic exposures. The research also investigated the effects of 
target antibiotics on the growth and physiology of a selection of algal species. A risk 
assessment approach for antibiotic mixtures was developed and performed. The main 
conclusions of this thesis are the following: 
1. The environmental occurrence and effects of APIs in the aquatic environment are issues 
that are increasingly important to the public and researchers. Algal species are interesting 
model organisms as they are sensitive to APIs and their short generation time allows the 
observation of negative effects from APIs.  
2. The use of a prioritization approach is practical to identify the substances of most concern. 
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Apart from the effects on the aquatic and terrestrial organisms at low trophic levels 
considered in previous prioritization exercises, the approach developed in this research 
firstly considered secondary poisoning on avian and mammalian wildlife (i.e. fish and 
earthworm-eating birds and mammals) via the food chain, but no potential risk was found 
through these pathways. 
3. Algal sensitivity towards antibiotics has been systematically evaluated using a battery of 
indicator species from chlorophytes, cyanobacteria and diatoms. One of the most 
significant findings is that the toxicity of trimethoprim to diatom is an order of magnitude 
higher than to chlorophytes and cyanobacteria. This evidence indicates that for some 
antibiotics chlorophytes and cyanobacterial species might not be the most appropriate test 
organisms. 
4. Photosynthesis of chlorophytes was a more sensitive endpoint than growth, but the 
situation was reversed when testing cyanobacteria and diatom. The ecotoxicological 
effects of three antibiotics could partly be explained by the influence on physiological 
endpoints including oxygen evolution rate, light-harvesting pigment synthesis and light 
utilisation efficiency.  
5. Research in this thesis demonstrated that CA-based model could well predict the 
combined effects of antibiotic mixtures on the cyanobacteria A. flos-aquae. Therefore, the 
concentration addition (CA) based risk assessment approach could be applied for 
antibiotic mixtures. The potential risk of antibiotic mixtures was likely in the regions of 
Europe. 
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7.3 Recommendations 
7.3.1 Recommendations specific resulting from this research 
1. Further development of the prioritisation approach – The risk based prioritisation approach 
that has been used, has employed available predictive models and data. There are 
uncertainties in the validity of some of these approaches for selected classes of 
pharmaceuticals. In the future, work should focus on further developing and validating the 
prioritisation approach to reduce these uncertainties. One important aspect would be the 
consideration of biodegradation during wastewater treatment. This process was not 
considered during the prioritisation and compounds that are susceptible to biodegradation will 
have had their environmental risk significantly overestimated. 
2. Filling of data gaps for less well studied priority substances – For the compounds identified 
as a priority, based on predicted data, and which are found to occur in effluents, it is 
recommended that attempts are made to develop experimental data on the chronic aquatic 
ecotoxicity of these compounds. Some of these data may have already been developed by the 
pharmaceutical industry as part of the market authorisation process so contact should be 
made with relevant companies and trade associations (ABPI, EFPIA) to attempt to gain access 
to these data. 
3. Consideration on sensitivity of different algal species in APIs risk assessment – Currently a 
number of toxicity data is available on the two freshwater algal species (P. subcapitata and D. 
subspicatus). Though the EMEA (2006) guideline has suggested using cyanobacteria species 
for testing some therapeutic class of APIs (e.g. antibiotics), the data on cyanobacteria is still 
limited. Almost no toxicity data is available on diatom species. The results for the single toxicity 
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test of three antibiotics on seven algal species indicate that the risk of some APIs to algae in 
the environment might be underestimated if hazards are only assessed by chlorophytes. It is 
therefore suggested that the toxicity data of APIs focusing on algal species such as 
cyanobacteria and diatom species should be produced.  
4. Assessment of mixture interactions in the prioritisation study - This assessment has 
considered single pharmaceutical ingredients. However many compounds will have the same 
mode of action and some compounds are known to interact toxicologically in patients (i.e. they 
are contraindicated). A logical extension to the prioritisation exercises would be to consider the 
potential interactions of high priority compounds which have the same mode of action of those 
which are contraindicated. The results of the joint toxicity tests indicate the reliable predictive 
capacity of concentration addition (CA) models, and therefore, the CA-based approach could 
be included in risk assessment of API mixtures.   
5. Investigation of APIs on the impairment process in algae – The results of the physiology 
study reveal that the algal physiological endpoints including oxygen evolution rate and 
light-harvesting pigment contents were vulnerable to a wide range of external stressors such 
as APIs. To completely understand the damage process and mechanisms of APIs to algal 
photosynthetic activity, it would be valuable to explore the effects of APIs on the algal 
physiology and biology such as enzymes and translation/ transcription process involved in the 
photosynthesis process. 
6. Utilisation of environment relevant exposure concentration in algal studies – The effects of 
APIs on the algal growth and physiology were investigated using high exposure concentrations 
which could obtain dose – response curves, to enable the comparison of endpoint sensitivities 
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between growth and photosynthesis at EC50 levels. In this case the adverse influence on algal 
physiology might be overestimated. To investigate whether these observed effects occur in the 
field, environment relevant exposure concentrations should be used in the future algal studies.  
7.3.2 General recommendations 
1. Targeted monitoring of less well studied prioritised substances and metabolites – Due to 
significant data gaps, a number of compounds were identified as a priority based on data 
generated from predictive methods. It is recommended that a targeted monitoring study be 
undertaken at a few treatment works to identify whether these high priority substances do 
occur in wastewater effluents and sludge or not. 
2. Development of data on the use and emissions of over - the - counter (OTC) medicines – In 
the prioritisation exercise quantitative information on the usage of OTC medicines was not 
obtained so it was not possible to prioritise these substances based on risk. Given the likely 
high use of these substances, it would be beneficial to generate data on usage patterns for 
these products and on the likelihood of emissions of these to the environment. It may be 
appropriate to monitor these substances in the future targeted monitoring study described in 1. 
3. Implementation of risk assessment by using occurrence data – To undertake exposure 
assessment of APIs in the environment, the current risk assessment regulation such as EMEA 
(2006) was used. However this only calculated predicted exposure concentrations, as 
monitored data was not always available for most of the substances. With the development of 
analytical instruments which have lowered the limit of detection in the last decade, an 
increasing number of detected concentrations of APIs have been reported worldwide. These 
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data might be collated and synthesised along with the growing dataset of ecotoxicity data to 
perform a more realistic risk assessment of APIs in the environment.  
4. Investigation of biotransformation and metabolism products of APIs – So far a substantial 
number of studies have focused on parent compounds. However, information on the 
occurrence, fate and effects of biotransformation products and metabolites in the environment 
is still very limited and therefore, more data should be produced to enable risk assessment on 
biotransformation products. 
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Appendix 1 
Table A1.1 Toxicity and environmental risk assessment of pharmaceuticals to chlorophytes 
Species Pharmaceutical/ 
Products 
Ingredient Test 
duration 
EC50 
(mg L-1) 
Reference PEC 
(mg L-1) 
PEC:PNEC 
ratio* 
Chlorella 
pyrenoidosa 
 
Chloramphenicol  
Florfenicol  
Thiamphenicol  
Carbamazepine  
I 
I 
I 
I 
72h 
72h  
72h  
96h 
14 
215 
1283 
49.4 
(Lai et al., 
2009) 1 
 
(Zhang et al., 
2012) 3 
6.4E-08 
NA 
NA 
0.00085 
4.57E-07 
NA 
NA 
0.0017 
Chlorella 
vulgaris 
 
Oxytetracycline 
 
Streptomycin 
 
I 
 
I 
48h  
 
96h 
 
6.4 
 
20.08  
 (Pro et al., 
2003) 3 
(Qian et al., 
2012) 3 
0.00047 
 
7.44E-10 
 
0.0073 
 
3.7E-09 
 
Desmodesmus 
subspicatus 
(Scenedesmus 
subspicatus) 
 
Atenolol 
 
Captopril 
Carbamazepine 
Clofibrinic acid 
Diclofenac 
Ibuprofen 
Metoprolol 
Metformin 
Naproxen 
Propranolol 
 
Allegra 
Alvedon 
Amaryl 
Aptivus 
Bisolvon 
Bisoprolol 
Bisostad 
Buscopan 
Carvedilol 
Carveratio 
Ciklosporin 
Clozapine 
Coramil 
Daonil 
Diklofenak 
I 
 
I 
I 
I 
I 
I 
I 
I 
I 
I 
 
Fexofenadin 
Paracetamol 
Glimepirid 
Tipranavir 
Bromhexin 
I 
Bisoprolol 
Butylscopolamine 
I 
Carvedilol 
Cyclosporin 
I 
Diltiazem 
Glibenclamide 
I 
72h 
 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
620 
 
168 
74  
115  
72  
315  
7.3  
>320  
>320  
5.8  
 
>200 
134 
610 
>40.4 
0.25 
11.5 
11.5 
>80 
14.8 
14.8 
>100 
2.38 
33.5 
735.5 
72 
(Cleuvers, 
2005) 2 
(Cleuvers, 
2003)3 
 
 
 
 
 
 
 
 
 (FASS, 
2012)3 
0.00061 
 
9.71E-06 
0.00085 
NA 
0.0033 
0.0057 
5.6E-05 
0.018 
0.0012 
0.00017 
 
NA 
4.59E-07 
1.84E-08 
3.28E-10 
NA 
2.65E-05 
NA 
1.43E-05 
7.11E-06 
NA 
NA 
8.41E-07 
NA 
4.75E-11 
NA 
9.8E-05 
 
5.78E-06 
0.0011 
NA 
0.0046 
0.0018 
0.00077 
0.0057 
0.00036 
0.003 
 
NA 
3.43E-07 
3.02E-09 
8.12E-10 
NA 
0.00023 
NA 
1.785E-05 
4.806E-05 
NA 
NA 
3.53E-05 
NA 
6.45E-12 
NA 
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Emconcor 
Fexofenadin Orifarm 
Furosemide 
Glimepirid 
Glucophage 
Granisetron 
Impugan 
Intelence 
Invega 
Kredex 
Kytril 
Lariam 
Lasix Retard 
Leponex  
Magnevist 
Medikinet 
Metformin 
Micardis 
Midazolam 
Minitran 
Naproxen 
Naprosyn 
Naramig 
Nefoxef 
Nexavar 
Pamol 
Paracetamol 
Perfalgan 
Persantin Depot 
Pindolol 
Pramipexol 
Primolut- Nor 
Pronaxen 
Ramipril 
Rilutek 
Riluzol 
Sandimmun 
Sandomigrin 
Serevent 
Sertralin 
Sifrol 
Sinalfa 
Sumatriptan 
Telfast 
Bisoprolol 
Fexofenadin 
I 
I 
Metformin 
I 
Furosemide 
Etravirine 
Paliperidon 
Carvedilol 
Granisetron 
Mefloquine 
Furosemide 
Clozapine 
Gadopentetsyra 
Methylphenidate 
I 
Telmisartan 
I 
Glyceryl trinitrate 
I 
Naproxen 
Naratriptan 
Fexofenadine 
Sorafenib 
Paracetamol 
I 
Paracetamol 
Dipyridamole 
I 
I 
Noretisteron 
Naproxen 
Ramipril 
Riluzol 
I 
Ciclosporin 
Pizotifen 
Salmeterol 
I 
Pramipexol 
Terazosin 
I 
Fexofenadine 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
96h 
72h 
72h 
72h 
11.5 
>200 
322.21 
610.72 
>320 
22.6 
322.2 
>0.0049 
14 
14.8 
22.6 
0.16 
322.21 
2.5 
>100 
6 
320 
9.88 
11.4 
0.4 
39 
39 
>100 
>200 
0.00054 
134.4 
134 
134.4 
>2.36 
11 
240 
0.4 
39 
>100 
4.48 
4.48 
>100 
0.98 
2.8 
240 
240 
160 
26 
>200 
NA 
0.00017 
0.00032 
1.63E-06 
0.0032 
1.18E-09 
NA 
7.87E-10 
2.5E-09 
NA 
6.82E-10 
9.55E-07 
1.1E-09 
NA 
NA 
1.19E-06 
0.018 
3.03E-05 
2.09E-07 
2.44E-07 
0.001161 
2.16E-05 
9.61E-08 
NA 
3.06E-11 
3.57E-10 
0.022 
3.73E-08 
0.0005 
8.11E-08 
1.7E-07 
4.91E-08 
NA 
9.62E-05 
1.05E-06 
1.05E-06 
1.11E-07 
NA 
2.33E-09 
0.00019 
NA 
NA 
1.39E-05 
6.88E-06 
NA 
8.67E-05 
9.77E-05 
2.62E-07 
0.00101 
5.22E-09 
NA 
1.61E-05 
1.79E-08 
NA 
3.02E-09 
0.0006 
3.426E-10 
NA 
NA 
1.98E-05 
0.0057 
0.00031 
1.83E-06 
6.09E-05 
0.00298 
5.53E-05 
9.61E-08 
NA 
5.71E-6 
2.66E-10 
0.017 
2.77E-08 
0.021 
7.37E-07 
7.1E-08 
1.23E-05 
NA 
9.62E-05 
2.35E-05 
2.35E-05 
1.11E-07 
NA 
8.33E-08 
7.88E-05 
NA 
NA 
5.34E-05 
3.44E-06 
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Telzir 
Terazosin 
Testim 
Testogel 
Tradil 
Transiderm-Nitro 
Triatec 
Ultravist 
Undestor Testocaps 
Velcade 
Visanne 
Visken 
Voltaren 
Voxra 
Xeplion 
Zyban 
 
Mixture 
Angemin 
 
Asasantin Retard 
 
Codalvonil 
 
Mollipect 
 
Neovletta 
 
Norgesic 
 
Panocod 
 
Qlaira 
 
Trionetta  
 
Yasminelle 
 
Yasmin 
 
Yaz 
 
I 
I 
Testosterone 
Testosterone 
Dexibuprofen 
Glyceryl trinitrate 
Ramipril 
Iopromide 
Testosterone 
Bortezomib 
Dienogest 
Pindolol 
Diclofenac 
Bupropion 
Paliperidon 
Bupropion 
 
 
Drospirenone 
Estradiol 
Aspirin 
Dipyridamole 
Codeine 
Paracetamol 
Bromhexine 
Ephedrine 
Etinylestradiol 
Levonorgestrel 
Orphenadrine 
Paracetamol 
Codeine 
Paracetamol 
Dienogest 
Estradiol 
Etinylestradiol 
Levonorgestrel 
Drospirenone 
Ethinylestradiol 
Drospirenone 
Ethinylestradiol 
Drospirenone 
Ethinylestradiol 
72h 
96h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
96h 
72h 
96h 
 
 
72h 
 
72h 
 
72h 
 
72h 
 
72h 
 
72h 
 
72h 
 
72h 
 
72h 
 
72h 
 
72h 
 
72h 
 
>100 
160   
0.5 
0.5 
7.1 
0.4 
>100 
10000 NOEC  
0.5 
0.3 
>16 
11 
72 
0.95 
14 
0.95 
 
 
5.5 
 
>2.36 
 
134.4 
 
0.25 
 
130 
 
134.4 
 
134.4 
 
>16 
 
>0.13 
 
130 
 
130 
 
130 
 
1.11E-08 
6.4E-07 
1.26E-06 
4.73E-06 
NA 
1.04E-06 
NA 
NA 
5.06E-10 
NA 
NA 
1.07E-07 
2.54E-09 
NA 
3.72E-10 
5.8E-06 
 
 
NA 
 
8.58E-05 
 
NA 
 
NA 
 
NA 
 
NA 
 
NA 
 
5.51E-08 
 
NA 
 
NA 
 
4.98E-08 
 
NA 
 
1.11E-08 
4E-07 
0.00025 
0.00095 
NA 
0.00026 
NA 
NA 
1.01E-07 
NA 
NA 
9.69E-07 
3.53E-09 
NA 
2.66E-09 
0.000604 
 
 
NA 
 
0.0036 
 
NA 
 
NA 
 
NA 
 
NA 
 
NA 
 
3.44E-07 
 
NA 
 
NA 
 
3.83E-08 
 
NA 
 
Dunaliella 
tertiolecta 
Clofibric acid 
Diclofenac 
I 
I 
96h 
96h 
224.2 
185.7 
(DeLorenzo 
and Fleming, 
NA  
0.0033 
NA  
0.0018 
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 Fluoxetine 
Simvastatin 
Triclosan 
I 
I 
I 
96h 
96h 
96h 
0.17 
22.8 
0.0036 
2008) 3 0.0001 
0.00096 
3.55E-10 
0.06 
0.0042 
9.99E-06 
Pseudokirchneri
ella subcapitata 
(Selenastrum 
capricornutum) 
Flumequine 
Oxytetracyline 
Streptomycin 
Sulphamethoxazole 
Trimethoprim 
Tylosin 
 
Chlortetracycline 
Clarithromycin 
Erythromycin 
Lincomycin 
Ofloxacin 
Olaquindox  
Spiramycin  
 
Tetracycline  
Tiamulin  
Streptomycin  
 
Naproxen 
Tylosin  
 
Aciclovir 
Albyl 
Alfuzosin 
Alimata 
Alli 
Amiodaron 
Amoxicillin 
Aprovel 
Arava 
Arkolamyl 
Asmanex Twisthaler 
Atriance 
Bambec  
Bamyl 
Baraclude 
Bondronat 
Bonviva 
Brevoxyl 
Bricanyl 
I 
I 
I 
I 
I 
I 
 
I 
I 
I 
I 
I 
I 
I 
 
I 
I 
I 
 
I 
I 
 
Acyclovir 
Aspirin 
I 
Pemetrexed 
Orlistat 
Amiodaron 
I 
Irbesartan 
Leflunomide 
Olanzapine 
Mometasone 
Nelarabine 
Bambuterol 
Aspirin 
Entecavir 
Ibandronate 
Ibandronate 
Benzoyl peroxide 
Terbutaline 
72h 
72h 
72h 
72h 
72h 
72h 
 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
 
72h 
72h 
72h 
 
72h 
72h 
 
72h 
72h 
72h 
72h 
10d 
72h 
72h 
96h 
72h 
14d 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
16  
0.6 
1.5  
0.52 
9  
0.0089  
 
3.1  
0.002  
0.02  
0.07  
1.44  
40  
2.3  
 
2.2  
0.17 
0.13 
 
31.82 
1.38  
 
>99 
15 
0.7 
63 
1.92  
>100 
630 
460 
22.4 
>141 
>3.2 
>100 
475 
15 
110 
1.4 
1.4 
0.07 
>500 
(van der 
Grinten et al., 
2010)2 
 
 
 
 
(Isidori et al., 
2005b)3 
 
 
 
 
 
 
(Halling-Soren
sen, 2000)2 
 
 
(Isidori et 
al.,2005a)3 
 
(FASS, 2012)3 
NA 
0.00047 
7.44E-10 
NA 
0.00019 
NA 
 
NA 
0.00025 
0.00045 
1.51E-05 
4.89E-06 
NA 
NA 
 
2.36E-05 
NA 
7.44E-10 
 
0.0012 
NA 
 
2.31E-06 
NA 
4.68E-06 
NA 
1.29E-06 
7.96E-05 
0.0022 
0.00039 
3.48E-08 
NA 
2.62E-08 
5.47E-12 
6.47E-08 
NA 
9.6E-10 
3.43E-07 
1.22E-06 
0.000011 
1.05E-07 
NA 
0.078 
4.96e-08 
NA 
0.0021 
NA 
 
NA 
12.33 
2.23 
0.022 
0.00034 
NA 
NA 
 
0.0011 
NA 
5.59E-07 
 
0.0037 
NA 
 
2.33E-06 
NA 
0.00067 
NA 
6.7E-05 
7.96E-05 
0.00035 
8.54E-05 
1.55E-07 
NA 
8.19E-07 
5.47E-12 
1.36E-08 
NA 
8.73E-10 
2.44E-05 
8.73E-05 
0.015 
2.1E-08 
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Budenofalk 
Budesonide 
Candesartan 
Candexetil 
Ceftriaxon 
Cefuroxime 
Cellcept 
 
Cialis 
Citanest 
Copegus 
Cordarone 
Cymbalta 
Danafusin 
Demoson 
Dermovat 
Desonix 
Dimor 
Durogesic 
Elocon 
EMEND 
Epivir 
Ergenyl 
Ery-Max 
Exelon 
Exjade 
Ezetrol 
Felodipine 
Fentanyl 
Fevarin 
Flagyl 
Fontex 
Formatris 
Fucidin 
Fucithalmic 
Fundan 
Fungoral 
Furadantin 
Galantamine 
Geavir 
Gemcitabine 
Gemzar 
Glibenklamid Recip 
Glivec 
Budesonide 
I 
Candesartan 
Candesartan 
Ceftriaxone 
I 
Mycophenolate- 
-mofetil 
Tadalafil 
Prilocaine 
Ribavirin 
Amiodarone 
Duloxetine 
Alfuzosin 
Mometasone 
Clobetasol 
Budesonide 
Loperamide 
Fentanyl 
Mometasone 
Aprepitant 
Lamivudine 
Valproic acid 
Erytromycin 
Rivastigmine 
Deferasirox 
Ezetimibe 
Felodipine 
I 
Fluvoxamine 
Metronidazole 
Fluoxetine 
Formoterol 
Fusidic acid 
Fusidic acid 
Ketoconazole 
Ketoconazole 
Nitrofurantoin 
I 
Acyclovir 
I 
Gemcitabine 
Glibenclamide 
Imatinib 
72h 
72h 
72h 
72h 
72h 
72h 
72h  
 
72h 
72h 
72h 
72h  
72h  
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
>8.6 
>8.6 
>56 
>56 
100 NOEC 
>76 
0.068 
 
>1.2 
154 
100 NOEC 
>100 
0.2 
52.7  
3.2 
4.2 
8.6 
76 
15.1 
3.2 
0.18 
96.9 
>100 
0.037 
83 
0.32 
4 
0.32 
15.1 
0.1 
>39.1 
0.027 
94 
4.3 
4.3 
0.032 
0.032 
2.3 
>100 
>99 
5.4 
5.4 
>1000 
2.5 
1.02E-07 
5.02E-06 
4.24E-05 
NA 
1.42E-07 
1.81E-06 
4.76E-05 
 
1.86E-06 
1.58E-11 
2.28E-07 
3.97E-07 
2.56E-05 
NA 
NA 
2.23E-05 
NA 
NA 
1.8E-09 
1.43E-05 
2.18E-09 
4.05E-08 
NA 
NA 
8.74E-07 
5.86E-07 
1.66E-05 
1.12E-05 
2.07E-08 
NA 
5.09E-07 
NA 
NA 
0.00049 
6.62E-07 
NA 
NA 
2.38E-08 
2.69E-06 
NA 
NA 
NA 
NA 
1.04E-06 
1.2E-06 
5.84E-05 
7.58E-05 
NA 
1.42E-07 
2.38E-06 
0.07 
 
0.00015 
1.03E-11 
2.28E-07 
3.97E-07 
0.013 
NA 
NA 
0.00053 
NA 
NA 
1.2E-08 
0.00045 
1.19E-06 
4.18E-08 
NA 
NA 
1.37E-07 
0.00018 
0.00042 
0.0035 
1.37E-07 
NA 
1.3E-06 
NA 
NA 
0.011 
1.54E-05 
NA 
NA 
1.03E-06 
2.69E-06 
NA 
NA 
NA 
NA 
4.18E-05 
Appendix                                                                      
182 
 
Glytrin 
Ibandronate 
Ibandronic acid 
Imacillin 
Imigran 
Inside 
Instanyl 
Instillagel 
Invanz 
Iomeron 
Irbesartan 
Iressa 
Ivemend 
Januvia 
Jevtana 
Kestine 
Ketoconazole 
Klopidogrel 
Lafunomy 
Lamictal 
Lamotrigine 
Leflunomide 
Leptanal  
Levofloxacin 
Lipanthyl 
Livostin 
Loperamide 
Loratadin 
Losec 
Matrifen 
Metomylan 
Metoprolol 
Metronidazol 
Montelukast 
Moxonidin 
Mozoc 
Mucoangin 
Multaq 
Mycophenolate mofetil 
Narop 
Nexium 
Nimvastid 
Nitroglycerin 
Nitrolingual 
Glyceryl trinitrate 
I 
Ibandronate 
Amoxicillin 
Sumatriptan 
Ranitidine 
Fentanyl 
Lidocaine 
Ertapenem 
Jomeprol 
I 
Gefitinib 
Fosaprepitant 
Sitagliptin 
Cabazitaxel 
Ebastine 
I 
Clopidogrel 
Alfuzosin 
Lamotrigine 
I 
Leflunomide 
Fentanyl 
I 
Fenofibrate 
Levocabastine 
Loperamide 
Loratadine 
Omeprazole 
Fentanyl 
Metoprolol 
I 
Metronidazole 
I 
Moxonidine 
Metoprolol 
Ambroxol 
Dronedarone 
I 
 
Ropivacaine 
Esomeprazole 
Rivastigmine 
Glyceryl trinitrate 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
96h 
72h 
72h 
72h 
72h 
 
72h 
72h 
72h 
96h 
0.4 
1.4 
1.4 
630 
26 
150 
15.1 
780 
545 
>1000 
79 
1.02 
0.18 
39 NOEC 
0.013 
9 
0.032 
0.85 
52.7 
39.7 
39.7 
22.4 
15.1 
7.4 
>0.102 
>10 
>54 
0.7 
85 
7.6 
22.8 
22.8 
39.1 
100 
210 
58.3 
25.6 
0.045 
0.068 
 
59 
85 
>83 
0.4 
2.51E-07 
NA 
1.99E-06 
NA 
1.82E-06 
NA 
6.52E-12 
2.65E-08 
8.45E-08 
NA 
0.004 
NA 
NA 
8.38E-05 
NA 
NA 
8.36E-07 
NA 
NA 
2.06E-05 
0.00017 
1.84E-06 
NA 
2.25E-06 
NA 
1.09E-13 
4.49E-06 
1.65E-05 
3.22E-06 
1.37E-09 
NA 
5.6E-05 
0.000025 
9.4E-06 
1.34E-07 
NA 
NA 
1.47E-05 
0.00017 
 
NA 
2.72E-05 
NA 
NA 
6.29E-05 
NA 
0.00014 
NA 
7.0E-06 
NA 
4.3E-11 
3.4E-09 
1.55E-08 
NA 
0.0005 
NA 
NA 
0.00022 
NA 
NA 
0.0026 
NA! 
NA 
5.18E-05 
0.00042 
8.22E-06 
NA 
3.04E-05 
NA 
1.09E-12 
8.3E-06 
0.0024 
3.79E-06 
1.8E-08 
NA 
9.6E-05 
2.45E-4 
9.4E-06 
6.39E-08 
NA 
NA 
0.033 
0.26 
 
NA 
3.19E-05 
NA 
NA 
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Novopulmon 
Noxafil 
Olanzapine 
Omecat 
Omeprazole 
Omniscan 
Optinate Septimum 
Oxis Turbuhaler 
Panodil 
Pevaryl 
Physiotens 
Prezista 
Primodium 
Pulmicort 
Ranitidine 
Reminyl 
Requip 
Reyataz 
Risedronat 
Risperdal 
Risperidone 
Rivastigmine 
Ropinirole 
Ropivacaine 
Rosazol 
Seloken 
Sporanox 
Stilnoct 
Stioxyl 
Stocrin 
Stomacid 
Tamiflu 
Tasigna  
Tavanic 
Temodal 
Temomedac 
Temozolomide 
Tetracyklin 
Teveten 
Topirmate 
Valaciclovir 
Valtrex 
Viramune 
Votubia 
Glyceryl trinitrate 
Budesonide 
Posaconazole 
I 
Omeprazole 
I 
Gadodiamide 
Risedronic acid 
Formoterol 
Paracetamol 
Econazole 
Moxonidine 
Darunavir 
Loperamide 
Budesonide 
I 
Galantamine 
Ropinirole 
Atazanavir 
Risedronic acid 
Risperidone 
I 
I 
Ropinirole 
I 
Metronidazole 
Metoprolol 
Itraconazole 
Zolpidem 
Benzoyl peroxide 
Efavirenz 
Ranitidine 
Oseltamivir 
Nilotinib 
Levofloxacin 
Temozolomide 
Temozolomide 
I 
Tetracycline 
Eprosartan 
I 
I 
Valaciclovir 
Nevirapine 
96h 
72h 
72h 
14d 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
96h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
10d 
72h 
72h 
72h 
72h 
96h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
0.4 
>8.6 
0.19 
> 141 
85 
85 
>3200 
0.76 
94 
134 
0.17 
210 
>43 
>54 
>8.6 
>150 
>100 
29.3 
>4.1 
0.76 
26 
26 
>83 
29.3 
59 
39.1 
58.3 
>1000 
2.2 
0.07 
>0.012 
>150 
463 
>0.016 
7.4 
>90 
>90 
>90 
0.31 
>100 
>93 
>99 
>99 
>43 
1.54E-06 
NA 
4.02E-08 
8.6E-06 
NA 
0.00037 
NA 
NA 
2.9E-11 
NA 
1.28E-07 
2.2E-09 
1.7E-08 
NA 
2.56E-08 
0.00073 
2.69E-06 
1.01E-06 
2.01E-08 
3.12E-06 
9.73E-08 
1.73E-06 
9.41E-07 
1.56E-06 
NA 
NA 
NA 
1.12E-06 
1.04E-07 
NA 
NA 
NA 
4.13E-07 
NA 
1.01E-06 
5.47E-13 
NA 
5.47E-13 
NA 
7.81E-05 
NA 
8.92E-06 
7.54E-07 
3.26E-08 
0.00038 
NA 
2.13E-05 
6.1E-06 
NA 
0.00043 
NA 
NA 
3.09E-11 
NA 
7.53E-05 
1.05E-09 
3.96E-08 
NA 
2.98E-07 
4.8E-4 
2.69E-06 
3.44E-06 
4.91E-07 
0.00041 
3.74E-07 
6.66E-06 
1.13E-06 
5.33E-06 
NA 
NA 
NA 
1.12E-07 
4.73E-06 
NA 
NA 
NA 
8.92E-08 
NA 
1.37E-05 
6.07E-13 
NA 
6.07E-13 
NA 
7.81E-05 
NA 
9.01E-06 
7.6E-07 
7.58E-08 
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Warfarin  
Xylocard 
Zantac 
Zeffix 
Ziagen 
Zidoval 
Zinacef 
Zinnat 
Zolpidem  
Zometa 
Zovirax  
Zyprexa 
ZYTIGA 
Everolimus 
I 
Lidocaine 
Ranitidine 
Lamivudine 
Abacavir 
Metronidazole 
Cefuroxime 
Cefuroxime 
I 
Zoledronic acid 
Acyclovir 
Olanzapine 
Abiraterone 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
14d  
72h 
>16 
11 
>780 
>150 
>96.9 
49.06 
39.1 
>76 
>76 
2.2 
15 
>99 
>141 
>1.0 
NA 
2.1E-05 
NA 
2.45E-05 
5.17E-07 
2.02E-08 
1.59E-07 
2.84E-08 
2.1E-07 
3.32E-06 
5.04E-12 
NA 
6.6E-06 
NA 
NA 
0.00019 
NA 
1.64E-05 
5.34E-07 
4.12E-08 
4.06E-07 
3.74E-08 
2.77E-07 
0.00015 
3.36E-11 
NA 
4.68E-06 
NA 
Atenolol 
 
I  257.5  
LOEC 
(Kuester et al., 
2010) 3 
0.00061 
 
0.00024 
Diclofenac 
 
I 96h 10 NOEC (Ferrari et al., 
2003) 1 
0.0033 0.033 
        
 Mixtures       
 Asasantin Retard Aspirin 
Dipyridamole 
72h 
 
>2.36 
 
(FASS, 2012)3 0.000086 
 
0.0036 
 
 Atacand Plus Hydrochlorothiazide 
Candesartan 
72h >56  9.49E-09 
 
1.69E-08 
 
 Axanum 
 
Aspirin 
Esomeprazole 
72h 
 
85 
 
 NA 
 
NA 
 
 Bactrim 
 
Sulfamethoxazole 
Trimethoprim 
72h 
 
70 
 
 NA 
 
NA 
 
 Bioclavid 
 
Amoxicillin 
Clavulanic 
72h 
 
630 
 
 NA 
 
NA 
 
 Duac 
 
Benzoyl peroxide 
Clindamycin 
72h 
 
0.07 
 
 1.97E-05 
 
0.028 
 
 Elosalic 
 
Mometasone 
Salicylic acid 
72h 
 
3.2 
 
 NA 
 
NA 
 
 Foradil 
 
Budesonide 
Formoterol 
72h 0.094 
 
 2.3E-10 
 
2.44E-07 
 
 Kivexa 
 
Abacavir 
Lamivudine 
72h 
 
49.06 
 
 5.63E-08 
 
1.15E-07 
 
 Logimax 
 
Felodipine 
Metoprolol 
72h 
 
>0.32 
 
 NA 
 
NA 
 
 Riamet 
 
Artemether 
Lumefantrine 
72h 
 
0.33 
 
 5.52E-10 
 
1.67E-07 
 
 Spektramox 
 
Amoxicillin 
Clavulanic 
72h 
 
630 
 
 NA 
 
NA 
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 Symbicort 
 
Budesonide 
Formoterol 
72h 
 
>8.6 
 
 2.19E-08 
 
2.54-07 
 
 Xylocain 
 
Epinephrine 
Lidocaine 
72h 
 
>780 
 
 3.93E-09 
 
5.04E-10 
 
 Xyloproct 
 
Hydrocortisone 
Lidocaine 
72h 
 
>780 
 
 4.43E-06 
 
5.68E-07 
 
Scenedesmus 
intermedius 
Chloramphenicol I 72h 0.1 (Sanchez-Fort
un et al., 
2009)3 
6.4E-08 6.4E-05 
Scenedesmus 
obliquus 
 
Cefradine  
 
Enrofloxacin 
 
Carbamazepine 
I 
 
I 
 
I 
72h 
 
72h 
 
96h 
1.77  
 
45.1 
 
70.1 
(Chen and 
Guo, 2012) 3 
(Qin et al., 
2012) 3  
(Zhang et al., 
2012)3 
2.52E-05 
 
NA 
 
0.00085 
0.0014 
 
NA 
 
0.0012 
Scenedesmus 
vacuolatus 
 
Diuron  
Lidocaine  
Norfluoxetine 
Trimipramine  
I 
I 
I 
I 
24h 
24h 
24h 
24h 
0.012 
134.7  
0.47  
15.6  
(Neuwoehner 
and Escher, 
2011) 3 
NA 
0.00013 
NA 
5.12E-06 
NA 
0.000093 
NA 
0.000033 
Tetraselmis chuii 
(chlorophyta) 
Chloramphenicol  
Florfenicol  
Oxytetracyline 
 
Florfenicol 
Thiamphenicol  
I 
I 
I 
 
I 
I 
72h 
96h  
96h  
 
72h 
72h 
41 
6.06  
11.18    
 
8  
158  
(Goncalves et 
al., 2007)3 
 
 
(Lai et al., 
2009)1 
6.4E-08 
NA 
0.00047 
 
NA 
NA 
1.56E-07 
NA 
0.0042 
 
NA 
NA 
*PNEC= EC50/100 
1 real concentration used; 2 nominal concentration used; 3 unknown. 
I represents ingredient. 
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Table A1.2 Toxicity and risk assessment of pharmaceuticals to cyanobacteria 
*PNEC= EC50/100 
1 real concentration used; 2 nominal concentration used; 3 unknown 
Species Pharmaceuticals  Ingredient Test duration EC50 
(mg L-1) 
Reference PEC 
(mg L-1) 
PEC:PNEC 
ratio* 
Anabaena 
flos-aquae 
Ceftazidim  
Fortum 
Multaq 
I 
Ceftazidim 
Dronedarone 
72h 
72h 
72h 
0.025 
0.025 
0.25  
(FASS, 2012)3 4.15E-07 
2.14E-07 
1.47E-05 
0.0017 
0.00086 
0.0059 
Microcystis 
aeruginosa 
 
Amoxicillin 
Spiramycin 
I 
I 
7d 
7d 
0.008 
0.0012 
(Liu et al., 
2012)3 
0.0022 
NA 
27.36 
NA 
BenzylpenicilliG 
chlortetracycline  
Olaquindox  
Spiramycin  
Streptomycin  
Tetracycline  
Tiamulin  
Tylosin  
I 
I 
I 
I 
I 
I 
I 
I 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
72h 
0.006 
0.05  
5.1   
0.005 
0.007  
0.09  
0.003  
0.034  
(Halling-Soren
sen, 2000)2 
1.99E-07 
NA 
NA 
NA 
7.44E-10 
2.36E-05 
NA 
NA 
0.0033 
NA 
NA 
NA 
1.06E-05 
0.026 
NA 
NA 
Cefradine  I 72h 1.38  (Chen and 
Guo,2012)3 
2.52E-05 0.0018 
Octylphenol  I 72h 0.068  (Baptista et al., 
2009)2 
NA NA 
Minocycline  I 72h 0.24  (Stoichev et 
al., 2011)2 
1.53E-05 0.0064 
Streptomycin I 96h 0.28  (Qian et al., 
2012)3 
NA NA 
Amoxicillin 
Livostin 
Sporanox 
Stocrin 
Visacor 
 
Mixture 
Bactrim 
 
 
Bioclavid 
 
Spektramox 
 
I 
Levocabastine 
Itraconazole 
Efavirenz 
Rosuvastatin 
 
 
Sulfamethoxa-zo
le 
Trimethoprim 
Amoxicillin 
Clavulanic 
Amoxicillin 
Clavulanic 
7d 
72h 
10d 
12d 
16d 
 
 
7d 
 
 
7d 
 
7d 
 
0.0037 
>32 
>1000 
>0.76 EC10 
330 NOEC 
 
 
112 
 
 
0.0037 
 
0.0037 
 
(FASS, 2012)3 0.0022 
1.09E-13 
1.12E-06 
NA 
NA 
 
 
NA 
 
 
NA 
 
NA 
 
59.4 
3.42E-13 
1.12E-07 
NA 
NA 
 
 
NA 
 
 
NA 
 
NA 
 
Synechococcus 
leopoliensis 
Amoxicillin  I 96h 0.0022    0.0022 444.84 
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I represents ingredient. 
 
Table A1.3 Toxicity and environmental risk assessment of pharmaceuticals to diatoms 
Species Pharmaceuticals Test duration EC50 
(mg L-1) 
Reference PEC 
(mg L-1) 
PEC:PNEC 
ratio* 
Skeletonema 
costatum 
Ibuprofen 96h 7.1 (Halling-Sor
ensen et al., 
1998)2 
0.0057 0.081 
*PNEC= EC50/100 
1 real concentration used. 
 
 
 
 
 
 
 
Table A1.4 Toxicity and environmental risk assessment of pharmaceuticals to algal 
communities 
Pharmaceuticals Sampling spot Test duration EC50 
(mg L-1) 
Reference PEC 
(mg L-1) 
PEC:PNEC 
ratio* 
Clotrimazole 
Fluoxetine 
Propranolol 
Triclosan 
Zinc-Pyrithione  
Bay of 
Kalvhagefjorden 
96h 
96h 
96h 
96h 
96h  
0.15 
0.038  
0.084 
0.34  
0.0023  
 
(Backhaus 
et al., 2011)1 
9.1E-05 
0.0001 
0.00017 
3.55E-10 
NA 
 
0.06 
0.26 
0.2 
1.05E-07 
NA 
 
Clotrimazole Bay of 
Kalvhagefjorden 
 0.0034-0.034 
mg L-1 lead to 
evident 
reduction in 
growth 
(Porsbring et 
al., 2009)1 
  
Ciprofloxacin 
Tergitol NP 10 
Triclosan   
 
upstream and 
downstream of the 
wastewater 
treatment plant in 
Kansas 
 No significant 
effects on 
growth showed. 
(Wilson et 
al., 2003) 3 
  
*PNEC= EC50/100 
1 real concentration used; 2 nominal concentration used; 3 unknown 
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Table A1.5 Measured environment concentrations (MEC) and MEC versus algal EC50 ratios of 
19 herbicides and 17 pharmaceuticals in surface water 
Pharmaceuticals MEC 
(ug L-1) 
Type Country Species 72h EC50 
(mg L-1) 
MEC:EC50 
amoxicillin 0.04 pharma. Spain1 Synechococcus 
leopoliensis 
0.0022 0.018 
atenolol 0.3 pharma. Spain2 Pseudokirchneriella 
subcapitata 
257.5 
(LOEC) 
1.2E-6 
bentazone 0.042 herbicide UK3 Anabaena flos-aquae 10.1 
(120h) 
4.2E-6 
bromoxynil 0.047 herbicide UK3 Navicula pelliculosa 0.12 4E-4 
carbamazepine 2.37 pharma. Ireland4 Chlorella pyrenoidosa 49.4 4.8E-5 
clarithromycin 2.4 pharma. Spain2 Pseudokirchneriella 
subcapitata 
0.002 1.2 
chloridazon 0.34 herbicide Swiss5 Pseudokirchneriella 
subcapitata 
3 1.1E-4 
clopyralid 0.055 herbicide UK3 Raphidocelis 
subcapitata 
30.5 1.8E-6 
clozapine 8.18 pharma. China6 Desmodesmus 
subspicatus 
2.38 0.0034 
dicamba 0.76 herbicide Swiss5 Skeletonema costatum 1.8 4.2E-4 
dichlorprop-p 0.047 herbicide UK3 Raphidocelis 
subcapitata 
67 7E-7 
diclofenac 0.35 pharma. Spain7 Pseudokirchneriella 
subcapitata 
10 
(96h 
NOEC) 
3.5E-5 
diquat 1.54 herbicide UK3 Psuedokirchneriella 
subcapitata 
0.011 0.14 
enrofloxacin 0.17 pharma. Spain7 Scenedesmus obliquus 45.1 3.7E-6 
erythromycin 0.065 pharma. Spain2 Pseudokirchneriella 
subcapitata 
0.02 0.0033 
fluoxetine 0.01 pharma. China6 Dunaliella tertiolecta 0.17 5.9E-5 
fluroxypyr 0.045 herbicide UK3 Pseudokirchneriella 
subcapitata 
49.8 9E-7 
furosemide 0.4 pharma. Spain8 Desmodesmus 
subspicatus 
322.21 1.2E-6 
glyphosate 0.1 herbicide UK3 Scenedesmus 
quadricauda 
4.4 2.3E-5 
ibuprofen 0.14 pharma. Spain1 Skeletonema costatum 7.1 1.9E-5 
irbesartan 0.69 pharma. Spain1 Pseudokirchneriella 
subcapitata 
79 8.7E-6 
linuron 0.14 herbicide Swiss5 Raphidocelis 0.016 0.0088 
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subcapitata 
ioxynil 200 herbicide UK3 n.a. 24 0.0083 
mcpa 0.14 herbicide Swiss5 Pseudokirchneriella 
subcapitata 
79.8 1.7E-6 
mcpb 0.15 herbicide Swiss5 Psuedokirchneriella 
subcapitata 
41 3.6E-6 
mecoprop-p 0.24 herbicide Swiss5 n.a 16.2 1.5E-5 
metazachlor 1.5 herbicide UK3 Psuedokirchneriella 
subcapitata 
0.016 0.093 
metoprolol 0.006 pharma. Spain2 Desmodesmus 
subspicatus 
7.3 8.1E-7 
napropamide 0.043 herbicide Swiss5 Pseudokirchneriella 
subcapitata 
3.4 1.3E-5 
naproxen 0.53 pharma. Spain2 Pseudokirchneriella 
subcapitata 
31.82 1.6E-5 
propyzamide 0.034 herbicide UK3 Raphidocelis 
subcapitata 
2.8 1.2E-5 
tralkoxydim 0.057 herbicide UK3 Pseudokirchneriella 
subcapitata 
5.1 1.1E-5 
triclopyr 0.046 herbicide UK3 Raphidocelis 
subcapitata 
75.8 6.1E-7 
triclosan 0.046 pharma. Spain8 Dunaliella tertiolecta 0.0036 0.013 
thiamphenicol 0.011 pharma. Spain8 Tetraselmis chuii 158 7E-8 
trimethoprim 1.19 pharma. Ireland4 Pseudokirchneriella 
subcapitata  
9 1.3E-4 
1 (Ortiz de Garcia et al., 2013); 2 (Moreno-Gonzalez et al., 2014); 3 (EA, 2013); 4 (McEneff et al., 2014); 5 (Moschet et 
al., 2015); 6 (Yuan et al., 2013); 7 (Collado et al., 2014); 8 (Carmona et al., 2014). All EC50 values for herbicides are 
extracted from Pesticide properties database (PPDB, 2014). 
Pharma.: pharmaceutical 
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Appendix 2
Subinhab =       (TGD, 2003)          Equation 3.1
𝐴𝑃 𝑥 106
𝑈𝐾𝑝𝑜𝑝 𝑥 365
Where:
Subinhab: Substance consumed per inhabitant per day for the UK population [mg inh d-1]
AP: Annual pharmaceutical usage [kg year-1]; 
UKPOP: UK population: 63.7 million (Statistics, 2012).
PECTR=           (TGD, 2003)          Equation3.2
 𝑆𝑢𝑏𝑖𝑛ℎ𝑎𝑏𝑊𝑎𝑠𝑡𝑒𝑊𝑖𝑛ℎ𝑎𝑏𝑥𝐷𝑖𝑙𝑢𝑡𝑖𝑜𝑛
Where:
PECTR: Predicted environmental concentration for surface water assuming a total residue 
approach [mg L-1];
Dilution: Dilution factor, default value 10 (from TGD (TGD, 2003)); and
WasteWinhab: Amount of wastewater per inhabitant per day, 200 [L inh d-1]
PECMET =  (TGD, 2003)          Equation 3.3
𝑆𝑢𝑏𝑖𝑛ℎ𝑎𝑏 𝑥 𝐹𝑒𝑥𝑐
𝑊𝑎𝑠𝑡𝑒𝑊𝑖𝑛ℎ𝑎𝑏 𝑥 𝐷𝑖𝑙𝑢𝑡𝑖𝑜𝑛
Where: 
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PECMET: Predicted environmental concentration for surface water assuming removal through 
patient metabolism (mg L-1); and
Fexc: Fraction of pharmaceutical excreted unchanged. 
PECWW =  x (1 - ) (TGD, 2003) 
𝑆𝑢𝑏𝑖𝑛ℎ𝑎𝑏
𝑊𝑎𝑠𝑡𝑒𝑊𝑖𝑛ℎ𝑎𝑏 𝑥 𝐷𝑖𝑙𝑢𝑡𝑖𝑜𝑛
𝑆𝑙𝑢𝑑𝑔𝑒𝑖𝑛ℎ𝑎𝑏 𝑥 𝐾𝑜𝑐 𝑥 𝑓𝑜𝑐𝑠𝑙𝑢𝑑𝑔𝑒
𝑊𝑎𝑠𝑡𝑒𝑊𝑖𝑛ℎ𝑎𝑏 + (𝑆𝑙𝑢𝑑𝑔𝑒𝑖𝑛ℎ𝑎𝑏 𝑥 𝐾𝑜𝑐 𝑥 𝑓𝑜𝑐𝑠𝑙𝑢𝑑𝑔𝑒)
Equation 3.4
Where:
PECWW:  Predicted environmental concentration for surface water assuming removal through 
wastewater treatment (adsorption only) [mg L-1];
Sludgeinhab: Mass of waste sludge per inhabitant per day, 0.074, [kg inh d-1]; 
KOC: Soil organic carbon-water partitioning coefficient [g mL-1]; and
focsludge: Fraction of sludge organic carbon, 0.326, calculated from Struijs et al. (Struijs et al., 
1991). 
 
PECSW =   x (1 - )(TGD, 2003) 
𝑆𝑢𝑏𝑖𝑛ℎ𝑎𝑏 𝑥 𝐹𝑒𝑥𝑐
𝑊𝑎𝑠𝑡𝑒𝑊𝑖𝑛ℎ𝑎𝑏 𝑥 𝐷𝑖𝑙𝑢𝑡𝑖𝑜𝑛
𝑆𝑙𝑢𝑑𝑔𝑒𝑖𝑛ℎ𝑎𝑏 𝑥 𝐾𝑜𝑐 𝑥 𝑓𝑜𝑐𝑠𝑙𝑢𝑑𝑔𝑒
𝑊𝑎𝑠𝑡𝑒𝑊𝑖𝑛ℎ𝑎𝑏 + (𝑆𝑙𝑢𝑑𝑔𝑒𝑖𝑛ℎ𝑎𝑏 𝑥 𝐾𝑜𝑐 𝑥 𝑓𝑜𝑐𝑠𝑙𝑢𝑑𝑔𝑒)
Equation 3.5
Where:
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PECSW: Predicted environmental concentration for surface water assuming removal through 
patient metabolism and wastewater treatment (adsorption only) [mg L-1].
PECsludge = Koc x focsludge x       (TGD, 2003)    Equation 3.6
𝑆𝑢𝑏𝑖𝑛ℎ𝑎𝑏
𝑊𝑎𝑠𝑡𝑒𝑊𝑖𝑛ℎ𝑎𝑏
Where:
PECsludge: Predicted environmental concentration for sludge [mg kg-1].
PECSOIL=                (TGD, 2003)   Equation 3.7
𝑃𝐸𝐶𝑠𝑙𝑢𝑑𝑔𝑒 𝑥 𝐴𝑠𝑙𝑢𝑑𝑔𝑒
𝐷𝑠𝑜𝑖𝑙 𝑥 𝑅𝐻𝑂𝑠𝑜𝑖𝑙
Where:
PECSOIL:Predicted environmental concentration for soil [mg kg-1];
Asludge: Sludge application rate to land, 0.5, [kg m-2 yr-1]; 
DSOIL: Soil mixing depth, 0.2, [m]; and
RHOSOIL: Bulk density of soil, 1700, [kg m-3]
Φn =                        (Franco and Trapp, 2008)        Equation 3.8
1
1 + 10
𝑎(𝑝𝐻 ‒ 𝑝𝐾𝑎)
Φion = 1 -Φn                                         (Franco and Trapp, 2008)       Equation 3.9
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Where a =1, pH = 5.8 for acids and a = -1, pH=4.5 for bases. pKa is the negative logarithm 
(log10) of the dissociation constant.
Log Koc = log (ΦnX +Φion )                       for acids        100.54𝑙𝑜𝑔𝑃𝑛 + 1.11 100.11𝑙𝑜𝑔𝑃𝑛 + 1.54
(Franco and Trapp, 2008)                                              Equation 3.10 
Log Koc = log (ΦnX +Φion10pKa
0.65 Xf0.14)                       for bases        100.37𝑙𝑜𝑔𝑃𝑛 + 1.70
(Franco and Trapp, 2008)                                              Equation 3.11 
Where log Pn is the log Kow of the neutral molecule; f =   (Franco and Trapp, 2008)
Kow
Kow + 1
When Log KOW <3, Log Pblood : water = 0.73 x log KOW – 0.88 (Fick et al., 2010) Equation 3.12                                
When Log KOW >3, Log Pblood : water = log[(100.73 x log KOW * 0.16) + 0.84]                     
(Fitzsimmons et al., 2001)                                              Equation 3.13
Where:
Pblood:water: Aqueous phase and fish arterial blood partition coefficient
KOW: Octanol/water partition coefficient
FSSPC = Pblood : water * PEC                       Equation 3.14
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Where:
FSSPC: Fish steady state plasma concentration [mg L-1]; and
PECSW: Predicted environmental concentration for surface water [mg L-1].
RCR = FSSPC/HTPC                   Equation 3.15
Where:
RCR: Risk characterisation ratio (this was converted from a toxicity exposure ratio in the 
original work)
fn =                            (Fu et al., 2009)              Equation 3.16
11 + 10𝑖(𝑝𝐾𝑎 ‒ 𝑝𝐻)
fd = 1- fn                                                    (Fu et al., 2009)             Equation 3.17
where i is 1 for bases and -1 for acids, pKa is the negative logarithm (log10) of the dissociation 
constant; pH is 7.
log BCF = log [fnX 10(0.64logKow-0.12) + fdX 10(0.37logKow+0.06pKa-0.51)]                    for acids    
(Fu et al., 2009)                                                      Equation 3.18
log BCF = log [fnX10(0.62logKow-0.15)+fdX10(0.28logKow-0.07pKa+0.84)]                 for bases    
(Fu et al., 2009)                                                      Equation 3.19
Appendix                                                 
195
PECFISH = PECSW x BCFfish x BMF              (TGD, 2003)      Equation 3.20
Where:
PECFISH: Predicted environmental concentration in fish as food [mg kg-1];
BMF: Biomagnification factor obtained from the technical guidance document (TGD, 2003).
     (TGD, 2003)  Equation 3.21𝐶𝐸𝐴𝑅𝑇𝐻𝑊𝑂𝑅𝑀 =  𝐵𝐶𝐹𝑒𝑎𝑟𝑡ℎ𝑤𝑜𝑟𝑚 𝑥 𝐶𝑝𝑜𝑟𝑒𝑤𝑎𝑡𝑒𝑟 + 𝐶𝑠𝑜𝑖𝑙 𝑥 𝐹𝑔𝑢𝑡 𝑥 𝐶𝑂𝑁𝑉𝑠𝑜𝑖𝑙1 +  𝐹𝑔𝑢𝑡 𝑥 𝐶𝑂𝑁𝑉 𝑠𝑜𝑖𝑙
Where:
CEARTHWORM (PECEARTHWORM): Concentration in earthworm on wet weight basis [mg kg-1];
Cporewater: Concentration in porewater [mg L-1];
CSOIL: Concentration in soil [mg kg-1]
Fgut: Fraction of gut loading in worm, 0.1; 
CONVSOIL: Conversion factor for soil concentration wet to dry weight soil, 1.133, calculated 
from TGD (TGD, 2003). 
Cporewater = PECsoil/ (focSOIL x Koc)    (TGD, 2003)       Equation 3.22
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Where
focSOIL: Fraction of soil organic carbon, 0.02.
BCFEARTHWORM = (0.84 x 0.012 x Log Kow)/ RHOearthworm   (TGD, 2003)     Equation 3.23
Where:
BCFEARTHWORM: Bioconcentration factor for earthworms [L kg-1]; and
RHOEARTHWORM: Density of earthworms (default of 1) [kg L-1].
PNEC =             (CHMP, 2006)    Equation 3.24
𝐸𝑐𝑜𝑇𝑜𝑥
𝐴𝐹
Where:
PNEC: Predicted No-effect concentration [mg L-1 or mg kg-1];
EcoTox: The most sensitive ecotoxicological data for the aquatic or terrestrial compartment 
[mg L-1 or mg kg-1]; and
AF: Safety factor (acute QSAR data 1000, acute experimental data 100, chronic QSAR data 
100, and chronic experimental data, 10 (CHMP, 2006)).
Log LC50 earthworm = 1.405 – 0.308 Log KOW        (TGD, 2003)       Equation 3.25
Appendix                                                 
197
Where:
LC50 EARTHWORM: Acute earthworm ecotoxicity, [mM kg-1 dry soil]
PNECDW =     (Schwab et al., 2005)      Equation 3.26
𝐴𝐷𝐼 × 𝐵𝑊 × 𝐴𝑇 
𝐼𝑛𝑔𝑅𝐷𝑊 × 𝐸𝐹 × 𝐸𝐷
Where:
PNECDW: Predicted no-effect concentration through consumption of drinking water [mg];
ADI: Acceptable daily intake, [mg day-1]; 
BW: Body weight, adult 70 and 14 child, [kg];
AT: ADI averaging time, adult 10950 and child 2190, [days];
IngRDW: Water consumption, adult 2 and child 1, [L day-1]; 
EF: Exposure frequency, adult 350 and child 350, [days year-1]; and 
ED: Exposure duration, adult 30 and child 6, [years] (Schwab et al., 2005).
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Appendix 3 
Table A3.1: Extrapolation of chemical recovery (%) for each time points (d) 
Tylosin Chemical recovery (%) 
 1d 2d 3d 4d 
Low     
AF 89.54 80.51 72.2 65.91 
SL 80 65.15 53.98 45.45 
High     
CV 96.39 92.96 89.69 86.57 
AF 96.46 93.09 89.87 86.81 
SL 92.49 85.72 79.61 74.09 
Lincomycin     
Low     
NP 95.14 90.59 86.33 82.34 
PT 94.64 89.65 85.02 80.71 
Trimethoprim     
Low     
PS 91.39 83.76 76.97 70.93 
AF 90.3 81.83 74.43 67.92 
SL 90.12 81.51 74 67.43 
High     
PS 88.54 78.8 70.49 63.37 
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Table A3.2: Summary of the effects of tested antibiotics in 1d ecotoxicological biotests. All toxicity values are in µmol L-1 (values in brackets are the range of 95% 
confidence limits). Seven algal species are P. subcapitata (PS), D. subspicatus (DS), C. vulgaris (CV), N. pelliculosa (NP), P. tricornutum (PT), A. flos-aquae 
(AF) and S. leopoliensis (SL). 
Spe. Lincomycin Tylosin Trimethoprim 
EC50 EC10 EC5 NOEC LOEC Model, r
2 EC50 EC10 EC5 NOEC LOEC model EC50 EC10 EC5 NOEC LOEC model 
PS n.a 2.16 1.52 135.4 >135.4 Weibull, 0.5 >45,58 n.a n.a 45.58 >45,58 n.a >304.99 n.a n.a 304.99 >304.99 n.a. 
DS >135.4 1.32 1.16 135.44 >135.44 Weibull,0.3 93.79 n.a n.a 93.79 >93.79 n.a >344.45 n.a n.a >344.45 >344.45 n.a. 
CV >225.73 n.a n.a 225.73 >225.73 n.a. >90.41 n.a. n.a 90.41 >90.41 n.a. >344.45 n.a n.a >344.45 >344.45 n.a. 
NP >225.73 n.a n.a 225.73 >225.73 n.a n.a n.a n.a 93.79 >93.79 n.a >275.56 n.a n.a 275.56 >275.56 n.a 
PT >225.73 n.a. n.a 225.73 >225.73 n.a n.a n.a n.a 93.79 >93.79 n.a >344.45 n.a n.a 344.45 >344.45 n.a 
AF >3.39 n.a. n.a 3.39 >3.39 n.a 0.34 
 
0.31  0.306 1.35 >1.35 Gompertz, 
0.25 
>344.45 n.a n.a 344.45 >344.45 n.a 
SL >3.39 n.a. n.a 3.39 >3.39 n.a >1.3 
 
n.a n.a 1.3 >1.3 n.a >344.45 n.a n.a 344.45 >344.45 n.a 
n.a. not available. Spe., species. 
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Table A3.3: Summary of the effects of tested antibiotics in 2d ecotoxicological biotests. All toxicity values are in µmol L-1 (values in brackets are the range of 95% 
confidence limits). Seven algal species are P. subcapitata (PS), D. subspicatus (DS), C. vulgaris (CV), N. pelliculosa (NP), P. tricornutum (PT), A. flos-aquae 
(AF) and S. leopoliensis (SL). 
Spe. Lincomycin Tylosin Trimethoprim 
EC50 EC10 EC5 NOEC LOEC Model, r
2 EC50 EC10 EC5 NOEC LOEC model EC50 EC10 EC5 NOEC LOEC model 
PS >135.44 0.12 0.085 135.44 >135.44 Gompertz, 
0.06 
>45.59 
 
4.14 
(n.a-15.2) 
1.6 45.59 
 
>45.59 
 
Weibull 
0.41 
>271.43 n.a n.a 271.43 >271.43 n.a. 
DS >135.4 0.77 0.078 135.4 >135.4 Weibull0.23 >93.79 n.a n.a 93.79 >93.79 n.a >344.45 n.a n.a >344.45 >344.45 n.a. 
CV >225.73 n.a n.a 225.73 >225.73 n.a. >87.19 n.a. n.a 87.19 >87.19 n.a. >344.45 n.a n.a >344.45 >344.45 n.a. 
NP >225.73 24.14 
(n.a-96.79) 
5.7 225.73 >225.73 Weibull 
0.31 
>93.79 1.56 
(n.a-6.43) 
0.57 93.79 >93.79 Weibull 
0.36 
>275.56 7.1 5.4 275.56 >275.56 Gompertz 
0.3 
PT >225.73 n.a. n.a 225.73 >225.73 n.a >93.79 n.a n.a 93.79 >93.79 n.a >344.45 n.a n.a 344.45 >344.45 n.a 
AF 0.16 0.12 0.11 0.14 0.27 Weibull 
0.75 
>1.31 
 
n.a n.a 1.31 
 
>1.31 
 
Gompertz 
0.27 
>344.45 n.a n.a 344.45 >344.45 n.a 
 
SL >0.048 n.a n.a 0.27 0.81 n.a >1.21 
 
0.29 0.24 0.29 0.56 logistic 
0.56 
>344.45 n.a n.a 344.45 >344.45 n.a 
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n.a. not available. Spe., species. 
 
Table A3.4: Summary of the effects of tested antibiotics in 3d ecotoxicological biotests. All toxicity values are in µmol L-1 (values in brackets are the range of 95% 
confidence limits). Seven algal species are P. subcapitata (PS), D. subspicatus (DS), C. vulgaris (CV), N. pelliculosa (NP), P. tricornutum (PT), A. flos-aquae 
(AF) and S. leopoliensis (SL). 
Spe. Lincomycin Tylosin Trimethoprim 
EC50 EC10 EC5 NOEC LOEC Model, r
2 EC50 EC10 EC5 NOEC LOEC model EC50 EC10 EC5 NOEC LOEC model 
PS >135.44 9.4 8.45 4.06 12.19 Gompertz, 
0.82 
>45.58 n.a n.a 1.69 5.06 Gompertz 
0.81 
>242.8 n.a n.a 242.8 >242.8 n.a. 
DS 100.2 0.19 
(70.3.-n.a) 
n.a 73.14 109.7 Gompertz 
0.79 
17.49 
(2.74-n.a) 
4.59 3.5 <9.38 9.38 Sigmoid 
0.76 
>344.45 n.a n.a 344.45 >344.45 n.a. 
CV >225.73 n.a n.a 225.73 >225.73 n.a. >84.12 n.a. n.a 84.12 >84.12 n.a. >344.45 n.a n.a 344.45 >344.45 n.a. 
NP >225.73 5.7 
(1.09-24.1
4) 
1.09 70.16 121.9 Weibull 
0.48 
1.82 
(1.36-2.74) 
0.9 0.78 1.13 1.88 Chapman 
0.88 
9.4 
(7.56-12.95) 
1.9 1.15 2.07 4.13 Chapman 
0.93 
PT >225.73 n.a. n.a 225.73 >225.73 n.a >93.79 3.66 2 50.65 75.03 Chapman 195.2 9.7 4.1 344.45 >344.45 Chapman 
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(0.9-12.42
) 
0.55 (53.55-n.a)  0.51 
AF 0.16 
(0.13- 
0.21) 
0.1 0.09 0.045 0.14 Hill 
0.94 
0.094 
 
0.071 0.06
7 
0.082 0.303 Chapman 
0.84 
>344.45 254 252.62 344.45 >344.45 Logistic 
0.34 
SL 0.78 
(0.29- 
n.a) 
0.048 0.045 0.045 0.14 Weibull 
0.8 
0.22 
(0.1- 
n.a) 
 
0.03 0.01
4 
0.061 0.27 Weibull 
0.81 
>344.45 n.a n.a 344.45 >344.45 n.a 
 
n.a. not available. Spe., species. 
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Table A3.5: Regression models used to derive concentration-response curves of algal species for each antibiotic tests. Seven algal species are P. subcapitata 
(PS), D. subspicatus (DS), C. vulgaris (CV), N. pelliculosa (NP), P. tricornutum (PT), A. flos-aquae (AF) and S. leopoliensis (SL). 
Chemicals species 3d Equation Parameters 4d Equation Parameter 
LIN PS Gompertz f = a*exp(-exp(-(x-x0)/b)) 
 
a=45.6875, 
b=2.4874, 
x0=10.4211 
Weibull 
f = if(x<=x0-b*ln(2)^(1/c), 0, 
a*(1-exp(-(abs(x-x0+b*ln(2)^(1/c))/b)^c))) 
a=70.8708, 
b=11.6837,  
c=0.6998, x0=7.9763 
 DS Gompertz f = a*exp(-exp(-(x-x0)/b)) a=60.4505, 
b=42.1549, 
c=30.5704 
Weibull 
f = if(x<=x0-b*ln(2)^(1/c), 0, 
a*(1-exp(-(abs(x-x0+b*ln(2)^(1/c))/b)^c))) 
a=86.2329,b=20.9654, 
c=0.5501, x0=10.768 
 CV n.a n.a n.a n.a 
 NP Weibull 
f = if(x<=x0-b*ln(2)^(1/c), 0, 
a*(1-exp(-(abs(x-x0+b*ln(2)^(1/c))/b)^c))) 
A=47.0386 
b=111.0582, 
c=0.4658, 
x0=50.5641 
Gompertz f = a*exp(-exp(-(x-x0)/b)) a=21.6183, b=36.7259 
X0=35.0287 
 PT n.a n.a n.a n.a 
 AF Hill, f = a*x^b/(c^b+x^b) a=88.8648, 
b=5.6126, 
c=0.1499 
Weibull 
f = if(x<=x0-b*ln(2)^(1/c), 0, 
a*(1-exp(-(abs(x-x0+b*ln(2)^(1/c))/b)^c))) 
A=93.7185, b=0.1588, 
c=1.3006, d=0.1191 
 SL Weibull 
f = if(x<=x0-b*ln(2)^(1/c), 0, 
a*(1-exp(-(abs(x-x0+b*ln(2)^(1/c))/b)^c))) 
A=60.7292, 
b=0.1935, 
c=0.4137, 
x0=0.124 
Hill f = a*x^b/(c^b+x^b) a=75.0196, b=1.6001, 
c=0.0631 
TYN PS Gompertz f = a*exp(-exp(-(x-x0)/b)) A=47.4673, 
b=0.0321, 
Gompertz f = a*exp(-exp(-(x-x0)/b)) a=71.2543, b=1.8516, 
x0=2.1838 
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c=2.1602 
 DS Sigmoid f = a/(1+exp(-(x-x0)/b)) A=50.043, 
b=1.5414, 
c=6.8725 
Chapman f = a*(1-exp(-b*x))^c a=72.2032, b=0.192, 
c=3.1928 
 CV n.a n.a n.a n.a 
 NP Chapman f = a*(1-exp(-b*x))^c A=59.5793, 
b=2.568, 
c=16.9521 
Chapman f = a*(1-exp(-b*x))^c a=73.5982, b=3.2995, 
c=30.9286 
 PT Chapman f = a*(1-exp(-b*x))^c a=46.7361, 
b=0.1217, 
c=1.4524 
Hill f = a*x^b/(c^b+x^b) a=70.4456, b=0.8089, 
c=1.8967 
 AF Chapman f = a*(1-exp(-b*x))^c A=81.5495 
b=64.4489, 
c=204.26 
Hill f = a*x^b/(c^b+x^b) A=95.3012, b=1.4859 
c=0.085 
 SL Weibull f = if(x<=x0-b*ln(2)^(1/c), 0, 
a*(1-exp(-(abs(x-x0+b*ln(2)^(1/c))/b)^c))) 
a=54.5819, 
b=0.1313, 
c=1.5378, 
d=0.0881 
Chapman 
f = a*(1-exp(-b*x))^c 
a=80.9504, b=9.9407, 
c=0.9057 
TMP PS n.a n.a n.a n.a 
 DS n.a n.a n.a n.a 
 CV n.a n.a n.a n.a 
 NP Chapman f = a*(1-exp(-b*x))^c a=71.0205, 
b=0.1677, 
c=1.5051 
Chapman f = a*(1-exp(-b*x))^c a=85.532, b=0.4897, 
c=18.7533 
 PT Chapman f = a*(1-exp(-b*x))^c a=52.2532, 
b=0.0152, 
Chapman f = a*(1-exp(-b*x))^c a=71.9952, b=0.022, 
c=1.6949 
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c=0.8351 
 AF Logistic f = if(x<=0, if(b<0,0,a), if(b>0, 
a/(1+abs(x/x0)^b),   a*abs((x/x0))^(abs(b))/ 
(1+(abs(x/x0))^(abs(b))))) r2=0.34 
a=38.3014, 
b=-158.5402 
X0=255.6558 
Logistic f = if(x<=0, if(b<0,0,a), if(b>0, 
a/(1+abs(x/x0)^b), 
a*abs((x/x0))^(abs(b))/(1+(abs(x/x0))^(abs(b))))) 
a=12744.8414 
b=-1.0041 
x0=78305.514 
 SL n.a n.a Sigmoid f = a/(1+exp(-(x-x0)/b)) a=41.7517 
b=83.6159 
x0=193.8341 
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Appendix 4 
Table A4.1: Extrapolation of chemical recovery (%) for each time points (d) 
Tylosin Chemical recovery (%) 
 1d 2d 3d 4d 
Low     
DS 94.19  88.82  83.86 79.27 
NP 90.18 81.63 74.15 67.61 
AF 89.54 80.51 72.7 65.91 
High     
PS 95.67 91.59 87.74 84.11 
DS 96.62 93.4 90.32 87.37 
NP 95.2 90.7 86.48 82.53 
AF 96.46 93.09 89.87 86.81 
Lincomycin     
Low     
PS 94.92 90.18 85.76 81.63 
NP 94.15 88.75 83.77 79.16 
High     
NP 90.39 82 74.64 68.18 
Trimethoprim     
Low     
PS 78.57 63.03 51.59 43.03 
AF 90.3 81.83 74.42 67.92 
High     
PS 85.43 73.62 63.98 56.07 
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Table A4.2: Regression models used to derive concentration-response curves for each antibiotics. 
Chemicals species  Equation based on the endpoint of growth Parameters Equation based on the endpoint of 
photosynthesis 
Parameter 
LIN PS Logistic f = if(x<=0, if(b<0,0,a), if(b>0, a/(1+abs(x/x0)^b), 
a*abs((x/x0))^(abs(b))/(1+(abs(x/x0))^(abs(b)))))  R2=0.99 
a=85.8243 
b=-1.5259 
c=19.5198 
Hill f = a*x^b/(c^b+x^b) R2=0.84  A=103.429 
B=0.9965 
C=12.7343 
 DS Hill f = a*x^b/(c^b+x^b)  R2=0.89 a=56.1954 
b=1.1138 
c=37.3791 
Chapman f = a*(1-exp(-b*x))^c R2=0.92 A=101.6327 
B=0.0035 
C=0.501 
 AF Weibull f = if(x<=x0-b*ln(2)^(1/c), 0, 
a*(1-exp(-(abs(x-x0+b*ln(2)^(1/c))/b)^c)))  R2=0.95 
A=65.8625 
B=2.1045 
C=3.5157 
X0=0.7774 
Hill f = a*x^b/(c^b+x^b) R2=0.4 
 
A=56.5253 
B=0.6066 
C=0.1657 
 NP n.a n.a n.a n.a 
TYN PS Weibull f = if(x<=x0-b*ln(2)^(1/c), 0, 
a*(1-exp(-(abs(x-x0+b*ln(2)^(1/c))/b)^c))) R2=0.99 
a=82.5802 
b=4.5983 
c=1.1741 
x0=3.855 
Weibull f = if(x<=x0-b*ln(2)^(1/c), 0, 
a*(1-exp(-(abs(x-x0+b*ln(2)^(1/c))/b)^c))) 
R2=0.91 
a=94.2789 
b=1.366 
c=0.6643 
d=1.9873 
 DS Weibull f = if(x<=x0-b*ln(2)^(1/c), 0, 
a*(1-exp(-(abs(x-x0+b*ln(2)^(1/c))/b)^c))) R2=0.92 
a=96.6334 
b=55.9902 
c=0.833 
x0=35.9337 
Sigmoid f = a/(1+exp(-(x-x0)/b)) R2=0.74 A=67.5547 
B=2.6127 
X0=14.8269 
 AF Chapman f = a*(1-exp(-b*x))^c R2=0.95 a=75.3458 
b=72.5115 
c=29.2359 
Gompertz f = a*exp(-exp(-(x-x0)/b)) R2=0.76 A=103.8338 
B=0.2401 
C=0.2535 
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D=0.2352 
 NP Logistic f = if(x<=0, if(b<0,0,a), if(b>0, a/(1+abs(x/x0)^b), 
a*abs((x/x0))^(abs(b))/(1+(abs(x/x0))^(abs(b))))) R2=0.99 
a=73.3678 
b=-1.0844 
c=2.1734 
Chapman f = a*(1-exp(-b*x))^c R2=0.73 A=73.3619 
B=0.1006 
C=0.5764 
TMP PS n.a n.a n.a n.a 
 DS n.a n.a n.a n.a 
 AF n.a n.a n.a n.a 
 NP Chapman f = a*(1-exp(-b*x))^c R2= 0.94 a=70.4873 
b=0.0276 
c=2.4677 
Chapman f = a*(1-exp(-b*x))^c R2= 0.54 A=98.6262 
B=0.0152 
C=5.0824 
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Appendix 5
Predicted environmental concentration (PEC) (µmol L-1) was calculated to determine the 
ratios of antibiotics in the mixture study (Equation 6.1)(EMEA, 2008)
PECsurface=                     Equation 6.1
380.46 × 𝑆𝑂𝐿 × 𝐷 × 𝐴𝐷 × 𝐵𝑊 × 𝑃 × 𝐹ℎ
𝑁𝑦 × 𝐻 × 𝑀𝑊 × (𝑉𝑃 × 𝑀𝑊 + 2369.49 × 𝑆𝑂𝐿 + 355.42𝐾𝑜𝑐)
Where D = Daily dose of the active ingredient [mg.kgbw-1.day-1]; Ad = Number of days of 
treatment [d]; BW = Animal body weight [kgbw], calves 140kg, cattle 450kg and pig 12.5kg; P 
= Animal turnover rate per place per year [place-1.year-1], calves 1.8, cattle 1 and pig 6.9; Fh = 
Fraction of herd treated, 1 for antibiotics (feed and water medication) and 0.5 for antibiotics 
(injectable); Ny= Nitrogen produced in one year per place [kg.N.place-1.year-1], calves 10, 
cattle 35 and pig 2.25; H = housing factor, calves 1, cattle 0.5 and pig 1; VP = Vapour 
pressure [Pa]; MW = Molar mass [g.mol-1]; SOL = Water solubility [mg.L-1]; Koc = water-
organic carbon distribution coefficient [1.kg]. Information on the daily dose of the active 
ingredient and number of days of treatment was obtained from the Compendium of Data 
Sheet for Animal Medicines (NOAH, 2011). Vapour pressure, water solubility and Koc were 
estimated by using the Environment Protection Agency EPI Suite (4.1 version) (EPA, 2013). 
Equation 6.1 derivation:
The predicted environmental concentration in soil-initial, PECsoil-initial [µg.kg-1] was 
calculated according to EMEA veterinary medicines and inspections guideline (2008) by 
Equation 6.6:
PECsoil-initial = (  ) 1000                             Equation 6.6
𝐷 × 𝐴𝑑 × 𝐵𝑊 × 𝑃 × 170 × 𝐹ℎ1500 × 10000 × 0.05 × 𝑁𝑦 × 𝐻  ×
Where 
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D = Daily dose of the active ingredient [mg.kgbw-1.d-1]
AD = Number of days of treatment [d]
BW = Animal body weight [kgbw]; Calves 140kg, cattle 450kg and pig 12.5kg.
P = Animal turnover rate per place per year [place-1.y-1]; Calves 1.8, cattle 1 and pig 6.9.
Fh = Fraction of herd treated; 1 for antibiotics (feed and water medication) and 0.5 for 
antibiotics (injectable).
Ny = Nitrogen produced in one year per place [kg.N.place-1.y-1]; Calves 10, cattle 35 and pig 
2.25. 
H = housing factor; Calves 1, cattle 0.5 and pig 1.
The concentration in porewater, PECporewater (equals PECgroundwater [µg.L-1]) was calculated by 
Equation 6.7:
PECporewater = PECgroundwater 
=                                             Equation 6.7
𝑃𝐸𝐶𝑠𝑜𝑖𝑙 × 𝑅𝐻𝑂𝑠𝑜𝑖𝑙
𝐾𝑠𝑜𝑖𝑙 ‒ 𝑤𝑎𝑡𝑒𝑟 × 1000
Where Ksoil-water was calculated by Equation 6.8
Ksoil-water = (Fairsoil  Kair-water) + Fwatersoil + (Fsolidsoil   RHOsolid)        Equation 6.8× ×  𝐾𝑝𝑠𝑜𝑖𝑙1000 ×
Where Kair-water and Kpsoil are calculated by Equations 6.9 & 6.10
Kair-water =                                                   Equation 6.9 
𝑉𝑃 × 𝑀𝑊
𝑆𝑂𝐿 × 𝑅 × 𝑇𝐸𝑀𝑃
Kpsoil = Focsoil Koc                                                   Equation 6.10 ×   
Where
RHOsoil = Bulk density of fresh soil [1700 kg.m-3]
RHOsolid = Density of soil solids [2500 kg.m-3]
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Fairsoil = Fraction of air in soil [0.2m3.m-3]
Fwatersoil = Fraction of solids in soil [0.2m3.m-3]
Fsolidsoil = Fraction of solids in soil [0.6m3.m-3]
Focsoil = Weight of organic carbon in soil [0.02kg.kg-1]
TEMP = Temperature at air-water interface [285K]
R = Gas constant [8.314 Pa.m3.mol-1.K-1]
VP = Vapour pressure [Pa]
MW = Molar mass [g.mol-1]
SOL = Water solubility [mg.L-1]
Ksoil-water = Partition coefficient of solids and water in soil (v/v) [m3.m-3]
Kpsoil = Partition coefficient of solids and water in soil (v/w) [L.kg-1]
Kair-water = Partition coefficient of air and water in soil [m3.m-3]
Koc = Water-organic carbon distribution coefficient [L.kg]
PECsoil = PECsoil is the PECsoil-initial calculated based on a mixing depth of 20 cm in the soil, 
namely PECsoil-initial/4 [ug.kg-1]
Finally, the predicted environmental concentration in surfacewater, PECsurfacewater [µg.L-1] was 
calculated by Equation 6.11:
PECsurfacewater =                                               Equation 6.11
𝑃𝐸𝐶𝑝𝑜𝑟𝑒𝑤𝑎𝑡𝑒𝑟3
Equation 6.12 was calculated by combining the default values derived from Equations 6.6 – 
6.11.
PECsurfacewater =                        Equation 6.12
380.46 × 𝑆𝑂𝐿 × 𝐷 × 𝐴𝐷 × 𝐵𝑊 × 𝑃 × 𝐹ℎ
𝑁𝑦 × 𝐻 × (𝑉𝑃 × 𝑀𝑊 + 2369.49 × 𝑆𝑂𝐿 + 355.42𝐾𝑜𝑐)
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Equation 6.1 converted the unit of PECsurfacewater from µg L-1 in Equation 12 to µmol L-1 by 
dividing the chemical molar mass [g.mol-1]
PECsurfacewater =                       Equation 6.1
380.46 × 𝑆𝑂𝐿 × 𝐷 × 𝐴𝐷 × 𝐵𝑊 × 𝑃 × 𝐹ℎ
𝑁𝑦 × 𝐻 × MW × (𝑉𝑃 × 𝑀𝑊 + 2369.49 × 𝑆𝑂𝐿 + 355.42𝐾𝑜𝑐)
Table A5.1 Risk assessment of three veterinary antibiotics based on maximum application 
rate prediction. TWAEC is in µmol L-1.
TMP TYN LIN
Scenario
TWAEC
PEC/PNEC
TWAEC
PEC/PNEC
TWAEC
PEC/PNEC
D1 ditch 0.026 0.0092 0.0094 7.18 7.06x10-5 0.05
D1 stream 0.016 0.0057 0.0059 4.49 4.72x10-5 0.034
D2 ditch 0.024 0.0085 0.011 8.45 0.00075 0.53
D2 stream 0.014 0.005 0.0064 4.88 0.00035 0.25
D4 pond 0.0012 0.000403 0.0012 0.88 8.73x10-5 0.062
D4 stream 0.0015 0.00054 0.0011 0.81 0.00012 0.083
D5 pond 0.0019 0.00059 0.002 1.5 0.00038 0.27
D5 stream 0.0011 0.00041 0.0018 1.41 0.00024 0.17
D6 ditch 0.003 0.00104 0.0025 1.94 0.00016 0.11
R1 pond 0.016 0.0054 0.0061 4.61 0.0004 0.28
R1 stream 0.031 0.011 0.015 11.68 0.004 2.88
R3 stream 0.084 0.029 0.073 55.83 0.011 8
R4 stream 0.044 0.015 0.027 20.4 0.00011 0.081
PNEC was calculated by PNEC = EC50/ AF. The 96 h EC50 of trimethoprim, tylosin and 
lincomycin to A. flos-aquae were 285.75, 0.13 and 0.14 µmol L-1, respectively; AF=100.
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Table A5.2 Risk assessment of three veterinary antibiotics based on medium application rate 
prediction. TWAEC is in µmol L-1. 
Scenario 
TMP 
PEC/PNEC 
TYN 
PEC/PNEC 
LIN 
PEC/PNEC 
TWAEC TWAEC TWAEC 
D1 ditch 0.0028 0.00098 0.0013 1.01 3.98x10-5 0.028 
D1 stream 0.0017 0.00061 0.00083 0.63 2.66 x10-5 0.019 
D2 ditch 0.0026 0.0009 0.0016 1.19 0.00042 0.3 
D2 stream 0.0015 0.00053 0.0009 0.69 0.0002 0.14 
D4 pond 0.00012 4.3 x10-5 0.00016 0.12 4.92x10-5 0.035 
D4 stream 0.00016 5.71 x10-5 0.00015 0.11 6.52x10-5 0.047 
D5 pond 0.00018 6.3 x10-5 0.00028 0.21 0.00022 0.15 
D5 stream 0.00013 4.4 x10-5 0.00026 0.2 0.00013 0.095 
D6 ditch 0.00033 0.00011 0.00036 0.27 8.88x10-5 0.063 
R1 pond 0.0017 0.00058 0.00086 0.65 0.00022 0.16 
R1 stream 0.0034 0.0012 0.0022 1.65 0.0023 1.62 
R3 stream 0.009 0.0031 0.0104 7.89 0.0063 4.51 
R4 stream 0.0047 0.0017 0.0038 2.88 6.37x10-5 0.046 
PNEC was calculated by PNEC = EC50/ AF. The 96 h EC50 of trimethoprim, tylosin and 
lincomycin to A. flos-aquae were 285.75, 0.13 and 0.14 µmol L-1, respectively; AF=100. 
 
Table A5.3 Risk assessment of three veterinary antibiotics based on minimum application rate 
prediction. TWAEC is in µmol L-1. 
Scenario 
TMP 
PEC/PNEC 
TYN 
PEC/PNEC 
LIN 
PEC/PNEC 
TWAEC TWAEC TWAEC 
D1 ditch 0.00011 3.77 x10-5 7.31x10-5 0.056 1.01x10-5 0.0072 
D1 stream 6.72 x10-5 2.35 x10-5 4.57x10-5 0.035 6.74x10-6 0.0048 
D2 ditch 9.92 x10-5 3.47 x10-5 8.62x10-5 0.066 0.00011 0.076 
D2 stream 5.86 x10-5 2.05 x10-5 4.98x10-5 0.038 4.99x10-5 0.036 
D4 pond 4.72 x10-6 1.65 x10-6 9x10-6 0.0069 1.25x10-5 0.0089 
D4 stream 6.27 x10-6 2.19 x10-6 8.27x10-6 0.0063 1.66x10-5 0.012 
D5 pond 6.92 x10-6 2.42 x10-6 1.53x10-5 0.012 5.49x10-5 0.039 
D5 stream 4.82 x10-6 1.69 x10-6 1.43x10-5 0.011 3.39x10-5 0.024 
D6 ditch 1.22 x10-5 4.26 x10-6 1.98x10-5 0.015 2.26x10-5 0.016 
R1 pond 6.37 x10-5 2.23 x10-5 4.7x10-5 0.036 5.66x10-5 0.04 
R1 stream 0.00013 4.51 x10-5 0.00012 0.091 0.00058 0.41 
R3 stream 0.00034 0.00012 0.00057 0.43 0.0016 1.14 
R4 stream 0.00018 6.35 x10-5 0.00021 0.16 1.62x10-5 0.012 
PNEC was calculated by PNEC = EC50/ AF. The 96 h EC50 of trimethoprim, tylosin and 
lincomycin to A. flos-aquae were 285.75, 0.13 and 0.14 µmol L-1, respectively; AF=100. 
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Table A5.4 Regressions used to derive concentration-response curves of A. flos-aquae for 
each antibiotic. 
Chemicals  Equation based on the endpoint of growth Parameters 
Tylosin Hill f = a*x^b/(c^b+x^b) R2=0.93 a=90.808 
b=1.9117 
c=0.1126 
Lincomycin Hill f = a*x^b/(c^b+x^b) R2=0.94 a=92.085 
b=2.2755 
c=0.1251 
Trimethoprim Sigmoid f = a/(1+exp(-(x-x0)/b)) R2=0.88 a=65.4152 
b=86.5556 
X0=184.2818 
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